Refine Search

Search Results -

Term	Documents
@AY	29885254
(22 AND (@AY > "2002")).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0
(L22@AY>2002).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L23

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, January 22, 2008 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=AND		
L23	L22@ay>2002	0	L23
L22	L21 and (dalton near nucleotide or kilodalton near nucleotide or kDa near nucleotide or Da near nucleotide or dalton near amino adj acid or kilodalton near amino adj acid or kDa near amino adj acid or Da near amino adj acid or dalton near protein or kilodalton near protein or kDa near protein or Da near protein)	171	L22
L21	L19 and sample	411	L21
L20	L19 and dalton or kilodalton	12269	L20
L19	L17 not L18	411	L19
L18	L17@ay>2002	279	L18

L17	L16 and (serum adj marker near amino adj acid or serum adj biomarker near amino adj acid or marker near amino adj acid or biomarker near amino adj acid or serum adj marker near protein or serum adj biomarker near protein or marker near protein or biomarker near protein)	690	L17
L16	L15 and (hepatocellular adj carcinoma or HCC near hepatocellular adj carcinoma)	2085	L16
L15	L14 and (serum adj marker or serum adj biomarker or marker or biomarker)	2085	L15
L14	L11 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	2085	L14
L13	L11 and protein.clm.	1259	L13
L12	L11 and (hepatocellular adj carcinoma.clm.)	86	L12
L11	L10 and hepatocellular adj carcinoma	2482	L11
L10	L9 and (dalton or kilodalton or kDa or Da)	2482	L10
L9	L8 and (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	2482	L9
L8	L6 and method	3283	L8
L7	L6 and (sample or fluid or serum)	3283	L7
L6	L5 and (sample or fluid or serum or plasma)	3284	L6
L5	L1 and L2 and L3 and L4	3304	L5
L4	nucleotide or amino adj acid or protein	741296	L4
L3	serum adj marker or serum adj biomarker or marker or biomarker	305573	L3
L2	dalton or kilodalton or kDa or Da or ,000 near dalton or ,000 near Da	290723	L2
L1	hepatocellular adj carcinoma	8662	L1

END OF SEARCH HISTORY

Refine Search

Your wildcard search against 10000 terms has yielded the results below.

Your result set for the last L# is incomplete.

The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

Search Results -

Term	Documents
METHOD	10569984
METHODS	2725139
DIAGNOS$	0
DIAGNOS	210
DIAGNOSA	1
DIAGNOSABILITIES	1
DIAGNOSABILITY	167
DIAGNOSABILITY-IDENTIFYING	1
DIAGNOSABILTY	3
DIAGNOSABLE	672
DIAGNOSABLE-ALTHOUGH	1
(L61 AND (METHOD NEAR DIAGNOS$ OR METHOD NEAR DETERMIN$ OR METHOD NEAR IDENTI$ OR METHOD NEAR ANALYZ$ OR METHOD NEAR TARGET$)).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	1984

There are more results than shown above. Click here to view the entire set.

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L62

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Tuesday, January 22, 2008 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=AND		
L62	L61 and (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	1984	L62
L61	L60 and (sample or fluid or serum)	2515	L61
L60	L59 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	2525	L60
L59	L58 and method	3066	L59
L58	L57 and (nucleotide or amino acid or protein)	3067	L58
L57	L56 and L26	3067	L57
L56	L24 and (dalton or kilodalton or kDa)	3790	L56
L55	L51 not L54	208	L55
L54	L51@py>2002	712	L54
L53	L51 not L52	486	L53
L52	L51@ay>2002	434	L52
L51	L50 (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	920	L51
L50	L47 and (sample or fluid or serum)	1140	L50
L49	L47 and (sample or serum)	1140	L49
L48	L47@ay>2002	532	L48
L47	L46 and method	1141	L47
L46	L45 and (hepatocellular adj carcinoma)	1141	L46
L45	L43 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	1141	L45
L44	L43@ay>2002	647	L44
L43	L42 and (dalton$ or kilodalton$)	1359	L43
L42	L38 and (daltons or dalton or kilodalton or kDa or (molecular adj weight near dalton))	2909	L42
L41	L39 not L40	28	L41
L40	L39@ay>2002	68	L40
L39	L38 and (hepatocellular adj carcinoma.clm. or hepato-cellular adj carcinoma.clm.)	96	L39
L38	L37 and method	2909	L38
L37	L36 and (nucleotide or amino acid or protein)	2910	L37
L36	L35 and L26	2910	L36
L35	L24 and L34	3600	L35
L34	daltons or dalton or kDA or (molecular adj weight near dalton)	113962	L34
L33	daltons or dalton or kDA or molecular adj weight near dalton	113962	L33
L32	L30 not L31	6	L32
L31	L30@ay>2002	15	L31
L30	L29 and (L24 near protein)	21	L30

L29	L28 and method	4745	L29
L28	L27 and (nucleotide or amino acid or protein)	4748	L28
L27	L24 and L25 and L26	4755	L27
L26	serum adj marker or serum adj biomarker or marker or biomarker	305573	L26
L25	daltons or dalton or kDA or da or molecular weight	1024782	L25
L24	hepatocellular adj carcinoma or hepato-cellular adj carcinoma	8708	L24
L23	L22@ay>2002	0	L23
L22	L21 and (dalton near nucleotide or kilodalton near nucleotide or kDa near nucleotide or Da near nucleotide or dalton near amino adj acid or kilodalton near amino adj acid or kDa near amino adj acid or Da near amino adj acid or dalton near protein or kilodalton near protein or kDa near protein or Da near protein)	171	L22
L21	L19 and sample	411	L21
L20	L19 and dalton or kilodalton	12269	L20
L19	L17 not L18	411	L19
L18	L17@ay>2002	279	L18
L17	L16 and (serum adj marker near amino adj acid or serum adj biomarker near amino adj acid or marker near amino adj acid or biomarker near amino adj acid or serum adj marker near protein or serum adj biomarker near protein or marker near protein or biomarker near protein)	690	L17
L16	L15 and (hepatocellular adj carcinoma or HCC near hepatocellular adj carcinoma)	2085	L16
L15	L14 and (serum adj marker or serum adj biomarker or marker or biomarker)	2085	L15
L14	L11 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	2085	L14
L13	L11 and protein.clm.	1259	L13
L12	L11 and (hepatocellular adj carcinoma.clm.)	86	L12
L11	L10 and hepatocellular adj carcinoma	2482	L11
L10	L9 and (dalton or kilodalton or kDa or Da)	2482	L10
L9	L8 and (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	2482	L9
L8	L6 and method	3283	L8
L7	L6 and (sample or fluid or serum)	3283	L7
L6	L5 and (sample or fluid or serum or plasma)	3284	L6
L5	L1 and L2 and L3 and L4	3304	L5
L4	nucleotide or amino adj acid or protein	741296	L4
L3	serum adj marker or serum adj biomarker or marker or biomarker	305573	L3
L2	dalton or kilodalton or kDa or Da or ,000 near dalton or ,000 near Da	290723	L2
L1	hepatocellular adj carcinoma	8662	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
CHAN	260962
CHANS	302
HEPATOCELLULAR	11152
HEPATOCELLULARS	0
(HEPATOCELLULAR AND (CHAN.IN.)).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	86
(CHAN.IN. AND HEPATOCELLULAR).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	86

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L67

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, January 22, 2008 Purge Queries Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=AND			
L67	chan.in. and hepatocellular	86	L67
L66	johnson-p.in. and hepatocellular	1	L66
L65	poon.in. and hepatocellular	10	L65
L64	L63 and hepatocellular	4	L64
L63	yip.in.	1732	L63

L62	L61 and (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	1984	L62
L61	L60 and (sample or fluid or serum)	2515	L61
L60	L59 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	2525	L60
L59	L58 and method	3066	L59
L58	L57 and (nucleotide or amino acid or protein)	3067	L58
L57	L56 and L26	3067	L57
L56	L24 and (dalton or kilodalton or kDa)	3790	L56
L55	L51 not L54	208	L55
L54	L51@py>2002	712	L54
L53	L51 not L52	486	L53
L52	L51@ay>2002	434	L52
L51	L50 (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	920	L51
L50	L47 and (sample or fluid or serum)	1140	L50
L49	L47 and (sample or serum)	1140	L49
L48	L47@ay>2002	532	L48
L47	L46 and method	1141	L47
L46	L45 and (hepatocellular adj carcinoma)	1141	L46
L45	L43 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	1141	L45
L44	L43@ay>2002	647	L44
L43	L42 and (dalton$ or kilodalton$)	1359	L43
L42	L38 and (daltons or dalton or kilodalton or kDa or (molecular adj weight near dalton))	2909	L42
L41	L39 not L40	28	L41
L40	L39@ay>2002	68	L40
L39	L38 and (hepatocellular adj carcinoma.clm. or hepato-cellular adj carcinoma.clm.)	96	L39
L38	L37 and method	2909	L38
L37	L36 and (nucleotide or amino acid or protein)	2910	L37
L36	L35 and L26	2910	L36
L35	L24 and L34	3600	L35
L34	daltons or dalton or kDA or (molecular adj weight near dalton)	113962	L34
L33	daltons or dalton or kDA or molecular adj weight near dalton	113962	L33
L32	L30 not L31	6	L32
L31	L30@ay>2002	15	L31
L30	L29 and (L24 near protein)	21	L30
L29	L28 and method	4745	L29
L28	L27 and (nucleotide or amino acid or protein)	4748	L28
L27	L24 and L25 and L26	4755	L27
L26	serum adj marker or serum adj biomarker or marker or biomarker	305573	L26
L25	daltons or dalton or kDA or da or molecular weight	1024782	L25

L24	hepatocellular adj carcinoma or hepato-cellular adj carcinoma	8708	L24
L23	L22@ay>2002	0	L23
L22	L21 and (dalton near nucleotide or kilodalton near nucleotide or kDa near nucleotide or Da near nucleotide or dalton near amino adj acid or kilodalton near amino adj acid or kDa near amino adj acid or Da near amino adj acid or dalton near protein or kilodalton near protein or kDa near protein or Da near protein)	171	L22
L21	L19 and sample	411	L21
L20	L19 and dalton or kilodalton	12269	L20
L19	L17 not L18	411	L19
L18	L17@ay>2002	279	L18
L17	L16 and (serum adj marker near amino adj acid or serum adj biomarker near amino adj acid or marker near amino adj acid or biomarker near amino adj acid or serum adj marker near protein or serum adj biomarker near protein or marker near protein or biomarker near protein)	690	L17
L16	L15 and (hepatocellular adj carcinoma or HCC near hepatocellular adj carcinoma)	2085	L16
L15	L14 and (serum adj marker or serum adj biomarker or marker or biomarker)	2085	L15
L14	L11 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	2085	L14
L13	L11 and protein.clm.	1259	L13
L12	L11 and (hepatocellular adj carcinoma.clm.)	86	L12
L11	L10 and hepatocellular adj carcinoma	2482	L11
L10	L9 and (dalton or kilodalton or kDa or Da)	2482	L10
L9	L8 and (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	2482	L9
L8	L6 and method	3283	L8
L7	L6 and (sample or fluid or serum)	3283	L7
L6	L5 and (sample or fluid or serum or plasma)	3284	L6
L5	L1 and L2 and L3 and L4	3304	L5
L4	nucleotide or amino adj acid or protein	741296	L4
L3	serum adj marker or serum adj biomarker or marker or biomarker	305573	L3
L2	dalton or kilodalton or kDa or Da or ,000 near dalton or ,000 near Da	290723	L2
L1	hepatocellular adj carcinoma	8662	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
CHAN	260962
CHANS	302
HEPATOCELLULAR	11152
HEPATOCELLULARS	0
(HEPATOCELLULAR AND (CHAN.IN.)).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	86
(CHAN.IN. AND HEPATOCELLULAR).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	86

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L67

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Tuesday, January 22, 2008 Purge Queries Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=AND		
L67	chan.in. and hepatocellular	86	L67
L66	johnson-p.in. and hepatocellular	1	L66
L65	poon.in. and hepatocellular	10	L65
L64	L63 and hepatocellular	4	L64
L63	yip.in.	1732	L63

L62	L61 and (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	1984	L62
L61	L60 and (sample or fluid or serum)	2515	L61
L60	L59 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	2525	L60
L59	L58 and method	3066	L59
L58	L57 and (nucleotide or amino acid or protein)	3067	L58
L57	L56 and L26	3067	L57
L56	L24 and (dalton or kilodalton or kDa)	3790	L56
L55	L51 not L54	208	L55
L54	L51@py>2002	712	L54
L53	L51 not L52	486	L53
L52	L51@ay>2002	434	L52
L51	L50 (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	920	L51
L50	L47 and (sample or fluid or serum)	1140	L50
L49	L47 and (sample or serum)	1140	L49
L48	L47@ay>2002	532	L48
L47	L46 and method	1141	L47
L46	L45 and (hepatocellular adj carcinoma)	1141	L46
L45	L43 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	1141	L45
L44	L43@ay>2002	647	L44
L43	L42 and (dalton$ or kilodalton$)	1359	L43
L42	L38 and (daltons or dalton or kilodalton or kDa or (molecular adj weight near dalton))	2909	L42
L41	L39 not L40	28	L41
L40	L39@ay>2002	68	L40
L39	L38 and (hepatocellular adj carcinoma.clm. or hepato-cellular adj carcinoma.clm.)	96	L39
L38	L37 and method	2909	L38
L37	L36 and (nucleotide or amino acid or protein)	2910	L37
L36	L35 and L26	2910	L36
L35	L24 and L34	3600	L35
L34	daltons or dalton or kDA or (molecular adj weight near dalton)	113962	L34
L33	daltons or dalton or kDA or molecular adj weight near dalton	113962	L33
L32	L30 not L31	6	L32
L31	L30@ay>2002	15	L31
L30	L29 and (L24 near protein)	21	L30
L29	L28 and method	4745	L29
L28	L27 and (nucleotide or amino acid or protein)	4748	L28
L27	L24 and L25 and L26	4755	L27
L26	serum adj marker or serum adj biomarker or marker or biomarker	305573	L26
L25	daltons or dalton or kDA or da or molecular weight	1024782	L25

L24	hepatocellular adj carcinoma or hepato-cellular adj carcinoma	8708	L24
L23	L22@ay>2002	0	L23
L22	L21 and (dalton near nucleotide or kilodalton near nucleotide or kDa near nucleotide or Da near nucleotide or dalton near amino adj acid or kilodalton near amino adj acid or kDa near amino adj acid or Da near amino adj acid or dalton near protein or kilodalton near protein or kDa near protein or Da near protein)	171	L22
L21	L19 and sample	411	L21
L20	L19 and dalton or kilodalton	12269	L20
L19	L17 not L18	411	L19
L18	L17@ay>2002	279	L18
L17	L16 and (serum adj marker near amino adj acid or serum adj biomarker near amino adj acid or marker near amino adj acid or biomarker near amino adj acid or serum adj marker near protein or serum adj biomarker near protein or marker near protein or biomarker near protein)	690	L17
L16	L15 and (hepatocellular adj carcinoma or HCC near hepatocellular adj carcinoma)	2085	L16
L15	L14 and (serum adj marker or serum adj biomarker or marker or biomarker)	2085	L15
L14	L11 and (nucleotide.clm. or amino adj acid.clm. or protein.clm.)	2085	L14
L13	L11 and protein.clm.	1259	L13
L12	L11 and (hepatocellular adj carcinoma.clm.)	86	L12
L11	L10 and hepatocellular adj carcinoma	2482	L11
L10	L9 and (dalton or kilodalton or kDa or Da)	2482	L10
L9	L8 and (method near diagnos$ or method near determin$ or method near identi$ or method near analyz$ or method near target$)	2482	L9
L8	L6 and method	3283	L8
L7	L6 and (sample or fluid or serum)	3283	L7
L6	L5 and (sample or fluid or serum or plasma)	3284	L6
L5	L1 and L2 and L3 and L4	3304	L5
L4	nucleotide or amino adj acid or protein	741296	L4
L3	serum adj marker or serum adj biomarker or marker or biomarker	305573	L3
L2	dalton or kilodalton or kDa or Da or ,000 near dalton or ,000 near Da	290723	L2
L1	hepatocellular adj carcinoma	8662	L1

END OF SEARCH HISTORY

```
? e au=yip-tai-tung.in.
Ref   Items  Index-term
E1        1  AU=YIP-SNEIDER MICHELE T
E2        1  AU=YIP-SNEIDER MT
E3        0  AU=YIP-TAI-TUNG.IN.
E4       25  AU=YIP-WAH CHUNG
E5        2  AU=YIP-WAH, C.
E6        1  AU=YIP-WONG, K.
E7        8  AU=YIP, A
E8       14  AU=YIP, A.
E9        1  AU=YIP, A. C.
E10       3  AU=YIP, A. G.
E11       3  AU=YIP, A. L. M.
E12      12  AU=YIP, A. M.
E13       2  AU=YIP, A. M. W.
E14       1  AU=YIP, A. N.
E15       5  AU=YIP, A. S. K.
E16       1  AU=YIP, A. T.
E17       2  AU=YIP, A. W.
E18       8  AU=YIP, A. W. C.
E19       2  AU=YIP, A. Y.
E20       4  AU=YIP, A. Y. N.
E21       1  AU=YIP, A. Y. S.
E22       1  AU=YIP, A. Y.-W
E23       2  AU=YIP, A.M.
E24       2  AU=YIP, A.Y.-W.
E25       1  AU=YIP, ADRIAN YUN-SAN
         Enter PAGE for more

? e au=yip, t?
Ref   Items  Index-term
E1        1  AU=YIP, T-T
E2        1  AU=YIP, T-T.
E3        0  AU=YIP, T?
E4        1  AU=YIP, TA-TUNG
E5        1  AU=YIP, TAI T.
E6       35  AU=YIP, TAI TUNG
E7       75  AU=YIP, TAI-TUNG
E8        1  AU=YIP, TAK CHUN
E9        2  AU=YIP, TAK-CHUN
E10       2  AU=YIP, TC
E11       2  AU=YIP, TERENCE
E12       2  AU=YIP, TERENCE POK SIU
E13       1  AU=YIP, TERESA
E14       2  AU=YIP, TERESA M.
E15       1  AU=YIP, TERRANCE
E16       1  AU=YIP, TERRANCE P
E17       1  AU=YIP, TERRANCE P.
E18       1  AU=YIP, TERRY SIU-HAN
E19       2  AU=YIP, THOMAS
E20       1  AU=YIP, THOMAS C.
E21       1  AU=YIP, THOMAS W. S.
E22       1  AU=YIP, THOMAS W.S.
E23       1  AU=YIP, THOMAS WAI-CHEONG
E24       1  AU=YIP, TIAN SIANG
E25      12  AU=YIP, TICK HON
         Enter PAGE for more

? s e4-e7
           1   AU=YIP, TA-TUNG
           1   AU=YIP, TAI T.
```

```
           35   AU=YIP, TAI TUNG
           75   AU=YIP, TAI-TUNG
S1        112   S E4-E7

?  s s1 and hepatocellular
          112   S1
       294510   HEPATOCELLULAR
S2          2   S S1 AND HEPATOCELLULAR

?  e au=poon, t?
Ref   Items  Index-term
E1        1  AU=POON, T.W.
E2        1  AU=POON, T.W.H.
E3        0  AU=POON, T?
E4        2  AU=POON, TAK
E5        1  AU=POON, TAK C.
E6        1  AU=POON, TAK-LAP
E7        1  AU=POON, TAK-SUN
E8       21  AU=POON, TERENCE C. W.
E9        1  AU=POON, TERENCE C.W.
E10       1  AU=POON, TERENCE CHEUN WAI
E11       1  AU=POON, TERENCE CHUEN-WAI
E12       1  AU=POON, TERENCE CW
E13       1  AU=POON, TERENCE K.
E14       5  AU=POON, TERENCE S. C.
E15       1  AU=POON, TERESA K. Y.
E16       1  AU=POON, TERRENCE
E17       2  AU=POON, TERRI
E18       1  AU=POON, TERRI H.
E19       1  AU=POON, TERRY
E20       1  AU=POON, TH
E21      86  AU=POON, THOMAS
E22       4  AU=POON, THOMAS H. W
E23      11  AU=POON, THOMAS H. W.
E24       1  AU=POON, THOMAS HONCHIU
E25       4  AU=POON, TIFFANY
           Enter PAGE for more

?  s e8-e14
          21   AU=POON, TERENCE C. W.
           1   AU=POON, TERENCE C.W.
           1   AU=POON, TERENCE CHEUN WAI
           1   AU=POON, TERENCE CHUEN-WAI
           1   AU=POON, TERENCE CW
           1   AU=POON, TERENCE K.
           5   AU=POON, TERENCE S. C.
S3        31   S E8-E14

?  s s3 and hepatocellular
          31   S3
       294510   HEPATOCELLULAR
S4         8   S S3 AND HEPATOCELLULAR

?  e au=johnson, p?
Ref   Items  Index-term
E1        1  AU=JOHNSON, P-N.T.
E2        1  AU=JOHNSON, P,
E3        0  AU=JOHNSON, P?
E4       65  AU=JOHNSON, PA
E5        2  AU=JOHNSON, PA*
E6        3  AU=JOHNSON, PAGE
E7        2  AU=JOHNSON, PAIGE E.
E8        1  AU=JOHNSON, PAIGE I.
```

```
E9          4  AU=JOHNSON, PAIGE L.
E10        28  AU=JOHNSON, PALEY
E11         1  AU=JOHNSON, PALMER OLIVER
E12        20  AU=JOHNSON, PAM
E13         3  AU=JOHNSON, PAM M.
E14         1  AU=JOHNSON, PAM MCALLISTER
E15         1  AU=JOHNSON, PAMALA
E16        24  AU=JOHNSON, PAMELA
E17         1  AU=JOHNSON, PAMELA ADAMS
E18         2  AU=JOHNSON, PAMELA ANN
E19         1  AU=JOHNSON, PAMELA CAROL
E20         1  AU=JOHNSON, PAMELA D.
E21         1  AU=JOHNSON, PAMELA DIANE
E22         1  AU=JOHNSON, PAMELA E.
E23         1  AU=JOHNSON, PAMELA ESTHER
E24         1  AU=JOHNSON, PAMELA G.
E25         2  AU=JOHNSON, PAMELA GAIL
           Enter PAGE for more

?  e au=poon, ph?
Ref    Items  Index-term
E1         1  AU=POON, PETULA
E2        12  AU=POON, PH
E3         0  AU=POON, PH?
E4         2  AU=POON, PHILIP
E5         5  AU=POON, PHILIP K. C.
E6         4  AU=POON, PHILLIP
E7         2  AU=POON, PHOENIX S. Y.
E8         3  AU=POON, PMK
E9        14  AU=POON, PO S.
E10        1  AU=POON, PO. S.
E11        4  AU=POON, POLLY M. S.
E12        1  AU=POON, POLLY M.S.
E13        1  AU=POON, POPO
E14        4  AU=POON, PP
E15        1  AU=POON, PRISCILLA
E16       10  AU=POON, PRISCILLA M. K.
E17        2  AU=POON, PRISCILLA M.K.
E18        3  AU=POON, PRISCILLA MIU-KUEN
E19        2  AU=POON, PS
E20        1  AU=POON, PUI HAN WINNIE
E21        1  AU=POON, PW
E22        1  AU=POON, PW-F
E23       16  AU=POON, PWF
E24        2  AU=POON, PWF*
E25        3  AU=POON, PY
           Enter PAGE for more

?  s e2--e7
>>>W:  Character "-" in invalid position
>>>E:  There is no result

?  s e2-e7
           12   AU=POON, PH
            0   AU=POON, PH?
            2   AU=POON, PHILIP
            5   AU=POON, PHILIP K. C.
            4   AU=POON, PHILLIP
            2   AU=POON, PHOENIX S. Y.
S5         25   S E2-E7

?  s s5 and hepatocellular
           25   S5
```

```
       294510   HEPATOCELLULAR
S6          0   S S5 AND HEPATOCELLULAR

?  e au=yip, v?
Ref   Items  Index-term
E1        1  AU=YIP, V. S.
E2        1  AU=YIP, V.F.S.
E3        0  AU=YIP, V?
E4        5  AU=YIP, VERA
E5        4  AU=YIP, VERONICA
E6        4  AU=YIP, VICTOR
E7        2  AU=YIP, VICTOR F.
E8        1  AU=YIP, VINCENT F.
E9        5  AU=YIP, VINCENT F. S.
E10       1  AU=YIP, VINCENT FOOK SENG
E11       2  AU=YIP, VIRGINIA
E12       1  AU=YIP, VIRGINIA CHOY-YIN
E13       2  AU=YIP, VIVIAN
E14       1  AU=YIP, VIVIAN L.
E15       3  AU=YIP, VIVIAN L. Y
E16      27  AU=YIP, VIVIAN L. Y.
E17       1  AU=YIP, VIVIAN L.Y.
E18       1  AU=YIP, VIVIAN LY
E19       2  AU=YIP, VLY
E20       1  AU=YIP, VS
E21       2  AU=YIP, W
E22      41  AU=YIP, W.
E23       5  AU=YIP, W. C
E24      18  AU=YIP, W. C.
E25      15  AU=YIP, W. C. L.
          Enter PAGE for more

?  s e7
S7          2   AU='YIP, VICTOR F.'

?  s s7 and hepatocellular
            2   S7
       294510   HEPATOCELLULAR
S8          1   S S7 AND HEPATOCELLULAR

?  e au=yip, christine?
Ref   Items  Index-term
E1        4  AU=YIP, CHRISTINE L.
E2        1  AU=YIP, CHRISTINE N. B. LAU
E3        0  AU=YIP, CHRISTINE?
E4        4  AU=YIP, CHRISTOPHER
E5        1  AU=YIP, CHRISTOPHER LEE
E6       16  AU=YIP, CHRISTOPHER M
E7       70  AU=YIP, CHRISTOPHER M.
E8        2  AU=YIP, CHRISTOPHER M. (UNIVERSITY OF TORONTO, ON
E9        2  AU=YIP, CHRISTOPHER MIN-FAR
E10       1  AU=YIP, CHUN K
E11       1  AU=YIP, CHUN K.
E12       1  AU=YIP, CHUN KIT
E13       1  AU=YIP, CHUN SENG
E14       1  AU=YIP, CHUN-SHING
E15       3  AU=YIP, CHUN-WING
E16       2  AU=YIP, CHUN-YU
E17       1  AU=YIP, CHUNG-WING
E18       1  AU=YIP, CK
E19       1  AU=YIP, CKM
E20       2  AU=YIP, CL
E21       1  AU=YIP, CLARWYN
```

```
E22         1  AU=YIP, CLEO
E23         1  AU=YIP, CLEO K.M.
E24         2  AU=YIP, CLIFFORD
E25         2  AU=YIP, CLT
           Enter PAGE for more

?  s e1-e3
             4   AU=YIP, CHRISTINE L.
             1   AU=YIP, CHRISTINE N. B. LAU
             0   AU=YIP, CHRISTINE?
S9           5   S E1-E3

?  s s9 and hepatocellular
             5   S9
        294510   HEPATOCELLULAR
S10          1   S S9 AND HEPATOCELLULAR

?  e au=chan, anthony
Ref    Items  Index-term
E1         1  AU=CHAN, ANSON C. K.
E2        25  AU=CHAN, ANTHONY
E3         1  AU=CHAN, ANTHONY A
E4         9  AU=CHAN, ANTHONY A.
E5         1  AU=CHAN, ANTHONY ARTHUR
E6         1  AU=CHAN, ANTHONY BERNARD
E7         4  AU=CHAN, ANTHONY C.-T.
E8         2  AU=CHAN, ANTHONY CHIH-TUNG
E9         2  AU=CHAN, ANTHONY CHO-LAI
E10        1  AU=CHAN, ANTHONY CHUNG-FUNG
E11        1  AU=CHAN, ANTHONY CT
E12        1  AU=CHAN, ANTHONY G.
E13        1  AU=CHAN, ANTHONY K C
E14        9  AU=CHAN, ANTHONY K.
E15        1  AU=CHAN, ANTHONY K. C
E16       40  AU=CHAN, ANTHONY K. C.
E17        2  AU=CHAN, ANTHONY K.C.
E18        5  AU=CHAN, ANTHONY KAM CHUEN
E19        2  AU=CHAN, ANTHONY KAM-YIN
E20        1  AU=CHAN, ANTHONY KIN WANG
E21        1  AU=CHAN, ANTHONY KWOK HING
E22        1  AU=CHAN, ANTHONY KWOK-HING
E23        1  AU=CHAN, ANTHONY RIVERA
E24       18  AU=CHAN, ANTHONY S. L.
E25        1  AU=CHAN, ANTHONY SAI-CHEUNG
           Enter PAGE for more

?  s e1-e25
Processing
             1   AU=CHAN, ANSON C. K.
            25   AU=CHAN, ANTHONY
             1   AU=CHAN, ANTHONY A
             9   AU=CHAN, ANTHONY A.
             1   AU=CHAN, ANTHONY ARTHUR
             1   AU=CHAN, ANTHONY BERNARD
             4   AU=CHAN, ANTHONY C.-T.
             2   AU=CHAN, ANTHONY CHIH-TUNG
             2   AU=CHAN, ANTHONY CHO-LAI
             1   AU=CHAN, ANTHONY CHUNG-FUNG
             1   AU=CHAN, ANTHONY CT
             1   AU=CHAN, ANTHONY G.
             1   AU=CHAN, ANTHONY K C
             9   AU=CHAN, ANTHONY K.
             1   AU=CHAN, ANTHONY K. C
```

```
            40   AU=CHAN, ANTHONY K. C.
             2   AU=CHAN, ANTHONY K.C.
             5   AU=CHAN, ANTHONY KAM CHUEN
             2   AU=CHAN, ANTHONY KAM-YIN
             1   AU=CHAN, ANTHONY KIN WANG
             1   AU=CHAN, ANTHONY KWOK HING
             1   AU=CHAN, ANTHONY KWOK-HING
             1   AU=CHAN, ANTHONY RIVERA
            18   AU=CHAN, ANTHONY S. L.
             1   AU=CHAN, ANTHONY SAI-CHEUNG
S11        132   S E1-E25

?  s s11 and hepatocellular
           132   S11
        294510   HEPATOCELLULAR
S12          1   S S11 AND HEPATOCELLULAR

?  d s
Set     Items   Description
S1        112   S E4-E7
S2          2   S S1 AND HEPATOCELLULAR
S3         31   S E8-E14
S4          8   S S3 AND HEPATOCELLULAR
S5         25   S E2-E7
S6          0   S S5 AND HEPATOCELLULAR
S7          2   AU='YIP, VICTOR F.' FROM 5, 6, 24, 34, 40, 41, 45, 50, 65, 71, 73,
98, 103, 136, 143, 144, 155, 156, 162, 172, 305, 369, 370, 393, 399, 434, 28, 35,
91, 110, 135, 164, 185, 357, 391, 467, 8, 99, 266, 315, 358, 149, 159, 444
S8          1   S S7 AND HEPATOCELLULAR
S9          5   S E1-E3
S10         1   S S9 AND HEPATOCELLULAR
S11       132   S E1-E25
S12         1   S S11 AND HEPATOCELLULAR

?  e au=yip, t?
Ref   Items  Index-term
E1        1  AU=YIP, T-T
E2        1  AU=YIP, T-T.
E3        0  AU=YIP, T?
E4        1  AU=YIP, TA-TUNG
E5        1  AU=YIP, TAI T.
E6       35  AU=YIP, TAI TUNG
E7       75  AU=YIP, TAI-TUNG
E8        1  AU=YIP, TAK CHUN
E9        2  AU=YIP, TAK-CHUN
E10       2  AU=YIP, TC
E11       2  AU=YIP, TERENCE
E12       2  AU=YIP, TERENCE POK SIU
E13       1  AU=YIP, TERESA
E14       2  AU=YIP, TERESA M.
E15       1  AU=YIP, TERRANCE
E16       1  AU=YIP, TERRANCE P
E17       1  AU=YIP, TERRANCE P.
E18       1  AU=YIP, TERRY SIU-HAN
E19       2  AU=YIP, THOMAS
E20       1  AU=YIP, THOMAS C.
E21       1  AU=YIP, THOMAS W. S.
E22       1  AU=YIP, THOMAS W.S.
E23       1  AU=YIP, THOMAS WAI-CHEONG
E24       1  AU=YIP, TIAN SIANG
E25      12  AU=YIP, TICK HON
         Enter PAGE for more
```

```
?
?  s e4-e7
             1   AU=YIP, TA-TUNG
             1   AU=YIP, TAI T.
            35   AU=YIP, TAI TUNG
            75   AU=YIP, TAI-TUNG
S13        112   S E4-E7

?  s s13 and hepatocellular
           112   S13
        294510   HEPATOCELLULAR
S14          2   S S13 AND HEPATOCELLULAR

?  t s14/3,k/1-2
>>>W:  KWIC option is not available in file(s): 399
 14/3,K/1 (Item 1 from file: 399)  Links
   Fulltext available through:    STIC Full Text Retrieval Options
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

140074827        CA: 140(6)74827f          JOURNAL
Comprehensive proteomic profiling identifies serum proteomic signatures for
detection of hepatocellular carcinoma and its subtypes
Author: Poon, Terence C. W.; Yip, Tai-Tung; Chan, Anthony T. C.; Yip, Christine;
Yip, Victor; Mok, Tony S. K.; Lee, Conrad C. Y.; Leung, Thomas W. T.; Ho, Stephen K.
W.; Johnson, Philip J.
Location: Department of Clinical Oncology, the Sir Y.K. Pao Centre for Cancer, The
Chinese University of Hong Kong, Hong Kong, Peop. Rep. China,
Journal: Clin. Chem. (Washington, DC, U. S.)
Date: 2003
Volume: 49 Number: 5 Pages: 752-760
CODEN: CLCHAU
ISSN: 0009-9147
Language: English
Publisher: American Association for Clinical Chemistry


 14/3,K/2 (Item 2 from file: 399)  Links
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

139321684        CA: 139(21)321684k          PATENT
Serum biomarkers in hepatocellular carcinoma
Inventor (Author): Yip, Tai-Tung; Poon, Terence C. W.; Johnson, Philip; Yip, Victor
F.; Yip, Christine L.; Chan, Anthony T. C.
Location: USA
Assignee: Ciphergen Biosystems, Inc.; The Chinese University of Hong Kong
Patent: PCT International ; WO 200386445 A1      Date: 20031023
Application: WO 2003US10489 (20030407) *US PV370239 (20020408)
Pages: 45 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
  Class:   A61K-038/00A; C07K-002/00B; C07K-004/00B; C07K-005/00B; C07K-007/00B;
C07K-014/00B; C07K-016/00B; C07K-017/00B; G01N-033/48B; G01N-033/00B; G01N-024/00B;
G01N-033/53B
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH;
CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID;
IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN;
MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN;
TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;
TM
Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG;
```

CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

```
?  s hepatocellular adj carcinoma or HCC
           0   HEPATOCELLULAR ADJ CARCINOMA
       78025   HCC
S1     78025   S HEPATOCELLULAR ADJ CARCINOMA OR HCC

?
?  s s1 and (dalton or kilodalton or kDa or Da)
       78025   S1
       35445   DALTON
       44384   KILODALTON
      752464   KDA
      509426   DA
S2       696   S S1 AND (DALTON OR KILODALTON OR KDA OR DA)

?
?  s s2 and (serum adj marker or serum adj biomarker or marker or biomarker)
         696   S2
           0   SERUM ADJ MARKER
           0   SERUM ADJ BIOMARKER
     1314164   MARKER
      137205   BIOMARKER
S3       109   S S2 AND (SERUM ADJ MARKER OR SERUM ADJ BIOMARKER OR MARKER OR
BIOMARKER)

?
?  rd
>>>W:  Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S4        56   RD  (UNIQUE ITEMS)

?  t s4/3,k/1-56
>>>W:  KWIC option is not available in file(s): 399
 4/3,K/1 (Item 1 from file: 5)  Links
   Fulltext available through:    STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rights reserved.
0019493671   Biosis No.: 200700153412
Proteomics-based identification of biomarkers for predicting sensitivity to a
PI3-kinase inhibitor in cancer

Author: Akashi Tetsuyuki; Nishimura Yumiko; Wakatabe Rumi; Shiwa Mieko; Yamori Takao
(Reprint)
Author Address: Japanese Fdn Canc Res, Div Mol Pharmacol, Canc Chemotherapy Ctr,
Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan**Japan
Author E-mail Address: yamori@jfcr.or.jp
Journal: Biochemical and Biophysical Research Communications   352 ( 2 ): p 514-521
JAN 12 2007 2007
ISSN: 0006-291X
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...integrated approach allowed us to identify peaks from two proteins,
11.6 and 11.8 kDa, that showed significant correlations with the sensitivity to a
P13K inhibitor, LY294002. We found that the 11.8 kDa protein was a phosphorylated
form of the 11.6 kDa protein. While the 11.8 kDa protein showed a positive
correlation with the sensitivity to LY294002, the 11.6 kDa protein showed a negative
correlation with that of the LY294002. The 11.6 kDa protein was purified
chromatographically, and was identified by SELDI-TOF MS as the ribosomal P2...
...for determining the sensitivity to LY294002, and that the ribosomal P2 could be a
potential biomarker for predicting chemo sensitivity. (c) 2006 Elsevier Inc. All
```

DESCRIPTORS:
Organisms: ...HCC-2998 cell line (Hominidae
Chemicals & Biochemicals: ...phosphorylation, biomarker

4/3,K/2 (Item 2 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

19132806 Biosis No.: 200600478201
Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma

Author: Orvisky Eduard; Drake Steven K; Martin Brian M; Abdel-Hamid Mohamed; Ressom Habtom W; Varghese Rency S; An Yanming; Saha Daniel; Hortin Glen L; Loffredo Christopher A; Goldman Radoslav (Reprint)
Author Address: Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, LCCC Room S183,3970 Reservoir Rd NW, Washington, DC 20057 USA**USA
Author E-mail Address: rg26@georgetown.edu
Journal: Proteomics 6 (9): p 2895-2902 MAY 2006 2006
ISSN: 1615-9853
Document Type: Article
Record Type: Abstract
Language: English

Abstract: A challenging aspect of biomarker discovery in serum is the interference of abundant proteins with identification of disease-related proteins... ...by denaturing ultrafiltration, which enables an efficient profiling and identification of peptides up to 5 kDa. We consistently detect several hundred peptide-peaks in MALDI-TOF and SELDI-TOF spectra of... ...demonstrate utility of the methods, we compared 20 enriched sera of patients with hepatocellular carcinoma (HCC) and 20 age-matched controls using MALDI-TOF. The comparison of 332 peaks at $p < 0.001$ identified 45 differentially abundant peaks that classified HCC with 90% accuracy in this small pilot study. Direct TOF/TOF sequencing of the most... ...serum facilitates an efficient discovery of peptides that could serve as biomarkers for detection of HCC as well as other diseases.

4/3,K/3 (Item 3 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

19132803 Biosis No.: 200600478198
Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach

Author: Lee I-Neng; Chen Chien-Hung; Sheu Jin-Chuan; Lee Hsuan-Shu; Huang Guan-Tam; Chen Ding-Shinn; Yu Chen-Yin; Wen Chu-Ling; Lu Fung-Jou; Chow Lu-Ping (Reprint)
Author Address: Natl Taiwan Univ, Coll Med, Grad Inst Biochem and Mol Biol, 1,Sec 1,1 Jen Ai Rd, Taipei 10018, Taiwan**Taiwan
Author E-mail Address: lupin@ha.mc.ntu.edu.tw
Journal: Proteomics 6 (9): p 2865-2873 MAY 2006 2006
ISSN: 1615-9853
Document Type: Article
Record Type: Abstract
Language: English
Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach

Abstract: Although the significant risk factors for hepatocellular carcinoma (HCC) are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death

worldwide. Thus, to identify any useful HCC-related biomarkers is still a need. We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals. A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and hepatitis C virus (HCV)related HCC. We identified this differentially expressed protein as complement C3a. The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC. The combination of SELDI-TOF MS and 2-DE provides a solution to identify disease...

4/3,K/4 (Item 4 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

19083278 Biosis No.: 200600428673
Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus

Author: Kuramitsu Yasuhiro; Harada Toshio; Takashima Motonari; Yokoyama Yuuichirou; Hidaka Isao; Iizuka Norio; Toda Tosifusa; Fujimoto Masanori; Zhang Xiulian; Sakaida Isao; Okita Kiwamu; Oka Masaaki; Nakamura Kazuyuki (Reprint)
Author Address: Yamaguchi Univ, Dept Biochem and Biomol Recognit, Sch Med, Minami Kogushi 1-1-1, Ube, Yamaguchi 7558505, Japan**Japan
Author E-mail Address: nakamura@yamaguchi-u.ac.jp
Journal: Electrophoresis 27 (8, Sp. Iss. SI): p 1651-1658 APR 2006 2006
ISSN: 0173-0835
Document Type: Article
Record Type: Abstract
Language: English

Abstract: Hepatocellular carcinoma (HCC) is one of the most common fatal cancers, and chronic infection with hepatitis C virus... ...be one of the main causes in Japan. To identify diagnostic or therapeutic biomarkers for HCC associated with HCV (HCV-HCC), we tried to elucidate the factors related to the products from cancerous tissues of HCV-infected patients. From proteomic differential display analysis of liver tissue samples from HCV-HCC cancerous tissues and corresponding non-cancerous tissues from patients, three protein spots of the same molecular mass (42 kDa), whose expression increased in well-differentiated cancerous tissues, were detected. Although their pI were different... ...The tryptic peptides of the most acidic GS isoform lost the signal of 899.5 Da, corresponding a peptide of SASIRIPR, and gained a signal of 1059.5 Da, which was submitted to PSD analysis. PSD analysis showed the neutral loss by elimination of two phosphate groups, supposed to be on serine residues of the 899.5-Da peptide, from serine 320 to arginine 327 in GS. PMF followed by PSD analysis is...
DESCRIPTORS:
Chemicals & Biochemicals: ...expression, phosphorylation, biomarker; ...
...expression, phosphorylation, biomarker

4/3,K/5 (Item 5 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

18536599 Biosis No.: 200510231099
Hepatitis B virus X protein: Structure-function relationships and role in viral pathogenesis

Book Title: Handbook of Experimental Pharmacology

Author: Kumar V (Reprint); Sarkar D P
Book Author/editor: Gossen M (Editor); Kaufmann J (Editor); Triezenberg SJ (Editor)
Author Address: Int Ctr Genet Engn and Biotechnol, Virol Grp, Aruna Asaf Ali Marg POB 10504, New Delhi 110067, India**India
Author E-mail Address: vijay@icgeb.res.in
Series Title: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 166 p 377-407 2004
Book Publisher: SPRINGER-VERLAG BERLIN, HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
ISSN: 0073-0033_(print) ISBN: 3-540-21095-4 (H)
Document Type: Book Chapter
Record Type: Abstract
Language: English

Abstract: The hepatitis B virus (HBV) genome codes for a 16.5-KDa protein termed pX or HBx which is a prevalent marker in the liver of patients with hepatitis B-associated hepatocellular carcinoma (HCC). Although the specific function of HBx in natural infection remains elusive, it is considered to play an important role in the etiology of HBV-induced HCC. It is a multifunctional regulatory protein that is best characterized as promiscuous transactivator. It can...

18187035 Biosis No.: 200500092948
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases

Author: Paradis Valerie (Reprint); Degos Francoise; Dargere Delphine; Pham Nanou; Belghiti Jacques; Degott Claude; Janeau Jean-Louis; Bezeaud Annie; Delforge Dominique; Cubizolles Myriam; Laurendeau Ingrid; Bedossa Pierre
Author Address: Serv Anat Pathol, Hop Beaujon, 100 Blvd Gen Leclerc, F-92100, Boulogne, France**France
Author E-mail Address: vparadis@teaser.fr
Journal: Hepatology 41 (1): p 40-47 January 2005 2005
Medium: print
ISSN: 0270-9139 _(ISSN print)
Document Type: Article
Record Type: Abstract
Language: English
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases

Abstract: ...any biological material studied. We used this approach to identify new biomarkers of hepatocellular carcinoma (HCC) in the sera of patients with cirrhosis. Sera from 82 patients with cirrhosis, either without (n = 38) or with (n = 44) HCC, were analyzed by SELDI-TOF MS, and the results of the two groups were compared. The most efficient protein peaks leading to discrimination of patients with HCC were selected (receiver operative characteristic curves). The highest-scoring peak combination was established in a... ...further. The intensity of 30 protein peaks significantly differed between cirrhotic patients with and without HCC. An algorithm including the six highest-scoring peaks allowed correct classification (presence or absence of HCC) of 92.5% of patients in the test sample set and 90% in the validation sample set. The highest discriminating peak (8,900 Da) was purified further and was characterized as the C-terminal part of the V10 fragment of vitronectin. An in vitro study suggested that the increase of the 8,900-Da fragment in the serum of patients with HCC may proceed from the cleavage of native vitronectin with metalloproteases, a family of enzymes whose activity is enhanced in HCC. In conclusion, global protein profiling is an efficient approach that enabled us to identify a catalytic fragment of vitronectin as a new serum marker of HCC in patients with chronic liver diseases.

4/3,K/7 (Item 7 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

17782856 Biosis No.: 200400149517
Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma.

Author: Takashima Motonari; Kuramitsu Yasuhiro; Yokoyama Yuuichiro; Iizuka Norio; Toda Toshifusa; Sakaida Isao; Okita Kiwamu; Oka Masaaki; Nakamura Kazuyuki (Reprint)

Author Address: Department of Biochemistry and Biomolecular Recognition, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan**Japan
Author E-mail Address: nakamura@yamaguchi-u.ac.jp
Journal: Proteomics 3 (12): p 2487-2493 December 2003 2003
Medium: print
ISSN: 1615-9853 _(ISSN print)
Document Type: Article
Record Type: Abstract
Language: English

Abstract: To identify proteins linked to the pathogenesis of hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV), we profiled protein expression levels in samples of HCC. To identify essential proteins, ten samples of HCV-related HCC were analyzed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time of... ...liver tissues. We focused on four members of the heat shock protein 70 family: 78 kDa glucose-regulated protein (GRP78), heat shock cognate 71 kDa protein (HSC70), 75 kDa glucose-regulated protein (GRP75), and heat shock 70 kDa protein 1 (HSP70.1). These results were confirmed by immunoblot analysis. In an additional 11... ...There has been no report describing overexpression of these four proteins simultaneously in HBV-related HCC as well as nonviral HCC. Our results suggest that these four proteins play important roles in the pathogenesis of HCV-related HCC and could be molecular targets for diagnosis and treatment of this disease.
DESCRIPTORS:
Chemicals & Biochemicals: ...biomarker; ... ...biomarker; ... ...cancer biomarker, proteomic profiling

4/3,K/8 (Item 8 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

17764972 Biosis No.: 200400132326
Identification of a new marker of hepatocellular carcinoma (HCC) by serum protein profiling of cirrhotic patients using SELDI-TOF proteinchip.

Author: Paradis Valerie (Reprint); Degos Francoise; Dargere Delphine; Pham Nanou; Belghiti Jacques; Degott Claude; Janeau Jean-Louis; Delforge Dominique; Cubizole Myriame; Bedossa Pierre
Author Address: CNRS, Hopital Beaujon, Clichy, France**France
Journal: Hepatology 38 (4 Suppl. 1): p 752A October 2003 2003
Medium: print
Conference/Meeting: 54th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, USA October 24-28, 2003; 20031024
Sponsor: American Association for the Study of Liver Diseases
ISSN: 0270-9139 _(ISSN print)
Document Type: Meeting; Meeting Abstract
Record Type: Abstract
Language: English
Identification of a new marker of hepatocellular carcinoma (HCC) by serum protein

profiling of cirrhotic patients using SELDI-TOF proteinchip.

Abstract: ...any biological material studied. We used this approach to identify new biomarkers of hepatocellular carcinomas (HCC) in serum of cirrhotic patients. Material and methods: Serum protein profiles of 83 cirrhotic patients without (n=43) or with HCC (n=40) were analysed by the SELDI-TOF technology and proteomic profiles of the two... ...were compared. The most efficient protein peaks allowing the discrimination of patients with or without HCC were selected. Diagnostic value of each peak isolated, or in combination, was assessed (ROC curves... ...An algorithm including the 5 most performing peaks allowed correct classification (presence or absence of HCC) of 93% of cases. The most performing peak (8900 Da) was further purified by sequential enrichment through affinity column, recovery of the band on a... ...profiling is a powerful approach that allowed the identification and characterisation of a new serum marker of HCC in patients with cirrhosis.

4/3,K/9 (Item 9 from file: 5) Links
Biosis Previews(R)

17660992 Biosis No.: 200400031749
SELDI-TOF-MS PROFILING OF SERUM FOR DETECTION OF HEPATOCELLULAR CARCINOMA PROGRESSION IN HEPATITIS B AND HEPATITIS C INFECTED PATIENTS.

Author: Drake Richard R (Reprint); Steel Laura F; Adam Bao-Ling; Marrero Jorge; Semmes O J; Hann Hie-Won; Block Timothy; Johnson David A
Author Address: Norfolk, VA, USA**USA
Journal: Digestive Disease Week Abstracts and Itinerary Planner 2003 p Abstract No. 755 2003 2003
Medium: e-file
Conference/Meeting: Digestive Disease 2003 FL, Orlando, USA May 17-22, 2003; 20030517
Sponsor: American Association for the Study of Liver Diseases
American Gastroenterological Association
American Society for Gastrointestinal Endoscopy
Society for Surgery of the Alimentary Tract
Document Type: Meeting; Meeting Abstract
Record Type: Abstract
Language: English

Abstract: ...HCV) and who are at high risk for the development of virus-associated hepatocellular carcinoma (HCC). METHODS: The SELDI-TOF-MS (Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry... ...of biological mixtures. In one set of experiments, serum samples from patients with HCV-related HCC (n = 8), patients with HCV cirrhosis (n= 8), patients with chronic non-cirrhotic HCV (n... ...diagnosed with HBV-associated cirrhosis, plus serum from these same 10 patients after progression to HCC were analyzed. Specimens were applied in duplicate to a Bioprocessor containing IMAC3-copper ProteinChip arrays... ...automated using the Biomek 2000 robot. Clustering and classification analyses were performed using the Ciphergen Biomarker Wizard and Biomarker Patterns software packages, respectively. The different classification trees were generated utilizing multiple protein peaks in the mass range of 2-10 kDa. RESULTS: The serum protein profiles of patients with HCV-associated HCC could be distinguished from healthy controls with a sensitivity and specificity of 81%. Profiles of... ...87%/94% in cirrhotic patients. Profiling comparisons of non-cirrhotic HCV patients with the HCV/HCC patients was effective (81%/75%), and non-cirrhotic HCV sera could be distinguished from cirrhotic... ...plus cirrhosis were compared to their matched samples taken at the time of diagnosis of HCC, differences in serum protein profiles were detected with a sensitivity of 94% and specificity of... ...system as a surveillance tool to follow progression of viral hepatitis, cirrhosis and development of HCC. Supported by the NCI Early Detection Research Network..

4/3,K/10 (Item 10 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

16847785 Biosis No.: 200200441296
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer

Author: Hoo Linda Soo; Zhang Jianying Y; Chan Edward K L (Reprint)
Author Address: Department of Molecular and Experimental Medicine, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA**USA
Journal: Oncogene 21 (32): p 5006-5015 25 July, 2002 2002
Medium: print
ISSN: 0950-9232
Document Type: Article
Record Type: Abstract
Language: English
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer

Abstract: ...II mRNA. p62 was initially shown to be recognized by auto-antibodies in hepatocellular carcinoma (HCC) but now anti-p62 has been described in diverse malignancies. p62 is uniformly expressed in fetal liver and prominently in 33% of HCC nodules, but not detectable in adult liver or normal tissue adjacent to HCC nodules. In this study, a 90 kDa protein (p90), auto-antibodies to which were found associated with anti-p62 responses in the same HCC patient group, was identified by cDNA expression cloning. Indirect immunofluorescence showed that, like p62, p90... ...anti-p62, anti-Koc, and anti-CENP-F, auto-antibodies to p90 represent a new marker for tumors such as HCC and gastric cancer. Our data support the working hypothesis that auto-antibody production in cancer ...

4/3,K/11 (Item 11 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

16847767 Biosis No.: 200200441278
Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma

Author: Zeng Jin-Zhang; Wang Hong-Yang (Reprint); Chen Zheng-Jun; Ullrich Axel; Wu Meng-Chao
Author Address: International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgical Institute, Secondary Military Medical University, 225 Changhai Road, Shanghai, 200438, China**China
Journal: Oncogene 21 (32): p 4932-4943 25 July, 2002 2002
Medium: print
ISSN: 0950-9232
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...gain new insight into the molecular mechanism underlying the pathogenesis of human primary hepatocellular carcinoma (HCC), we searched for HCC-specific molecules through screening genes that are differentially expressed between cancerous and noncancerous counterparts of liver and identified a novel HCC-associated gene, HCCA1 encoding a apprx80 kDa cytoplasmic protein that contains several proline-rich motifs likely for SH3-binding. HCCA1 transcript, albeit present in some adult tissues, is up-regulated selectively in HCC but not in other tumor cells. High expression of HCCA1 occurs as a late event... ...the degree of tumor progression. When treated with antisense oligonucleotides to HCCA1, HCCA1 expression in HCC cells (HuH-7) was effectively suppressed and cell growth was down-regulated in a time... ...data strongly suggest that HCCA1 is a positive effector in cell proliferation and contributes to HCC carcinogenesis and progression. We believe that

this protein will serve as a novel useful marker for HCC and is a potential target for pharmaceutical intervention of this malignant disease.

4/3,K/12 (Item 12 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

15335731 Biosis No.: 200000054044
Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis

Author: Correale M (Reprint); Giannuzzi V; Iacovazzi P A; Valenza M A; Lanzillotta S; Abbate I; Quaranta M; Caruso M L; Elba S; Manghisi O G
Author Address: IRCCS "S.De Bellis", Via Andrea da Bari 84, 70121, Bari, Italy**Italy
Journal: Anticancer Research 19 (4C): p 3469-3472 July-Aug., 1999 1999
Medium: print
ISSN: 0250-7005
Document Type: Article
Record Type: Abstract
Language: English

Abstract: 90K/MAC-2BP glycoprotein is a serum tumour marker, member of the scavenger receptor cysteine rich (SRCR) protein superfamily, involved in different immunological mechanisms... ...monoclonal antibody in 11 chronic active hepatitis (CAH), 48 liver cirrhosis and 36 hepatocellular carcinoma (HCC). In comparison, the same samples were also tested for AFP. According to a cut-off... ...specificity in 50 controls, we observed increasing positivities from CAH to cirrhosis and then to HCC (27%, 50% and 78%, respectively). In cirrhotic patients 90K levels were associated with the presence... ...hepatic patients. However, further investigations are needed before proposing 90K as a clinical useful tumour marker in the progression from cirrhosis to HCC.
DESCRIPTORS:
Chemicals & Biochemicals: 90-kilodalton-MAC-2BP glycoprotein... ...serum level, tumor progression marker

4/3,K/13 (Item 13 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

11842279 Biosis No.: 199396006695
A new tumor-associated antigen defined by a monoclonal antibody directed to gastric adenocarcinoma

Author: Watanabe Ryoji; Johzaki Hiroshi; Iwasaki Hiroshi (Reprint); Kikuchi Masahiro; Ikeda Seiyo
Author Address: Dep. Pathology, Fukuoka Univ. Sch. Med., 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-01, Japan**Japan
Journal: Cancer (Philadelphia) 71 (8): p 2439-2447 1993
ISSN: 0008-543X
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...In addition, the MoAb recognized cholangiocarcinomas (CC), but it did not react with hepatocellular carcinomas (HCC). Furthermore, in the combined type tumor consisting of a mixture of HCC and CC, the MoAb react only with CC element, but not with pseudoglandular structures in the HCC areas. These results indicate that FU-MK-1 is a useful antigenic marker for distinguishing HCC from CC in the liver. Furthermore, because this MoAb retains its reactivity with formalin-fixed ... ...molecular weight of the FU-MK-1 antigen was estimated to be ca. 41,000 dalton by the Western blot analysis. Periodic acid and trypsin treatment on the antigen

suggested that...

4/3,K/14 (Item 1 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

15942052 Genuine Article#: 119TJ No. References: 39
New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples

Author: Gobel T; Vorderwulbecke S; Hauck K; Fey H; Haussinger D; Erhardt A (REPRINT)

Corporate Source: Univ Dusseldorf,Klin Gastroenterol Hepatol & Infektiol,Moorenstr 5/D-40225 Dusseldorf//Germany/ (REPRINT); Univ Dusseldorf,Klin Gastroenterol Hepatol & Infektiol,D-40225 Dusseldorf//Germany/; Ciphergen Biosyst,D-16761 Hennigsdorf//Germany/
Journal: WORLD JOURNAL OF GASTROENTEROLOGY , 2006 , V 12 , N47 (DEC 21) , P 7604-7612
ISSN: 1007-9327 Publication date: 20061221
Publisher: W J G PRESS , PO BOX 2345, BEIJING 100023, PEOPLES R CHINA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: ...for detection and differentiation of liver fibrosis F1-F2), liver cirrhosis (F4) and hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV).

METHODS: Serum samples of 39 patients with F1/F2 fibrosis, 44 patients with F4 fibrosis, 34 patients with HCC were applied to CM10 arrays and analyzed using the SELDI-TOF ProteinChip System (PBS-II... ...after anion-exchange fractionation. All patients had chronic hepatitis C and histologically confirmed fibrosis stage/HCC. Data were analyzed for protein patterns by multivariate statistical techniques and artificial neural networks.

RESULTS: A 4 peptide/protein multimarker panel (7486, 12843, 44293 and 53598 Da) correctly identified HCCs with a sensitivity of 100% and specificity of 85% in a two... ...HCV-cirrhosis versus HCVHCC training samples (AUROC 0.943). Sensitivity and specificity for identification of HCC were 68% and 80% for random test samples. Cirrhotic patients could be discriminated against patients... ...F2 fibrosis using a 5 peptide/protein multimarker pattern (2873, 6646, 7775, 10525 and 67867 Da) with a specificity of 100% and a sensitivity of 85% in training samples (AUROC 0... ...a sensitivity and specificity of 80% and 67% for random test samples. Combination of the biomarker classifiers with APRI score and alfa-fetopotein (AFP) improved the diagnostic performance. The 6646 Da marker protein for liver fibrosis was identified as apolipoprotein C-I.

CONCLUSION: SELDI-TOF-MS technology...

4/3,K/15 (Item 2 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

15563913 Genuine Article#: 087AK No. References: 27
Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis

Author: Shibata R; Mori T; Du WL; Chuma M; Gotoh M; Shimazu M; Ueda M; Hirohashi S; Sakamoto M (REPRINT)
Corporate Source: Keio Univ,Sch Med, Dept Pathol, Shinjuku Ku,35 Shinanomachi/Tokyo 1608582//Japan/ (REPRINT); Keio Univ,Sch Med, Dept Pathol, Shinjuku Ku,Tokyo 1608582//Japan/; Keio Univ,Sch Med, Div Diagnost Pathol,Tokyo 1608582//Japan/; Keio Univ,Sch Med, Dept Surg,Tokyo 1608582//Japan/; Natl Canc Ctr,Res Inst, Div Pathol,Tokyo 104//Japan/ (msakamot@sc.itc.keio.ac.jp)
Journal: CLINICAL CANCER RESEARCH , 2006 , V 12 , N18 (SEP 15) , P 5363-5368

ISSN: 1078-0432 Publication date: 20060915
Publisher: AMER ASSOC CANCER RESEARCH , 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: Purpose: Hepatocellular carcinoma (HCC) associated with chronic liver disease is known to show an obvious multistage process of tumor progression. We previously identified heat shock protein 70 as a molecular marker of early HCC during investigation of expression profiling in multistage hepatocarcinogenesis. In this report, we examined cyclase-associated protein 2 (CAP2), which is also listed as an up-regulated gene in early HCC.

Experimental Design: We measured the level of CAP2 mRNA by real-time quantitative PCR. We... ...antibody against CAP2 and we confirmed the expression of CAP2 by immunoblotting and immunohistochemistry in HCC cell lines and HCC tissues.

Results: According to real-time quantitative PCR, the level of CAP2 mRNA was up-regulated in early HCC when compared with noncancerous liver tissue, and it was further up-regulated in progressed HCC. We raised a polyclonal antibody against CAP2, which showed a single 53-kDa band of strong intensity in the human HCC cell lines and HCC tissues but only a weak band in the noncancerous liver tissues in Western blot analysis. Immunohistochemical examination of CAP2 revealed its significant overexpression in early HCC when compared with noncancerous and precancerous lesions and in progressed HCC when compared with early HCC.

Conclusion: Our findings show that CAP2 is up-regulated in HCC when compared with noncancerous and precancerous lesions. This is the first report that proves that...

4/3,K/16 (Item 3 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options

14828876 Genuine Article#: 010JF No. References: 25
Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis

Author: Ward DG; Cheng Y; N'Kontchou G; Thar TT; Barget N; Wei W; Billingham LJ; Martin A; Beaugrand M; Johnson PJ (REPRINT)
Corporate Source: Univ Birmingham,Sch Med, Canc Res UK Inst Canc Studies,Birmingham B15 2TT/W Midlands/England/ (REPRINT); Univ Birmingham,Sch Med, Canc Res UK Inst Canc Studies,Birmingham B15 2TT/W Midlands/England/; Univ Paris 13,UFR SMBH, UPRES EA 3409,Heptogastroenterol & Pathol Dept, Assistance Publ Hosp ,Bondy//France/ (p.johnson@bham.ac.uk)
Journal: BRITISH JOURNAL OF CANCER , 2006 , V 94 , N2 (JAN 30) , P 287-292
ISSN: 0007-0920 Publication date: 20060130
Publisher: NATURE PUBLISHING GROUP , MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: Early diagnosis of hepatocellular carcinoma (HCC) is the key to the delivery of effective therapies. The conventional serological diagnostic test, estimation... ...to complement ultrasound scanning, the major modality for surveillance of groups at high risk of HCC. We have analysed the serum proteome of 182 patients with hepatitis C-induced liver cirrhosis (77 with HCC) by surface-enhanced laser desorption/ ionisation time-of-flight mass spectrometry (SELDI). The patients were split into a training set (84 non-HCC, 60 HCC) and a 'blind' test set (21 non-HCC, 17 HCC). Neural networks developed on the training set were able to classify the blind test set... ...and 86% specificity (95% CI 65 - 95%). Two of the SELDI peaks (23/23.5 kDa) were elevated by an average of 50% in the serum of HCC patients ($P < 0.001$) and were identified as kappa and lambda immunoglobulin light chains. This... ...identification of several individual proteins, which, in combination, may offer a novel way to diagnose HCC.
Identifiers-- ...ARTIFICIAL NEURAL-NETWORKS; CANCER; DISCOVERY; IDENTIFICATION;

BIOMARKERS; MARKER; STAGE

4/3,K/17 (Item 4 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

12700424 Genuine Article#: 811HV No. References: 33
Proteomic analysis of cholangiocarcinoma cell line

Author: Srisomsap C; Sawangareetrakul P; Subhasitanont P; Panichakul T; Keeratichamroen S; Lirdprapamongkol K; Chokchaichamnankit D; Sirisinha S; Svasti J (REPRINT)
Corporate Source: Chulabhorn Res Inst,Biochem Lab,Vibhavadee Rangsit Rd/Bangkok 10210//Thailand/ (REPRINT); Chulabhorn Res Inst,Biochem Lab,Bangkok 10210//Thailand/; Chulabhorn Res Inst,Immunol Lab,Bangkok 10210//Thailand/; Mahidol Univ,Dept Microbiol,Bangkok 10700//Thailand/; Mahidol Univ,Dept Biochem,Bangkok 10700//Thailand/
Journal: PROTEOMICS , 2004 , V 4 , N4 (APR) , P 1135-1144
ISSN: 1615-9853 Publication date: 20040400
Publisher: WILEY-V C H VERLAG GMBH , PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: ...with a higher incidence in tropical countries, such as Thailand. Distinguishing CCA from hepatocellular carcinoma (HCC) of the liver often requires the use of histochemistry, so molecular markers for diagnosis and... ...cell line (HuCCA-1) has been compared to human hepatocellular carcinoma cell lines (HepG2 and HCC-S102) and a human breast epithelial cancer cell line (MCF-7). Our results show that... ...MS (ESI-MS/MS). Cytokeratins CK8 and CK18 were overexpressed in both HuCCA-1 and HCC, while CK7 and CK19 were only expressed in HuCCA-1. Four specific proteins with MW... ...U2 showed high expression in HuCCA-1, while U1 and U4 showed high expression in HCC-S102. U2 could be separated in 2 proteins, U2/1 (alpha-enolase) and U2/2... ...HuCCA-1 by 1-DE immunodetection, and gave only one spot with MW 32.9 kDa and p/8.29 on 2-DE immunoblotting, Thus, certain proteins, namely CK7, CK19, U2...

4/3,K/18 (Item 1 from file: 45) Links
Fulltext available through: STIC Full Text Retrieval Options
EMCare

01951531 EMCare No: 44268169
Global proteomic analysis of microdissected cirrhotic nodules reveals significant biomarkers associated with clonal expansion

Guedj N.; Dargere D.; Degos F.; Janneau J.L.; Vidaud D.; Belghiti J.; Bedossa P.; Paradis V.
Dr. V. Paradis, Service d'Anatomie Pathologique, Hopital Beaujon, 110 bd du Gen. Leclerc, 92118 Clichy Cedex France
AUTHOR EMAIL: vparadis@teaser.fr
Laboratory Investigation (LAB. INVEST.) (United Kingdom) 05 SEP 2006 , 86/9 (951-958)
CODEN: LAINA ISSN: 0023-6837 eISSN: 1530-0307
PUBLISHER ITEM IDENTIFIER: 3700450
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33
RECORD TYPE: Abstract

...tissue composed of polyclonal regenerative and monoclonal neoplastic, potentially malignant nodules from which hepatocellular carcinoma (HCC) might develop. The aim of this study was to investigate proteomic profile changes

associated with... ...malignant transformation of monoclonal nodules. Seventy-one cirrhotic nodules from 10 female patients with six HCC were dissected from liver surgical specimen by laser capture microdissection. Clonal status of each nodule... ...n=26) identified three differentially expressed protein peaks (10 092, 54 025 and 62 133 Da). All were upregulated in monoclonal nodules. Twelve peaks were differentially expressed between monoclonal nodules and HCC with nine proteins upregulated in cancer samples. This study confirms that proteome analysis can be...
DESCRIPTORS:
* liver nodule; *liver cirrhosis; *biological marker

4/3,K/19 (Item 2 from file: 45) Links
Fulltext available through: STIC Full Text Retrieval Options
EMCare

01161253 EMCare No: 35332910
Differential expression of beta-galactoside alpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma

Cao Y.; Merling A.; Crocker P.R.; Keller R.; Schwartz-Albiez R.
Dr. R. Schwartz-Albiez, Division of Cellular Immunology, German Cancer Research Centre, Im Neuenheimer Feld 280, D-69120 Heidelberg Germany
AUTHOR EMAIL: r.s-albiez@dkfz.de
Laboratory Investigation (LAB. INVEST.) (United States) 01 NOV 2002 , 82/11 (1515-1524)
CODEN: LAINA ISSN: 0023-6837
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 43
RECORD TYPE: Abstract

...alpha2,6 sialyltransferase (ST6Gal I) and sialoglycans in normal liver, cirrhotic liver, and hepatocellular carcinoma (HCC) using a new ST6Gal I-specific mAb and recombinant fusion proteins of CD22 and sialoadhesin... ...in Kupffer cells, bile ducts, endothelial cells, and oval cells. Well-differentiated and moderately differentiated HCC showed Golgi and diffuse cytoplasmic staining of ST6Gal I and sialoglycans, whereas the cytoplasmic staining for ST6Gal I and sialoglycans was decreased or even absent in poorly differentiated HCC. Detection of sialoglycans by the recombinant fusion proteins in Western blots of cell lysates derived from cell lines revealed two major double bands of sialoglycoproteins at 65 and 120 kDa for hepatocytes, three major bands at 54, 49, and 44 kDa for colonic epithelial cells, and one band at 60 kDa for endothelial cells. Our results describe the expression patterns of ST6Gal I and sialoglycans in...
DESCRIPTORS:
hybrid protein; sialoglycoprotein; sialoadhesin; plasma protein; unclassified drug; cell enzyme; enzyme; marker; antigen; liver cell; intrahepatic bile duct; endothelium cell; staining; cell differentiation; bile duct; human cell... ...journal; liver cirrhosis; protein localization; rat; controlled study; cell line; protein expression; enzyme activity; disease marker; cell lysate; colon mucosa; liver disease; immunohistology; epithelium cell; animal cell

4/3,K/20 (Item 1 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0082103458 EMBASE No: 2007548023
Using protein chip technology to screen for tissue proteomic profiles and tumor markers in hepatocellular carcinoma

Li D.; Zhang J.-Z.; Zheng Y.-H. // Ji X.-L.; Shu Q.-M.; Fan L.-N. // You H. // Li

X.-C. // Zhang J.-Z.
Department of Pathology, 306 Hospital of Chinese PLA, Beijing 100101, China // Department of Pathology, General Hospital of Armed Police Force of Chinese PLA, Beijing 100080, China // Research Center of Liver Disease, Beijing Friendship Hospital, Beijing 100053, China // Department of Sergeant, Academy of Equipment Command and Technology of Chinese PLA, Beijing 102249, China // Department of Pathology, 306 Hospital of Chinese PLA, 9 Anxiang North Road, Beijing 100101, China
Author email: zhangjz55@sina.com; zhangjz55@sina.com
Corresp. Author: Zhang J.-Z.
Corresp. Author Affil: Department of Pathology, 306 Hospital of Chinese PLA, 9 Anxiang North Road, Beijing 100101, China
Corresp. Author email: zhangjz55@sina.com

World Chinese Journal of Digestology (World Chin. J. Dig.) (China) August 1, 2007 , 15/22 (2424-2430)
CODEN: SHXZF ISSN: 10093079
Document Type: Journal ; Article Record Type: Abstract
Language: Chinese Summary language: English; Chinese
Number of References: 32

...spectrometry (SELDI-TOF-MS) technique to screen for tissue biomarkers in patients with hepatocellular carcinoma (HCC), but with different clinicopathological features. METHODS: Proteomic spectra were examined and analyzed by mass spectroscopy in 44 cases, including 26 specimens of HCC tissue that had been pathologically confirmed in patients aged 34-68 years, and 18 specimens... ...cirrhosis tissue in patients aged 38-70 years. The spectra obtained were analyzed using the biomarker wizard system, and the biomarkers were defined by searching www.ExPasy.org. RESULTS: A total... ...16 distinguished proteomic biomarkers, 7 up-regulated and 9 down-regulated, were detected from screening HCC tissue, in contrast with liver cirrhosis tissue. There were significant differences in the protein peaks of different molecular masses of 4.7, 7.2 and 9.8 kDa between HCC and liver cirrhosis tissues. Eleven distinguished proteomic biomarkers were screened when comparing cases of moderately and highly differentiated HCC tissue. All proteins were confirmed by searches of www.ExPasy.org. CONCLUSION: The SELDI-TOF-MS technique offers a unique platform for proteomic detection in HCC. It is also a non-invasive method for studying proteomic changes in the development and progression of HCC.
Drug Descriptors:
tumor marker

4/3,K/21 (Item 2 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0082012034 EMBASE No: 2007451057
Artificial neural networks and decision tree model analysis of liver cancer proteomes

Luk J.M.; Lam B.Y.; Lee N.P.Y.; Ho D.W.; Chen L.; Fan S.-T. // Sham P.C. // Chen L.; Peng J.; Leng X. // Day P.J.
Department of Surgery, Center for Cancer Research, University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong // Genome Research Centre, Department of Psychiatry, University of Hong Kong, Pokfulam, Hong Kong // Department of Surgery, People's Hospital, Peking University, Beijing, China // The Manchester Interdisciplinary Biocentre, University of Manchester, Manchester, United Kingdom
Author email: jmluk@hkucc.hku.hk
Corresp. Author: Luk J.M.
Corresp. Author Affil: Department of Surgery, Center for Cancer Research, University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong
Corresp. Author email: jmluk@hkucc.hku.hk

Biochemical and Biophysical Research Communications (Biochem. Biophys. Res. Commun.) (United States) September 14, 2007 , 361/1 (68-73)

CODEN: BBRCA ISSN: 0006291X eISSN: 10902104
Publisher Item Identifier: S0006291X07014003
Item Identifier (DOI): 10.1016/j.bbrc.2007.06.172
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 25

Hepatocellular carcinoma (HCC) is a heterogeneous cancer and usually diagnosed at late advanced tumor stages of high lethality. The present study attempted to obtain a proteome-wide analysis of HCC in comparison with adjacent non-tumor liver tissues, in order to facilitate biomarkers' discovery and to investigate the mechanisms of HCC development. A cohort of 66 Chinese patients with HCC was included for proteomic profiling study by two-dimensional gel electrophoresis (2-DE) analysis. Artificial... ...employed to analyze the profiling data and to delineate significant patterns and trends for discriminating HCC from non-malignant liver tissues. Protein markers were identified by tandem MS/MS. A total... ...each with 230 consolidated protein expression intensities. Both the data-mining algorithms successfully distinguished the HCC phenotype from other non-malignant liver samples. The detection sensitivity and specificity of ANN were... ...three biological classifiers in the CART model were identified as cytochrome b5, heat shock 70 kDa protein 8 isoform 2, and cathepsin B. The 2-DE-based proteomic profiling approach combined with the ANN or CART algorithm yielded satisfactory performance on identifying HCC and revealed potential candidate cancer biomarkers.
Drug Descriptors:
biological marker--endogenous compound--ec; cathepsin B--endogenous compound--ec; cytochrome b5--endogenous compound--ec; heat shock...

4/3,K/22 (Item 3 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0081549702 EMBASE No: 2006613339
Application of surface enhanced laser desorption ionization time-of-flight mass spectrometry technology in the diagnosis of hepatocellular carcinoma

Tian Z.-B.; Kong X.-J.; Zhang C.-P. // Liu H. // Sun G.-R. // Wang B. // Tian Z.-B.
Department of Gastroenterology, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China // Department of Endoscopy, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China // Clinical Immunologic Center, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China // Department of Microbiology, Qingdao University Medical College, Qingdao 266021, Shandong Province, China // Department of Gastroenterology, Affiliated Hospital of Medical College Qingdao University, 16 Jiangsu Road, Qingdao 266003, Shandong Province, China
Author email: tianzb@qdumh.qd.sd.cn; tianzb@qdumh.qd.sd.cn
Corresp. Author: Tian Z.-B.
Corresp. Author Affil: Department of Gastroenterology, Affiliated Hospital of Medical College Qingdao University, 16 Jiangsu Road, Qingdao 266003, Shandong Province, China
Corresp. Author email: tianzb@qdumh.qd.sd.cn

World Chinese Journal of Digestology (World Chin. J. Dig.) (China) September 1, 2006 , 14/25 (2499-2503)
CODEN: SHXZF ISSN: 10093079
Document Type: Journal ; Article Record Type: Abstract
Language: Chinese Summary language: English; Chinese
Number of References: 11

AIM: To explore tumor markers for the diagnosis of hepatocellular carcinoma (HCC)

through detecting the serum protein spectrum differently expressed between hepatitis B virus (HBV) carriers and HCC patients. METHODS: We detected the serum protein spectrum in 27 HCC patients, 27 HBV carriers and 25 healthy controls using surface enhanced laser desorption ionization time... ...TOF-MS) technique, and the diagnosis model was established through analyzing the detected data by biomarker patterns software (BPS) 5.0. RESULTS: The protein peaks, which could discriminate HBV carriers from HCC patients and healthy individuals, as well as healthy individuals from HCC patients, were detected. A diagnosis model based on the detected data was established with the... ...of 93%, 96%, 84%, and sensitivity of 85%, 96%, 89%, respectively. In addition, the 8141-Da protein in HCC patients had a higher expression than that in HBV carriers (P < 10 SUP -5); the expression of 3448-Da protein was higher both in HCC patients and HBV carriers than that in healthy controls (P < 10 SUP -5), but it had no significant difference between HCC patients and HBV carriers (P > 0.05), indicating that 3448-Da protein might be a potential marker for HBV infection; 7771-Da protein was differently expressed between the three groups of patients. CONCLUSION: With a high specificity... ...quickly by SELDI-TOF-MS technique, which provides a serological way for the diagnosis of HCC.
Drug Descriptors:
plasma protein--endogenous compound--ec; tumor marker--endogenous compound--ec

4/3,K/23 (Item 4 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0081416312 EMBASE No: 2006479235
Establishment of serum protein pattern model for screening hepatocellular carcinoma by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Liu C.-B.; Pan C.-Q.; Sun L.-F. // Liu C.-B.
Taizhou Municipal Hospital, Taizhou 318000, Zhejiang Province, China // Taizhou Municipal Hospital, 381 Zhongshan Rd., Jiaojiang Dist., Taizhou 318000, Zhejiang Province, China
Author email: liuchibo@56.com; liuchibo@56.com
Corresp. Author: Liu C.-B.
Corresp. Author Affil: Taizhou Municipal Hospital, 381 Zhongshan Rd., Jiaojiang Dist., Taizhou 318000, Zhejiang Province, China
Corresp. Author email: liuchibo@56.com

World Chinese Journal of Digestology (World Chin. J. Dig.) (China) August 1, 2006 , 14/23 (2354-2357)
CODEN: SHXZF ISSN: 10093079
Document Type: Journal ; Article Record Type: Abstract
Language: Chinese Summary language: English; Chinese
Number of References: 7

...spectrometry (SELDI-TOF-MS) on WCX2 chips. The collected data were compared and analyzed by Biomarker Wizard software. RESULTS: A group of proteomic peaks were detected. The expression of five protein molecules (4477, 8943, 5181, 8617, 13 761 Da) in patients with hepatic cellular carcinoma was significantly higher than those in the controls, and the expression of 4477- and 13 761-Da proteins were higher while the 4097-Da one was lower in HCC patients than cirrhosis ones. The specificity and sensitivity of SELDI-TOF-MS were 100% (60/60) and 90% (18/20), respectively. Four protein molecules (4477, 8943, 13 761, 4097 Da) were screened as a proteomic model. CONCLUSION: The discovered serum protein pattern model can efficiently...

4/3,K/24 (Item 5 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0075922659 EMBASE No: 1994352496

Expression of peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase enzyme and its mRNA in peroxisome proliferator-induced liver tumors

Rao M.S.; Ide H.; Yeldandi A.V.; Kumar S.; Reddy J.K.
Department of Pathology, NW University Medical School, 303 East Chicago Avenue, Chicago, IL 60611, United States
Corresp. Author: Rao M.S.
Corresp. Author Affil: Department of Pathology, Northwestern Univ. Medical School, 303 East Chicago Avenue, Chicago, IL 60611, United States

Carcinogenesis (CARCINOGENESIS) (United Kingdom) November 1, 1994 , 15/11 (2619-2622)
CODEN: CRNGD ISSN: 01433334
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 27

...to the adjacent non-neoplastic liver. SDS-polyacrylamide gel electrophoresis of postnuclear fractions of six HCC and adjacent liver tissue showed a marked increase in an 80 kDa polypeptide. Immunoblot and Northern blot analysis showed a marked increase in PBE enzyme and PBE mRNA respectively in HCC and adjacent non-neoplastic liver tissue. In control livers (animals not treated with peroxisome proliferators...
Drug Descriptors:
antibody; ciprofibrate; prasterone; tumor marker

4/3,K/25 (Item 1 from file: 144) Links
Pascal

15962183 PASCAL No.: 03-0105753

Expression of p33 SUP I SUP N SUP G SUP 1 in hepatocellular carcinoma: Relationships to tumour differentiation and cyclin E kinase activity

OHGI T; MASAKI T; NAKAI S; MORISHITA A; YUKIMASA S; NAGAI M; MIYAUCHI Y; FUNAKI T; KUROKOHCHI K; WATANABE S; KURIYAMA S
Third and First Depts. of Internal Medicine, Kagawa Medical University, Miki-cho, Kita-gun, Kagawa, Japan
Journal: Scandinavian journal of gastroenterology
, 2002, 37 (12
) 1440-1448
Language: English

... 1 (ING1) is a new candidate for the tumour suppressor gene that encodes a 33k Da protein (p33 SUP I SUP N SUP G SUP 1). While reduction of p33 SUP...
... expression of p33 SUP I SUP N SUP G SUP 1 in human hepatocellular carcinoma (HCC) remains to be examined. We evaluated p33 SUP I SUP N SUP G SUP 1 expression in various liver diseases including HCC. Methods: Expression of p33 SUP I SUP N SUP G SUP 1 was evaluated immunohistochemically...

... the normal liver (n = 5), hut also in specimens of chronic hepatitis (n = 39) and HCC (n = 86). We also analysed the relationship between p33 SUP I SUP N SUP G...

...Results: Expression of p33 SUP I SUP N SUP G SUP 1 was reduced in HCC , especially in moderately and poorly differentiated HCCs, and

those at advanced stages. Furthermore, expression of...

... G SUP 1 may contribute to the process of malignant transformation, progression and dedifferentiation of HCC via an increase of cyclin E kinase activity.

English Descriptors: Hepatocellular carcinoma; Tumoral marker; Tumor suppressor gene; Tumor progression; Mechanism of action; Increase; Enzymatic activity; Cyclin E; Kinase; Cell...

4/3,K/26 (Item 2 from file: 144) Links
Pascal

15778005 PASCAL No.: 02-0491582

Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer

SOO HOO Linda; ZHANG Jianying Y; CHAN Edward K L
WM Keck Autoimmune Disease Center and DNA Core Laboratory for Structural Analysis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California, CA 92037, United States
Journal: Oncogene : (Basingstoke), 2002, 21 (32) 5006-5015
Language: English

Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer
... II mRNA. p62 was initially shown to be recognized by auto-antibodies in hepatocellular carcinoma (HCC) but now anti-p62 has been described in diverse malignancies. p62 is uniformly expressed in fetal liver and prominently in 33% of HCC nodules, but not detectable in adult liver or normal tissue adjacent to HCC nodules. In this study, a 90 kDa protein (p90), auto-antibodies to which were found associated with anti-p62 responses in the same HCC patient group, was identified by cDNA expression cloning. Indirect immunofluorescence showed that, like p62, p90...

... anti-p62, anti-Koc, and anti-CENP-F, auto-antibodies to p90 represent a new marker for tumors such as HCC and gastric cancer. Our data support the working hypothesis that auto-antibody production in cancer ...

4/3,K/27 (Item 1 from file: 135) Links
NewsRx Weekly Reports

0000553015 (USE FORMAT 7 OR 9 FOR FULLTEXT)

National Taiwan University, Taiwan, scientists detail new medical studies and findings

Pharma Business Week, June 25, 2007, p.2637

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1097

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). "Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University. "We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals. "A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported. "The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed. They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/28 (Item 2 from file: 135) Links
NewsRx Weekly Reports

0000544063 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Results of recent studies reported by University of Toronto, Canada

Science Letter, June 12, 2007, p.3027

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1254

...TEXT: cancer. "Tumor recurrence remains the major cause of death after curative resection for hepatocellular carcinoma (HCC). The purpose of this study was to identify risk factors for the recurrence of HCC and to examine long-term outcomes after resection," scientists in Toronto, Canada report. "From July...
...2004, 193 consecutive patients who underwent hepatic resection as primary therapy with curative intent for HCC were included in this single-center analysis. The perioperative mortality rate was 5%. Time to...

...Despite recurrences in >50% of patients, long-term survival can be achieved after resection of HCC," wrote S.A. Shah and colleagues, University of Toronto, Department of Surgery. The researchers concluded...
... Avenue, Toronto, ON M4N 3M5, Canada. Study 3: The Mycobacterium marinum early secretory antigenic 6 kDa/culture filtrate protein 10 secretion system modulates phagosome maturation. "Virulence of Mycobacterium tuberculosis and related pathogenic mycobacteria requires the secretion of early secretory antigenic 6 kDa (ESAT-6) and culture filtrate protein 10 (CFP-10), two small proteins that lack traditional...

...were analyzed in infected macrophages by confocal and electron microscopy using the late endosome/lysosome marker LAMP-1, along with various fluid-phase markers such as rhodamine-dextran and ferritin and ...

4/3,K/29 (Item 3 from file: 135) Links
NewsRx Weekly Reports

0000527462 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' work from National Taiwan University, Taiwan, adds to body of knowledge

Life Science Weekly, May 22, 2007, p.5019

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1074

...TEXT: 100 ms or longer 6 h postresuscitation predicts poor survival outcomes and serves as a marker of poor prognosis." Chang and colleagues published their study in Intensive Care Medicine (Postresuscitation myocardial...
... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). "Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University. "We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A

total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals. "A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported. "The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed. They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/30 (Item 4 from file: 135) Links
NewsRx Weekly Reports

0000504046 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent studies involving Keio University, Japan, highlighted

Pharma Business Week, April 23, 2007, p.2613

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1219

...TEXT: in multistage hepatocarcinogenesis," are detailed in a study published in Clinical Cancer Research. "Hepatocellular carcinoma (HCC) associated with chronic liver disease is known to show an obvious multistage process of tumor progression. We previously identified heat shock protein 70 as a molecular marker of early HCC during investigation of expression profiling in multistage hepatocarcinogenesis," scientists writing in the journal Clinical Cancer...

...associated protein 2 (CAP2), which is also listed as an up-regulated gene in early HCC. We measured the level of CAP2 mRNA by real-time quantitative PCR. We raised a...

...antibody against CAP2 and we confirmed the expression of CAP2 by immunoblotting and immunohistochemistry in HCC cell lines and HCC tissues. According to real-time quantitative PCR, the level of CAP2 mRNA was up-regulated in early HCC when compared with noncancerous liver tissue, and it was further up-regulated in progressed HCC. We raised a polyclonal antibody against CAP2, which showed a single 53-kDa band of strong intensity in the human HCC cell lines and HCC tissues but only a weak band in the noncancerous liver tissues in Western blot analysis. Immunohistochemical examination of CAP2 revealed its significant overexpression in early HCC when compared with noncancerous and precancerous lesions and in progressed HCC when compared with early HCC. Our findings show that CAP2 is

up-regulated in HCC when compared with noncancerous and precancerous lesions," wrote R. Shibata and colleagues, Keio University, National...

4/3,K/31 (Item 5 from file: 135) Links
NewsRx Weekly Reports

0000493315 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from National Taiwan University, Taiwan, highlight most recent findings

Life Science Weekly, April 10, 2007, p.4318

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1118

...TEXT: received surgical resection," is now available. According to a study from Taipei, Taiwan, "Hepatocellular carcinoma (HCC) is one the most common malignancies in the world. As the prognosis for HCC patients is poor, the quality of life (QOL) is becoming more important on the outcome assessments." "The aim of this study was to evaluate QOL in HCC patients. A total of 161 patients with HCC were enrolled at a university hospital. Most of these patients received surgical resections. They were...

...WHOQOL-BREF, EORTC QLQ-C30, and utility measures. The WHOQOL-BREF domain scores for the HCC patients were compared to healthy normative Taiwan population, using general linear models controlling for gender...

...explore association between a better QOL and clinical/sociodemographic variables. Compared with healthy people, the HCC patients had reduced QOL in physical domains, but better environmental QOL. After controlling gender, age, education, and employment, duration of HCC more than 1 year was associated with better QOL scores. WHOQOL-BREF could be cross-validated with EORTC QLQ-C30. Survival over 1 year was associated with better QOL in HCC patients," wrote L.J. Lee and colleagues, National Taiwan University. The researchers concluded: "WHOQOL-BREF could be a valid QOL instrument for the assessments of QOL in HCC patients." Lee and colleagues published the results of their research in the Journal of Surgical...

...C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). "Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University. "We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48

patients with chronic hepatitis and 9 healthy individuals. "A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported. "The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed. They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

n Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/32 (Item 6 from file: 135) Links
NewsRx Weekly Reports

0000466630 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research by Kanazawa University, Japan, advances understanding of human health

Pharma Business Week, March 12, 2007, p.1779

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1053

Study 1: Researchers detail in "Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy," new data in systemic sclerosis...
...polymyositis (PM). In this study, we identified a novel MSA reactive with 155 and 140 kDa nuclear proteins [anti-155/140 antibody (Ab)] and determined the clinical feature of DM patients...

...immunofluorescence staining. Seven of the 52 (13%) Japanese patients with DM immunoprecipitated 155 and 140 kDa proteins from 35S-labelled K562 leukaemia cell extract. No patients with SLE, systemic sclerosis or...

...novel MSA is associated with cancer-associated DM and may serve as a diagnostic serological marker for this specific subset."

Kaji and colleagues published their study in Rheumatology (Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology, 2007;46(1):25...

...AFP)-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma (HCC).

"AFP has been proposed as a potential target for T-cell-based immunotherapy for HCC, but the number of its epitopes that have been identified is limited and the status of AFP-specific immunological responses in HCC patients has not been well-characterized.

"To address the issue," wrote E. Mizukoshi and colleagues...

...analyzed the relationship between its frequency of occurrence and clinical features associated with patients having HCC."
They continued, "Five AFP-derived peptides containing HLA-A*2402 binding motifs and showing high...

...Analyses of the relationships between AFP-specific CTL responses and clinical features of patients with HCC revealed that AFP epitopes were more frequently recognized by CTLs in patients with advanced HCC correlating to tumor factors or the stage of TNM classification. The analyses of CTL responses before and after HCC treatments showed that the treatments changed the frequency of AFP-specific CTLs," the authors reported...

...epitopes derived from AFP. The newly identified AFP epitopes could be a valuable component of HCC immunotherapy and for analyzing host immune responses to HCC."
Mizukoshi and colleagues published their study in International Journal of Cancer (Identification of alpha-fetoprotein...

4/3,K/33 (Item 7 from file: 135) Links
NewsRx Weekly Reports

0000461760 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New findings from National Taiwan University, Taiwan, described

Pharma Business Week, March 5, 2007, p.2661

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1149

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).
"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.
"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.
"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.
"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/34 (Item 8 from file: 135) Links.
NewsRx Weekly Reports

0000433458 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Scientists from National Taiwan University, Taiwan, publish new research findings

Science Letter, February 6, 2007, p.2150

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1044

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...biomarkers."

Lee and colleagues published their study in (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/35 (Item 9 from file: 135) Links
NewsRx Weekly Reports

0000431300 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from Heinrich-Heine University have provided new information about hepatocellular cancer

Biotech Business Week, February 5, 2007, p.104

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
491

...TEXT: for detection and differentiation of liver fibrosis (F1-F2), liver cirrhosis (F4) and hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV). Serum samples of 39 patients with F1/F2 fibrosis, 44 patients with F4 fibrosis, 34 patients with HCC were applied to CM10 arrays and analyzed using the SELDI-TOF ProteinChip System (PBS-IIc...

...after anion-exchange fractionation.".

"All patients had chronic hepatitis C and histologically confirmed fibrosis stage/HCC. Data were analyzed for protein patterns by multivariate statistical techniques and artificial neural networks. A 4 peptide/protein multimarker panel (7486, 12,843, 44,293 and 53,598 Da) correctly identified HCCs with a sensitivity of 100% and specificity of 85% in a two way-comparison of HCV-cirrhosis versus HCV-HCC training samples (AUROC 0.943). Sensitivity and specificity for identification of HCC were 68% and 80% for random test samples. Cirrhotic patients could be discriminated against patients...

...using a 5 peptide/protein multimarker pattern (2873, 6646, 7775, 10,525 and 67,867 Da) with a specificity of 100% and a sensitivity of 85% in training samples (AUROC 0...

...a sensitivity and specificity of 80% and 67% for random test samples. Combination of the biomarker classifiers with APRI score and alfa-fetopotein (AFP) improved the diagnostic performance. The 6646 Da marker protein for liver fibrosis was identified as apolipoprotein C-I. SELDI-TOF-MS technology combined...

4/3,K/36 (Item 10 from file: 135) Links
NewsRx Weekly Reports

0000421039 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Scientists at Keio University, National Cancer Center Research Institute describe research in cancer immunology

Clinical Oncology Week, January 29, 2007, p.230

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
413

...TEXT: in multistage hepatocarcinogenesis," are detailed in a study published in Clinical Cancer Research. "Hepatocellular carcinoma (HCC) associated with chronic liver disease is known to show an obvious multistage process of tumor progression. We previously identified heat shock protein 70 as a molecular marker of early HCC during investigation of expression profiling in multistage hepatocarcinogenesis," scientists writing in the journal Clinical Cancer...

...associated protein 2 (CAP2), which is also listed as an up-regulated gene in early HCC. We measured the level of CAP2 mRNA by real-time quantitative PCR. We raised a...

...antibody against CAP2 and we confirmed the expression of CAP2 by immunoblotting and immunohistochemistry in HCC cell lines and HCC tissues. According to real-time quantitative PCR, the level of CAP2 mRNA was up-regulated in early HCC when compared with noncancerous liver tissue, and it was further up-regulated in progressed HCC. We raised a polyclonal antibody against CAP2, which showed a single 53-kDa band of strong intensity in the human HCC cell lines and HCC tissues but only a weak band in the noncancerous liver tissues in Western blot analysis. Immunohistochemical examination of CAP2 revealed its significant overexpression in early HCC when compared with noncancerous and precancerous lesions and in progressed HCC when compared with early HCC. Our findings show that CAP2 is up-regulated in HCC when compared with noncancerous and precancerous lesions," wrote R. Shibata and colleagues, Keio University, National...

4/3,K/37 (Item 11 from file: 135) Links
NewsRx Weekly Reports

0000414604 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New hepatocellular carcinoma study findings recently were reported by scientists in Japan

Hepatitis Weekly, January 22, 2007, p.93

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1100

... 1 (YB-1), the prototype member of this family, is reported to be a prognostic marker of malignant diseases other than hepatocellular carcinoma," wrote M. Yasen and colleagues, Juntendo University.

"The...
...region was related to the nuclear localization of dbpA."

DbpA was a more significant prognostic marker of hepatocellular carcinoma than YB-1," the authors reported.

They concluded, "The T-to-G...

...study from Japan has documented clinical features of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and their association with alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II.

"We investigated the differences in clinical features between AFP-predominant HCC and protein induced by vitamin K absence or antagonist-II (PIVKA-II)-predominant HCC, especially regarding host factors thought to contribute to hepatocarcinogenesis in chronic hepatitis C virus (HCV) infection," wrote Y. Yano and colleagues, Saga Social Insurance Hospital.

"HCV-related HCC patients (n=306) were divided into four groups according to median AFP (48.1 ng...

...platelet count (x 10 /ml) were, respectively, 81, 67, and 8.2 in AFP-predominant HCC (group A; n=66) vs. 50, 42, and 11.4 in PIVKA-II-predominant HCC (group P; n=52)," the authors reported.

"Tumor sizes (mm) in groups A and P...

...nodule in group A, and albumin and tumor distribution in group P. PIVKA-II-predominant HCC had a milder hepatitis and a better-preserved platelet count compared with AFP-predominant HCC," the investigators wrote.

The scientists concluded, "Considering the strong relation between hepatocarcinogenesis and hepatic inflammation with chronic HCV infection, these differences indicate that hepatocarcinogenic mechanisms in PIVKA-II-predominant HCC may differ from those in AFP-predominant HCC."

Yano and colleagues published their study in (Clinical features of hepatitis C virus-related hepatocellular...

...researchers in Japan reported on a proteomic analysis of autoantibodies in patients with hepatocellular carcinoma (HCC).

"To detect autoantibodies that could be diagnostic markers for HCC, we analyzed serum autoantibodies comprehensively that showed immunoreactivity to proteins in tumor tissue obtained from patients with HCC. Fifteen paired samples of HCC tissue and corresponding nontumorous liver tissue as well as five normal liver tissue samples were ...

...DE gels were identified by LC-MS/MS. These immunoreactive proteins were heat shock 70 kDa protein 1 (HSP70), glyceraldehyde 3-phosphate dehydrogenase, peroxiredoxin, and manganese superoxide dismutase (Mn-SOD).

"In HCC sera, occurrences of autoantibodies against these proteins were 7/15 (46.7%), 5/15 (33...

...statistical analysis, autoantibodies against FISP70, peroxiredoxin, and Mn-SOD showed significantly high-frequency immunoreaction in HCC sera," the scientists wrote.

The authors concluded, "The three antibodies were considered patient-specific antibodies in HCC and may be candidate diagnostic biomarkers for HCC."

Takashima and colleagues published their study in (Proteomic analysis of autoantibodies in patients with hepatocellular...

4/3,K/38 (Item 12 from file: 135) Links
NewsRx Weekly Reports

0000412955 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from Chinese University of Hong Kong, People's Republic of China, publish new studies and findings

Pharma Business Week, January 22, 2007, p.1086

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1169

... According to recent research from Hong Kong, People's Republic of China, "A monomeric 17-kDa hemolysin designated as eryngeolysin was isolated from fresh fruiting bodies of the mushroom Pleurotus eryngii...

...China, quality of life (QoL) is predictive of survival in patients with unresectable hepatocellular carcinoma (HCC).
"Patients with unresectable HCC have a dismal prognosis. The objective of this study was to evaluate whether patient-reported...

...and colleagues, Chinese University of Hong Kong.
"Two hundred and thirty-three patients with unresectable HCC (mainly hepatitis B-associated) who were recruited into two separate randomized phase III clinical studies...

...QoL questionnaire, were associated with longer survival," the investigators wrote.
They concluded, "In the studied HCC population, patient-reported baseline QoL provides additional prognostic information that supplements traditional clinical factors, and is a new prognostic marker for survival for patients with unresectable HCC."
Yeo and colleagues published the results of their research in Annals of Oncology (Quality of...

4/3,K/39 (Item 13 from file: 135) Links
NewsRx Weekly Reports

0000398205 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' work from University of Tokyo, Japan, adds to cancer treatment body of knowledge

Clinical Oncology Week, January 8, 2007, p.532

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1079

...TEXT: using three tumor markers" new findings in hepatocellular cancer. "Three tumor markers for hepatocellular carcinoma (HCC) are available in daily practice in Japan: alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP...
...fraction of alpha-fetoprotein (AFP-L3). To elucidate the predictability of these tumor markers on HCC recurrence after curative ablation, we enrolled 416 consecutive patients with naove HCC who had been treated by percutaneous ablation at our department from July 1997 to December...
"Tumor marker levels were determined immediately before and 2 months after the treatment. Complete ablation was defined...

...of Gastroenterology.
The researchers concluded: "Tumor markers pre-and post-ablation were significant predictors for HCC recurrence and can complement imaging modalities in the evaluation of treatment efficacy."
Tateishi and colleagues...

...Japan.
Study 2: Recent research from Japan has reported on the identification of TOMM34 (34 kDa-translocase of the outer mitochondrial membrane), which shows elevated expression in the majority of human...

4/3,K/40 (Item 14 from file: 135) Links
NewsRx Weekly Reports

0000378742 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Journal reports outline National Taiwan University, Taiwan, research

Life Science Weekly, December 12, 2006, p.901

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1096

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).
"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.
"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/41 (Item 15 from file: 135) Links
NewsRx Weekly Reports

0000371573 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from National Taiwan University, Taiwan, report details of new studies and findings

Biotech Business Week, November 27, 2006, p.530

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1143

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification

of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/42 (Item 16 from file: 135) Links
NewsRx Weekly Reports

0000367319 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New data from Kumamoto University, Japan, shed light on cancer treatment research

Cancer Vaccine Week, November 20, 2006, p.12

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1011

According to investigators in Japan, "Heat shock protein (HSP) 105 is a 105-kDa protein, recently discovered by serological analysis of recombinant cDNA expression libraries prepared from tumor cells...

...hepatocellular carcinoma.

"We previously reported that glypican-3 (GPC3) was overexpressed, specifically in hepatocellular carcinoma (HCC) and melanoma in humans, and it was useful as a novel tumor marker. We also reported that the preimmunization of BALB/c mice with dendritic cells pulsed with...

...GPC3 peptide therefore seemed to be useful for the immunotherapy of HLA-A24+ patients with HCC and melanoma," scientists in Japan report.

"In this report, we investigated whether the GPC3298-306...

...GPC3-reactive CTLs from the peripheral blood mononuclear cells (PBMC) of HLA-A24 (A*2402)+ HCC patients," said Hiroyuki Komori at Kumamoto University and collaborators in Japan. "In addition, we used...

...restricted GPC3 epitopes to expand the applications of GPC3-based immunotherapy to the HLA-A2+ HCC patients. We found that the GPC3 (FVGEFFTDV) peptide could induce peptide-reactive CTLs in HLA...

...without inducing autoimmunity."

Komori and colleagues reported, "In five out of eight HLA-A2+ GPC3+ HCC patients, the GPC3 peptide-reactive CTLs were generated from PBMCs by in vitro stimulation with...

...peptide-reactive CTLs were also generated from PBMCs in four of six HLA-A24+ GPC3+ HCC patients."

The researchers concluded: "The inoculation of these CTLs reduced the human HCC tumor mass implanted into nonobese diabetic/severe combined immunodeficiency mice. Our study raises the possibility...

...these GPC3 peptides may therefore be applicable to cancer immunotherapy for a large number of HCC patients."

Komori and colleagues published their study in Clinical Cancer Research (Identification of HLA-A2...

4/3,K/43 (Item 17 from file: 135) Links
NewsRx Weekly Reports

0000337170 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from Israel, Taiwan and France add new findings to diagnostics body of knowledge

AIDS Weekly, September 25, 2006, p.58

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1156

... Recently, non-invasive biomarkers have been used to assess histological features. The most thoroughly evaluated biomarker is the FibroTest (FT) (AUROC 0.80 for fibrosis stages F2F3F4 vs. F0F1)."

Y. Maor...

...is in concordance with APRI and/or Forns, then we may confidently rely on the biomarker," reported the authors.

"Concordance rate for patients with presumably advanced or minimal liver disease was...

...C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/44 (Item 18 from file: 135) Links
NewsRx Weekly Reports

0000327571 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent findings in diagnostics described by researchers from Taiwan, the United States and France

Cancer Weekly, August 22, 2006, p.409

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1156

...TEXT: C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...
...to cancer researchers in the United States, the "utility of EBV load as a tumor marker" in NPC patients "suggests that it might also serve as a screening test for individuals...

4/3,K/45 (Item 19 from file: 135) Links
NewsRx Weekly Reports

0000319893 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New findings from Taiwan, the United States and France in the area of diagnostics described

Cancer Weekly, July 25, 2006, p.393

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1156

...TEXT: C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...
...to cancer researchers in the United States, the "utility of EBV load as a tumor marker" in NPC patients "suggests that it might also serve as a screening test for individuals...

4/3,K/46 (Item 20 from file: 135) Links
NewsRx Weekly Reports

0000316265 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Complement C3a may be diagnostic of chronic hepatitis C and HCV-related HCC

Cancer Weekly, July 11, 2006, p.139

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
360

Complement C3a may be diagnostic of chronic hepatitis C and HCV-related HCC

...TEXT: C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

4/3,K/47 (Item 21 from file: 135) Links
NewsRx Weekly Reports

0000198973 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Protein profiles find cancer markers in patients with chronic liver disease

Cancer Vaccine Week, March 14, 2005, p.31

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
421

...TEXT: any biological material studied. We used this approach to identify new biomarkers of hepatocellular carcinoma (HCC) in the sera of patients with cirrhosis.".

"Sera from 82 patients with cirrhosis, either without (n=38) or with (n=44) HCC, were analyzed by SELDI-TOF MS, and the results of the two groups were compared...

...Anatomical Pathology service wrote.

"The most efficient protein peaks leading to discrimination of patients with HCC were selected (receiver operative characteristic curves). The highest-scoring peak combination was established in a...

...further.

"The intensity of 30 protein peaks significantly differed between cirrhotic patients with and without HCC. An algorithm including the 6 highest-scoring peaks allowed correct classification (presence or absence of HCC) of 92.5% of patients in the test sample set and 90% in the validation sample set. The highest discriminating peak (8900 Da) was purified further and was characterized as the C-terminal part of the V10 fragment of vitronectin.

"An in vitro study suggested that the increase of the 8900-Da fragment in the serum of patients with HCC may proceed from the cleavage of native vitronectin with metalloproteases, a family of enzymes whose activity is enhanced in HCC," researchers commented.

"In conclusion, global protein profiling is an efficient approach that enabled us to identify a catalytic fragment of vitronectin as a new serum marker of HCC in patients with chronic liver diseases," they said.

Paradis and colleagues published their study in Hepatology (Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology, 2005 ...

4/3,K/48 (Item 22 from file: 135) Links
NewsRx Weekly Reports

0000003188 (USE FORMAT 7 OR 9 FOR FULLTEXT)

"Liposomes for Targeted Gene Delivery in Vivo: Intracellular Fate of Liposome-Encapsulated DNA in Rodent Lines."

Gene Therapy Weekly, July 31, 1995, p.13

DOCUMENT TYPE: Research News LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
584

...TEXT: the tissue. Part of this DNA follows the subcellular fractionation profile of the mitochondrial matrix marker, malate dehydrogenase. In contrast, 14% of the liposomal DNA taken up by the liver was...

...by covalently attaching a monoclonal antibody (AF-20) which recognizes with high affinity a 180 KDa cell surface glycoprotein that is abundantly expressed on the surface of human HCC cells and that undergoes rapid internaliation upon antibody binding. A plasmid containing the lac Z...

4/3,K/49 (Item 1 from file: 357) Links
Derwent Biotech Res.

0304067 DBA Accession No.: 2003-05852 PATENT
Diagnosing neoplasm and inhibiting tumor growth, by contacting tissue of mammal with detectably-labeled antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase antibody production against enzyme protein, vector expression in host cell for use in disease gene therapy

Author: WANDS J R; DE LA MONTE S M; DEUTCH A H; GHANBARI H A
Patent Assignee: WANDS J R; DE LA MONTE S M; DEUTCH A H; GHANBARI H A 2002
Patent Number: US 20020110559 Patent Date: 20020815 WPI Accession No.: 2003-066676 (200306)
Priority Application Number: US 859604 Application Date: 20010517
National Application Number: US 859604 Application Date: 20010517
Language: English
Abstract: ...a transfection enhancing agent. Preferred Kit: The kit further comprises a means (e.g. detectable marker such as radioactive compound or Gd3+ or Fe++, for detecting binding of (I) to the... ...were specifically overexpressed in transformed malignant cells of human hepatocyte origin, the FOCUS hepatocellular carcinoma (HCC) cell line was used as an immunogen to generate monoclonal antibodies (mAb) that specifically or... ...recognize proteins associated with the malignant phenotype. A lambdagt11 cDNA expression library derived from HepG2 HCC cells was screened, ...cultures that were 70-80% confluent demonstrated that constitutively increased levels of AAH expression (85 kDa) in pHAAH-transfected cells were associated with significantly increased levels of PCNA (35 kDa) and Bcl-2 (25 kDa) and reduced levels of p21/Wafl (21 kDa) and p16 (16 kDa). However, the pHAAH stable transfectants also exhibited higher levels of wild-type p53 (53-55 kDa). Although AAH expression (85 kDa protein) in the stable transfectants was increased by only 75-100%, the levels of p16...

4/3,K/50 (Item 1 from file: 266) Links
FEDRIP

00599661
Identifying No.: 2R01CA093840-05A2 Agency Code: CRISP
Genesis of Liver Carcinomas with Oval Cell Traits

Principal Investigator: HIXSON, DOUGLAS C
Address: DOUGLAS HIXSON@BROWN.EDU RHODE ISLAND HOSPITAL 593 EDDY STREET PROVIDENCE, RI 02903
Performing Org.: RHODE ISLAND HOSPITAL (PROVIDENCE, RI) , PROVIDENCE , RHODE ISLAND
Sponsoring Org.: NATIONAL CANCER INSTITUTE
Dates: 2004/01/02 To 2005/31/12 Fy : 2007
Summary: ...role in hepato-and cholangio-carcinogenesis. Over the past 4 years, our studies of cholangiocyte marker positive (CMP), bipotent, fetal liver epithelial cells (FLEC) have yielded novel monoclonal antibody based schemes... ...oval cells and will retain this capacity following spontaneous transformation in vitro and progression to HCC in vivo. In Specific Aim 1, we will employ a rapid transplantation model that replaces... ...with mitomycin C (mitoC/PH) to test the hypothesis that the expression of the cholangiocyte marker OC.4, a marker first seen at 2 after birth, identifies mature CMP-LEC that have a greatly diminished... ...BDEC will undergo incomplete hepatocytic differentiation in mitoC/PH treated rats

and progress to CMP-HCC. Spontaneous transformation of CMP-LEC will be accelerated by selection on plastic and/or soft... ...invasive growth. Specific Aim 4 will continue with the characterization of BD.1, a 170 kDa protein expressed by cholangiocytes but not oval cells that forms stable complexes with CLIP170, a...

4/3,K/51 (Item 1 from file: 149) Links
TGG Health&Wellness DB(SM)

02944498 Supplier Number: 106422241 (USE FORMAT 7 OR 9 FOR FULL TEXT)
The role of genetic polymorphisms in environmental health. (Research Review).

Kelada, Samir N.; Eaton, David L.; Wang, Sophia S.; Rothman, Nathaniel R.; Khoury, Muin J.
Environmental Health Perspectives , 111 , 8 , 1055(10)
June 15 ,
2003
Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
Word Count: 11400 Line Count: 01145

...sub.1), a mycotoxin found in some foodstuffs, and an established risk for hepatocellular carcinoma (HCC), especially when combined with hepatitis virus exposure (Ross et al. 1992). The biotransformation of aflatoxin...

...a lack of enzyme and less active enzyme, respectively, was shown to result in increased HCC risk (London et al. 1995; McGlynn et al. 1995). Similarly, functional variants in CYP1A2 and...

...phase I metabolism (epoxidation) of aflatoxin (B.sub.1), would also be expected to modify HCC risk in exposed persons, although epidemiologic data for this have not yet been gathered. Biomarker studies of urinary aflatoxin metabolites and aflatoxin--albumin adducts in peripheral blood have validated their use as indicators of HCC risk at the group level, and polymorphisms in GSTM1 and EPHX1 yielded higher levels of...

...studies of exposures to environmental toxicants and toxins. Stratification of a studied health outcome or biomarker by relevant genotype (or phenotype) may allow for detection of different levels of risk among...

...epidemiologic studies and ultimately contributed to the development of a chemoprevention strategy for aflatoxin-induced HCC.
Additionally, studies on the health effects of exposure to regulated environmental contaminants that incorporate genetic...

profiles	UROD	
Alcohol	Esophageal cancer	ALDH2
Aflatoxin (B.sub.1)	Aflatoxin-albumin adducts	CYP1A2
		CYP3A4
	HCC	GSTM1
		EPHX1
Heterocyclic amines	Colon cancer	NAT2
	Breast cancer	NAT2
		SULT1A1
Aromatic amines	Bladder cancer...	

...Binkova B, Lewtas J, Miskova I, Rossner P, Cerna M, Mrackova G, et al. 1996. Biomarker studies in northern Bohemia. Environ Health Perspect

104:591-597.
Botto LD, Khoury MJ. 2001...

...Tokyo 110:559-565.
Heath EM, Morken NW, Campbell KA, Tkach D, Boyd EA, Strom DA. 2001. Use of buccal cells collected in mouthwash as a source of DNA for clinical...

...and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22:917-922.
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. 1993. The molecular basis of the human...CF, Haugen A, Valerio F, et al. 1998. Urinary excretion of 1-hydroxypyrene as a marker for exposure to urban air levels of polycyclic aromatic hydrocarbons. Cancer EpidemioI Biomarkers Prey 7...

...337-340.
Richeldi L, Sorrentino R, Saltini C. 1993. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 262:242-244.
Rosipal R, Lamoril J, Puy H, Da Silva V, Gouya L, De Rooij FW, et al. 1999. Systematic analysis of coproporphyrinogen oxidase...

...Rothman N, Stewart WF, Schulte PA. 1995. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. Cancer Epidemiol Biomarkers Prev 4:301-311.
Rothman N, Wacholder S...

...Rebbeck TR. 1999. Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect 107:517-520.
Ward MH, Nuckols JR, Weigel SJ, Maxwell SK...

...Perspect 102:215-219.
Whyatt RM, Perera FP, Jedrychowski W, Santella RM, Garte S, Bell DA. 2000. Association between polycyclic aromatic hydrocarbon-DNA adduct levels in maternal and newborn white blood...

4/3,K/52 (Item 2 from file: 149) Links
TGG Health&Wellness DB(SM)

02923077 Supplier Number: 80744269 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Variability in Aflatoxin-Albumin adduct levels and effects of hepatitis B and C virus infection and glutathione S-transferase M1 and T1 genotype. (Articles).

Ahsan, Habibul; Wang, Li-Yu; Chen, Chien-Jen; Tsai, Wei-Yann; Santella, Regina M.
Environmental Health Perspectives , 109 , 8 , 833(5)
August ,
2001
Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
Word Count: 5183 Line Count: 00477

Text:

...the intraindividual variability in AF(B.sub.1)-albumin adducts, the most reliable long-term biomarker of AF(B.sub.1) exposure, and whether the baseline or follow-up adduct levels...

****

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in the world. In Taiwan, it is the most common cause of cancer death among men (1). Risk factors for HCC include chronic hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, cigarette smoking, and...

...albumin adduct, but AF(B.sub.1)-albumin adducts have been considered the most reliable biomarker of AF(B.sub.1) exposure in humans (5). Because of a relatively long half...

...months (5). AF(B.sub.1)-albumin adduct has been shown to be related to HCC risk in a dose-response fashion among HBV surface antigen (HBsAg) carriers, and the biological...

...Hu-Hsi, Ma-Kung, and Pai-Hsa) in Penghu Islets, an area with the highest HCC incidence in Taiwan, but in a manner so that half (n = 132) of them were...

...status could not be determined.

Discussion

Although HBV infection is the key etiologic element in HCC, AF(B.sub.1) exposure is an important cofactor in HCC carcinogenesis. AF(B.sub.1)-albumin adduct is considered a reliable indicator of the biologically...

...recruitment (i.e., at time 1), the respondents were briefed about the risk factors for HCC, including hepatitis viruses and dietary aria-toxin exposure. Therefore, one possibility is that the participants...

...nested study carried out in Shanghai that found an association between aflatoxin-albumin adducts and HCC found no association with dietary aflatoxin consumption based on in-person food frequency interview combined ...

...of 42 residents of Guangxi Province in China established that albumin adducts were a valid marker of aflatoxin exposure by comparing adduct levels to the levels of aflatoxin in portions of...

...Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, Hirvonen A, Bell DA, Santella RM. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and...risk of hepatocellular carcinoma in Taiwan. Int J Cancer 87:620-625 (1996).

(9.) Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure...

4/3,K/53 (Item 3 from file: 149) Links

02915238 Supplier Number: 67183911 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Applying Biomarker Research.

Bennett, David A.; Waters, Michael D.

Environmental Health Perspectives , 108 , 9 , 907
Sept ,
2000
Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
Word Count: 4152 Line Count: 00364

Applying Biomarker Research.

...to understand environmentally mediated disease and to improve the process of risk assessment. A valid biomarker could also be considered a key event linking a specific environmental exposure to a health...

...most closely related to the disease.
(Figure 1 ILLUSTRATION OMITTED)
Over the last decade the biomarker model has resulted in considerable research enterprise and nourished and challenged the emerging field of...

...field and their extension into the clinical environment. At the same time, much of the biomarker research has remained confined to the laboratory, with the promise of successful applications to improve public health or mitigate disease largely unmet.
A biomarker should allow better measurements of exposure or earlier identification of health effects. Biomarkers can provide...

...U.S. EPA held "Biomarkers: Taking Stock, An EPA/NIEHS In-House Workshop on Applying Biomarker Research" on 30-31 August 1999 in Chapel Hill, North Carolina. Approximately 90 participants explored biomarker research through presentations by invited plenary speakers, posters on individual research projects, and breakout discussion...

...precursor step that is a necessary element of the mode of action or is a marker for such an element. Examples of key events include metabolism, receptor--ligand changes, increased cell...

...to accidental mercury or methylparathion exposures. Lead in blood, plasma, or bone is an excellent biomarker of exposure and potentially of effects. Lead biomarkers also illustrate a challenge in understanding the...

...backward to look at populations that have exposures to various agents to see if the biomarker rises as their exposure rises. In either case establishing linkage between exposure and disease is...

...relating a) exposures to aflatoxin (B.sub.1), b) the etiology of human hepatocellular carcinoma (HCC), and c) intervention with oltipraz as a chemo-preventive agent for HCC (8). Biomarkers included aflatoxin--albumin adducts in serum and aflatoxin--mercapturic acid excreted in urine...

...one might develop an hypothesis to test. This was appropriate in the early stages of biomarker validation. Our understanding of the science supporting molecular epidemiology has now advanced so that we...

...studies and the regulatory community trying to apply this information.
An intended use of the biomarker may be in the clinical setting, where the focus is on the individual and there...

...fetus. Environ Health Perspect 107(suppl 3):451-460 (1999).
(10.) El-Masri HA, Bell DA, Portier CJ. Effects of glutathione transferase polymorphism on the risk estimates of dichloromethane to humans ...

...NW, Washington DC 20460. Telephone: (703) 603-8759. Fax: (703) 603-9146. E-mail: bennett.da@epa.gov
(*) On assignment from the U.S. EPA Office of Emergency and Remedial Response...

4/3,K/54 (Item 4 from file: 149) Links
TGG Health&Wellness DB(SM)

01713503 Supplier Number: 19696795 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Hepatitis G virus: is it a hepatitis virus?

Cheung, Ramsey C.; Keeffe, Emmet B.; Greenberg, Harry B.
The Western Journal of Medicine , v167 , n1 , p23(11)
July ,
1997
Publication Format: Magazine/Journal; Refereed
ISSN: 0093-0415
Language: English
Record Type: Fulltext; Abstract Target Audience: Professional
Word Count: 9257 Line Count: 00752

...antibodies to recombinant HGV putative envelope protein E2 was recently described as a potential serological marker for immunity to HGV infection.(20) Antibodies to E2 were found in 9% of 80...
...became HGV RNA negative. These data suggest that antibodies to E2 might be a serological marker for diagnosing recovery from HGV infection, but further studies are necessary. Detection of HGV RNA...44) The disease in the three patients with HGV RNA as the only identifiable viral marker was mild, and only one remained persistently viremic with elevated SGPT levels for 4 years...positive posttransplant.
Hepatocellular Carcinoma
Serum HGV RNA has been found in patients with hepatocellular carcinoma (HCC). HGV RNA was found in only one of 28 HCV-infected patients with HCC.(77) Among patients transplanted with HCC. HGV RNA was found in four of 34 patients of whom three were coinfected with ...

...with HBV.(78) GBV-C RNA was found in 11 of 111 (10%) cases of HCC in Japan, but 10 of 11 were coinfected with HCV and one with HBV. HGV...

...found as the only infectious viral agent in seven (8%) of 85 Austrian patients with HCC.(79) Since the majority of patients with HCC were coinfected with either HBV or HCV, the role of HGV in the etiology of HCC is unclear. Therefore, with the exception of the Austrian study,(71) HGV is unlikely to be a major etiologic agent of HCC.
Response of HGV to Antiviral Therapy
There are no data on treatment of patients who...Med 1996; 336:747-754
(45.) Aach RD. Stevens CE, Hollinger FB, Mosley JW, Peterson DA , Taylor PE. et al. Hepatitis C virus infection in post-transfusion hepatitis. N Engl J...

4/3,K/55 (Item 5 from file: 149) Links
TGG Health&Wellness DB(SM)

01438001 Supplier Number: 14699208 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Molecular virology and pathogenesis of hepatitis B.

Lau, Johnson Y.N.; Wright, Teresa L.
The Lancet , v342 , n8883 , p1335(6)
Nov 27 ,
1993
Publication Format: Magazine/Journal

ISSN: 0099-5355
Language: English
Record Type: Fulltext; Abstract Target Audience: Professional
Word Count: 4638 Line Count: 00403

...HBV-associated hepatocarcinogenesis, and current and future approaches to treatment.

Testing	Assays	Clinical significance
HBSAg		Marker of HBV infection
Anti-HBs		Immune against/protected from HBV([dagger])
HBeAg	RIA/EIA/RPHA...	

...and HBsAg. The smallest transcript (0.7 kb) encodes the X protein.

HBV proteln	Size (kDa)(*)	Function, clinical significance
Core	p21	Protein of core particle; kinase activity (role in replication?)
Pre-core (HBeAg)	p25[right arrow]p p16	Pre-core/core cleaves to HBeAg; good marker of active HBV replication and role in inducing immunotolerance
Surface (HBsAg)	p24/gp27	Envelope protein...

...Even though the pre-core sequence is not essential for replication, HBeAg is a good marker of active HBV replication because the pre-core/core gene product is generated from the...enhancer and hence replication.

Hepatocarcinogenesis

The strong association of persistent HBV infection and hepatocellular carcinoma (HCC) is intriguing, yet poorly understood. Although the relative risk of HCC developing in HBV carriers is as high as 100 times that in matched controls, it usually takes decades for HCC to emerge. Since HBV integration can occur early, this suggests that HBV does not have...

...c-ras, have been implicated but none has been shown to be consistently activated in HCC. The strong association of cirrhosis with HCC suggests that the common pathway for hepatocarcinogenesis may be chronic hepatic injury and regeneration, which in some way promote the induction or selection of a malignant clone.

HCC may well be a heterogeneous disease with cellular oncogene and common pathway models both operating...

...Further understanding of this heterogeneity may help in the establishment of the mechanisms involved in HCC--as happened with our understanding of the pathobiology of lymphoma and leukaemia in the wake ...

4/3,K/56 (Item 1 from file: 444) Links
New England Journal of Med.

00126660

Case 23-2005: A 57-Year-Old Man with a Mass in the Liver (Case Records of the Massachusetts General Hospital)

Tanabe, Kenneth K.; Blaszkowsky, Lawrence S.; Chung, Raymond T.; Blake, Michael A.; Lauwers, Gregory Y.
The New England Journal of Medicine
Jul 28 , 2005 ; 353 (4),pp 401-410
Line Count: 00429 Word Count: 05928

Text:
...products from the precore or core region yield secreted hepatitis B e antigen (HBeAg), a marker of active replication that can also be confirmed by molecular tests for circulating HBV DNA... ...growth control and set the stage for malignant transformation in the form of hepatocellular carcinoma (HCC). The illustration is adapted from Chisari (Ref. 4) *.**FIGURE OMITTED...

Cited References
...hepatocellular carcinoma. Am J Surg 1995;169:28-34.
34. Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of...

```
?  d s
Set     Items   Description
S1      78025   S HEPATOCELLULAR ADJ CARCINOMA OR HCC
S2        696   S S1 AND (DALTON OR KILODALTON OR KDA OR DA)
S3        109   S S2 AND (SERUM ADJ MARKER OR SERUM ADJ BIOMARKER OR MARKER OR
BIOMARKER)
S4         56   RD  (unique items)

?  s s1 and (DALTON OR KILODALTON OR KDA OR DA or molecular(w)weight)
Processing
Processing
        78025   S1
        35445   DALTON
        44384   KILODALTON
       752464   KDA
       509426   DA
     14051742   MOLECULAR
      4192629   WEIGHT
      1043306   MOLECULAR(W)WEIGHT
S5        951   S S1 AND (DALTON OR KILODALTON OR KDA OR DA OR MOLECULAR(W)WEIGHT)

?
?  s s5 AND (SERUM(W)MARKER OR SERUM(W)BIOMARKER OR MARKER OR BIOMARKER)
Processing
          951   S5
      3949820   SERUM
      1314164   MARKER
         8587   SERUM(W)MARKER
      3949820   SERUM
       137205   BIOMARKER
          878   SERUM(W)BIOMARKER
      1314164   MARKER
       137205   BIOMARKER
S6        128   S S5 AND (SERUM(W)MARKER OR SERUM(W)BIOMARKER OR MARKER OR
BIOMARKER)

?  rd
>>>W:  Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S7         67   RD  (UNIQUE ITEMS)
```

```
? t s7/3,k/1-67
>>>W: KWIC option is not available in file(s): 399
 7/3,K/1 (Item 1 from file: 5) Links
   Fulltext available through:    STIC Full Text Retrieval Options
Biosis Previews(R)
```

```
0019956371   Biosis No.: 200800003310
Candidate markers for the detection of hepatocellular carcinoma in low- molecular
weight fraction of serum

Author: Goldman Radoslav (Reprint); Ressom Habtom W; Abdel-Hamid Mohamed; Goldman
Lenka; Wang Antai; Varghese Rency S; An Yanming; Loffredo Christopher A; Drake
Steven K; Eissa Sohair A; Gouda Iman; Ezzat Sameera; Moiseiwitsch Francoise Seillier

Author Address: Georgetown Univ, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW,
Washington, DC 20057 USA**USA
Author E-mail Address: rg26@georgetown.edu
Journal: Carcinogenesis (Oxford)   28 ( 10 ): p 2149-2153 OCT 2007 2007
Item Identifier: doi:10.1093/carcin/bgm177
ISSN: 0143-3334
Document Type: Article
Record Type: Abstract
Language: English
Candidate markers for the detection of hepatocellular carcinoma in low- molecular
weight fraction of serum

Abstract: Hepatocellular carcinoma (HCC) represents an important public health
problem in Egypt where up to 90% of HCC cases are attributable to hepatitis C viral
(HCV) infection. Serum alpha-fetoprotein is elevated in only similar to 60% of HCC
patients. The development of effective markers for the detection of HCC could have
an impact on cancer mortality and significant public health implications worldwide.
The objective of our study was to assess six candidate markers for detection of HCC
identified by mass spectrometric analysis of enriched serum. The study examined 78
HCC cases and 72 age- and gender-matched cancer-free controls recruited from the
Egyptian population. Matrix-assisted laser desorption-ionization time-of-flight mass
spectrometric analysis of enriched low-molecular weight fraction of serum was used
for identification of the candidate markers. Our analyses show that all six
candidate markers are associated with HCC after adjustment for important covariates
including HCV and hepatitis B viral infections. The marker candidates are
independently predictive of HCC with areas under the receiver operating
characteristic (AuROC) curve ranging from 63-93%. A combination... ...C3 and C4. In
conclusion, a set of six peptides distinguished with high prediction accuracy HCC
from controls in an Egyptian population with a high rate of chronic HCV infection.
Further evaluation of these marker candidates for the diagnosis of HCC is needed.
DESCRIPTORS:
 Chemicals & Biochemicals:   candidate marker
 Miscellaneous Terms: Concept Codes: low-molecular weight


 7/3,K/2 (Item 2 from file: 5) Links
   Fulltext available through:    STIC Full Text Retrieval Options
Biosis Previews(R)
```

```
0019493671   Biosis No.: 200700153412
Proteomics-based identification of biomarkers for predicting sensitivity to a
PI3-kinase inhibitor in cancer

Author: Akashi Tetsuyuki; Nishimura Yumiko; Wakatabe Rumi; Shiwa Mieko; Yamori Takao
(Reprint)
Author Address: Japanese Fdn Canc Res, Div Mol Pharmacol, Canc Chemotherapy Ctr,
Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan**Japan
Author E-mail Address: yamori@jfcr.or.jp
```

Journal: Biochemical and Biophysical Research Communications 352 (2): p 514-521 JAN 12 2007 2007
ISSN: 0006-291X
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...integrated approach allowed us to identify peaks from two proteins, 11.6 and 11.8 kDa, that showed significant correlations with the sensitivity to a P13K inhibitor, LY294002. We found that the 11.8 kDa protein was a phosphorylated form of the 11.6 kDa protein. While the 11.8 kDa protein showed a positive correlation with the sensitivity to LY294002, the 11.6 kDa protein showed a negative correlation with that of the LY294002. The 11.6 kDa protein was purified chromatographically, and was identified by SELDI-TOF MS as the ribosomal P2... ...for determining the sensitivity to LY294002, and that the ribosomal P2 could be a potential biomarker for predicting chemo sensitivity.
DESCRIPTORS:
Organisms: ...HCC-2998 cell line (Hominidae
Chemicals & Biochemicals: ...phosphorylation, biomarker

7/3,K/3 (Item 3 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

19132806 Biosis No.: 200600478201
Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma

Author: Orvisky Eduard; Drake Steven K; Martin Brian M; Abdel-Hamid Mohamed; Ressom Habtom W; Varghese Rency S; An Yanming; Saha Daniel; Hortin Glen L; Loffredo Christopher A; Goldman Radoslav (Reprint)
Author Address: Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, LCCC Room S183,3970 Reservoir Rd NW, Washington, DC 20057 USA**USA
Author E-mail Address: rg26@georgetown.edu
Journal: Proteomics 6 (9): p 2895-2902 MAY 2006 2006
ISSN: 1615-9853
Document Type: Article
Record Type: Abstract
Language: English
Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma

Abstract: A challenging aspect of biomarker discovery in serum is the interference of abundant proteins with identification of disease-related proteins... ...by denaturing ultrafiltration, which enables an efficient profiling and identification of peptides up to 5 kDa. We consistently detect several hundred peptide-peaks in MALDI-TOF and SELDI-TOF spectra of... ...demonstrate utility of the methods, we compared 20 enriched sera of patients with hepatocellular carcinoma (HCC) and 20 age-matched controls using MALDI-TOF. The comparison of 332 peaks at $p < 0.001$ identified 45 differentially abundant peaks that classified HCC with 90% accuracy in this small pilot study. Direct TOF/TOF sequencing of the most... ...with high probability des-Ala-fibrinopeptide A. This study shows that enrichment of the low molecular weight fraction of serum facilitates an efficient discovery of peptides that could serve as biomarkers for detection of HCC as well as other diseases.

7/3,K/4 (Item 4 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

19132803 Biosis No.: 200600478198

Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach

Author: Lee I-Neng; Chen Chien-Hung; Sheu Jin-Chuan; Lee Hsuan-Shu; Huang Guan-Tam; Chen Ding-Shinn; Yu Chen-Yin; Wen Chu-Ling; Lu Fung-Jou; Chow Lu-Ping (Reprint)
Author Address: Natl Taiwan Univ, Coll Med, Grad Inst Biochem and Mol Biol, 1,Sec 1,1 Jen Ai Rd, Taipei 10018, Taiwan**Taiwan
Author E-mail Address: lupin@ha.mc.ntu.edu.tw
Journal: Proteomics 6 (9): p 2865-2873 MAY 2006 2006
ISSN: 1615-9853
Document Type: Article
Record Type: Abstract
Language: English
Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach

Abstract: Although the significant risk factors for hepatocellular carcinoma (HCC) are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need. We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals. A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and hepatitis C virus (HCV)related HCC. We identified this differentially expressed protein as complement C3a. The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC. The combination of SELDI-TOF MS and 2-DE provides a solution to identify disease...

7/3,K/5 (Item 5 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options

19083278 Biosis No.: 200600428673
Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus

Author: Kuramitsu Yasuhiro; Harada Toshio; Takashima Motonari; Yokoyama Yuuichirou; Hidaka Isao; Iizuka Norio; Toda Tosifusa; Fujimoto Masanori; Zhang Xiulian; Sakaida Isao; Okita Kiwamu; Oka Masaaki; Nakamura Kazuyuki (Reprint)
Author Address: Yamaguchi Univ, Dept Biochem and Biomol Recognit, Sch Med, Minami Kogushi 1-1-1, Ube, Yamaguchi 7558505, Japan**Japan
Author E-mail Address: nakamura@yamaguchi-u.ac.jp
Journal: Electrophoresis 27 (8, Sp. Iss. SI): p 1651-1658 APR 2006 2006
ISSN: 0173-0835
Document Type: Article
Record Type: Abstract
Language: English

Abstract: Hepatocellular carcinoma (HCC) is one of the most common fatal cancers, and chronic infection with hepatitis C virus... ...be one of the main causes in Japan. To identify diagnostic or therapeutic biomarkers for HCC associated with HCV (HCV-HCC), we tried to elucidate the factors related to the products from cancerous tissues of HCV-infected patients. From proteomic differential display analysis of liver tissue samples from HCV-HCC cancerous tissues and corresponding non-cancerous tissues from patients, three protein spots of the same molecular mass (42 kDa), whose expression increased in well-differentiated cancerous tissues, were detected. Although their pI were different... ...The tryptic peptides of the most acidic GS

isoform lost the signal of 899.5 Da, corresponding a peptide of SASIRIPR, and gained a signal of 1059.5 Da, which was submitted to PSD analysis. PSD analysis showed the neutral loss by elimination of two phosphate groups, supposed to be on serine residues of the 899.5-Da peptide, from serine 320 to arginine 327 in GS. PMF followed by PSD analysis is...
DESCRIPTORS:
Chemicals & Biochemicals: ...expression, phosphorylation, biomarker; ...
...expression, phosphorylation, biomarker

7/3,K/6 (Item 6 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

18536599 Biosis No.: 200510231099
Hepatitis B virus X protein: Structure-function relationships and role in viral pathogenesis

Book Title: Handbook of Experimental Pharmacology
Author: Kumar V (Reprint); Sarkar D P
Book Author/editor: Gossen M (Editor); Kaufmann J (Editor); Triezenberg SJ (Editor)
Author Address: Int Ctr Genet Engn and Biotechnol, Virol Grp, Aruna Asaf Ali Marg POB 10504, New Delhi 110067, India**India
Author E-mail Address: vijay@icgeb.res.in
Series Title: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 166 p 377-407 2004
Book Publisher: SPRINGER-VERLAG BERLIN, HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
ISSN: 0073-0033_(print) ISBN: 3-540-21095-4 (H)
Document Type: Book Chapter
Record Type: Abstract
Language: English

Abstract: The hepatitis B virus (HBV) genome codes for a 16.5-KDa protein termed pX or HBx which is a prevalent marker in the liver of patients with hepatitis B-associated hepatocellular carcinoma (HCC). Although the specific function of HBx in natural infection remains elusive, it is considered to play an important role in the etiology of HBV-induced HCC. It is a multifunctional regulatory protein that is best characterized as promiscuous transactivator. It can...

7/3,K/7 (Item 7 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

18187035 Biosis No.: 200500092948
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases

Author: Paradis Valerie (Reprint); Degos Francoise; Dargere Delphine; Pham Nanou; Belghiti Jacques; Degott Claude; Janeau Jean-Louis; Bezeaud Annie; Delforge Dominique; Cubizolles Myriam; Laurendeau Ingrid; Bedossa Pierre
Author Address: Serv Anat Pathol, Hop Beaujon, 100 Blvd Gen Leclerc, F-92100, Boulogne, France**France
Author E-mail Address: vparadis@teaser.fr
Journal: Hepatology 41 (1): p 40-47 January 2005 2005
Medium: print
ISSN: 0270-9139 _(ISSN print)
Document Type: Article
Record Type: Abstract
Language: English
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases

Abstract: ...any biological material studied. We used this approach to identify new biomarkers of hepatocellular carcinoma (HCC) in the sera of patients with cirrhosis. Sera from 82 patients with cirrhosis, either without (n = 38) or with (n = 44) HCC, were analyzed by SELDI-TOF MS, and the results of the two groups were compared. The most efficient protein peaks leading to discrimination of patients with HCC were selected (receiver operative characteristic curves). The highest-scoring peak combination was established in a... ...further. The intensity of 30 protein peaks significantly differed between cirrhotic patients with and without HCC. An algorithm including the six highest-scoring peaks allowed correct classification (presence or absence of HCC) of 92.5% of patients in the test sample set and 90% in the validation sample set. The highest discriminating peak (8,900 Da) was purified further and was characterized as the C-terminal part of the V10 fragment of vitronectin. An in vitro study suggested that the increase of the 8,900-Da fragment in the serum of patients with HCC may proceed from the cleavage of native vitronectin with metalloproteases, a family of enzymes whose activity is enhanced in HCC. In conclusion, global protein profiling is an efficient approach that enabled us to identify a catalytic fragment of vitronectin as a new serum marker of HCC in patients with chronic liver diseases.

7/3,K/8 (Item 8 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

17782856 Biosis No.: 200400149517
Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma.

Author: Takashima Motonari; Kuramitsu Yasuhiro; Yokoyama Yuuichiro; Iizuka Norio; Toda Toshifusa; Sakaida Isao; Okita Kiwamu; Oka Masaaki; Nakamura Kazuyuki (Reprint)

Author Address: Department of Biochemistry and Biomolecular Recognition, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan**Japan
Author E-mail Address: nakamura@yamaguchi-u.ac.jp
Journal: Proteomics 3 (12): p 2487-2493 December 2003 2003
Medium: print
ISSN: 1615-9853 _(ISSN print)
Document Type: Article
Record Type: Abstract
Language: English

Abstract: To identify proteins linked to the pathogenesis of hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV), we profiled protein expression levels in samples of HCC. To identify essential proteins, ten samples of HCV-related HCC were analyzed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time of... ...liver tissues. We focused on four members of the heat shock protein 70 family: 78 kDa glucose-regulated protein (GRP78), heat shock cognate 71 kDa protein (HSC70), 75 kDa glucose-regulated protein (GRP75), and heat shock 70 kDa protein 1 (HSP70.1). These results were confirmed by immunoblot analysis. In an additional 11... ...There has been no report describing overexpression of these four proteins simultaneously in HBV-related HCC as well as nonviral HCC. Our results suggest that these four proteins play important roles in the pathogenesis of HCV-related HCC and could be molecular targets for diagnosis and treatment of this disease.
DESCRIPTORS:
Chemicals & Biochemicals: ...biomarker; ... ...biomarker; ... ...cancer biomarker, proteomic profiling

7/3,K/9 (Item 9 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

17764972 Biosis No.: 200400132326
Identification of a new marker of hepatocellular carcinoma (HCC) by serum protein profiling of cirrhotic patients using SELDI-TOF proteinchip.

Author: Paradis Valerie (Reprint); Degos Francoise; Dargere Delphine; Pham Nanou; Belghiti Jacques; Degott Claude; Janeau Jean-Louis; Delforge Dominique; Cubizole Myriame; Bedossa Pierre
Author Address: CNRS, Hopital Beaujon, Clichy, France**France
Journal: Hepatology 38 (4 Suppl. 1): p 752A October 2003 2003
Medium: print
Conference/Meeting: 54th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, USA October 24-28, 2003; 20031024
Sponsor: American Association for the Study of Liver Diseases
ISSN: 0270-9139 _(ISSN print)
Document Type: Meeting; Meeting Abstract
Record Type: Abstract
Language: English
Identification of a new marker of hepatocellular carcinoma (HCC) by serum protein profiling of cirrhotic patients using SELDI-TOF proteinchip.

Abstract: ...any biological material studied. We used this approach to identify new biomarkers of hepatocellular carcinomas (HCC) in serum of cirrhotic patients. Material and methods: Serum protein profiles of 83 cirrhotic patients without (n=43) or with HCC (n=40) were analysed by the SELDI-TOF technology and proteomic profiles of the two... ...were compared. The most efficient protein peaks allowing the discrimination of patients with or without HCC were selected. Diagnostic value of each peak isolated, or in combination, was assessed (ROC curves... ...An algorithm including the 5 most performing peaks allowed correct classification (presence or absence of HCC) of 93% of cases. The most performing peak (8900 Da) was further purified by sequential enrichment through affinity column, recovery of the band on a... ...protein profiling is a powerful approach that allowed the identification and characterisation of a new serum marker of HCC in patients with cirrhosis.

7/3,K/10 (Item 10 from file: 5) Links
Biosis Previews(R)

17660992 Biosis No.: 200400031749
SELDI-TOF-MS PROFILING OF SERUM FOR DETECTION OF HEPATOCELLULAR CARCINOMA PROGRESSION IN HEPATITIS B AND HEPATITIS C INFECTED PATIENTS.

Author: Drake Richard R (Reprint); Steel Laura F; Adam Bao-Ling; Marrero Jorge; Semmes O J; Hann Hie-Won; Block Timothy; Johnson David A
Author Address: Norfolk, VA, USA**USA
Journal: Digestive Disease Week Abstracts and Itinerary Planner 2003 p Abstract No. 755 2003 2003
Medium: e-file
Conference/Meeting: Digestive Disease 2003 FL, Orlando, USA May 17-22, 2003; 20030517
Sponsor: American Association for the Study of Liver Diseases
American Gastroenterological Association
American Society for Gastrointestinal Endoscopy
Society for Surgery of the Alimentary Tract
Document Type: Meeting; Meeting Abstract
Record Type: Abstract
Language: English

Abstract: ...HCV) and who are at high risk for the development of virus-associated hepatocellular carcinoma (HCC). METHODS: The SELDI-TOF-MS (Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry... ...of biological mixtures. In one set of experiments, serum samples from patients with HCV-related HCC (n = 8), patients with HCV cirrhosis (n= 8), patients with chronic non-cirrhotic HCV (n...

...diagnosed with HBV-associated cirrhosis, plus serum from these same 10 patients after progression to HCC were analyzed. Specimens were applied in duplicate to a Bioprocessor containing IMAC3-copper ProteinChip arrays... ...automated using the Biomek 2000 robot. Clustering and classification analyses were performed using the Ciphergen Biomarker Wizard and Biomarker Patterns software packages, respectively. The different classification trees were generated utilizing multiple protein peaks in the mass range of 2-10 kDa. RESULTS: The serum protein profiles of patients with HCV-associated HCC could be distinguished from healthy controls with a sensitivity and specificity of 81%. Profiles of... ...87%/94% in cirrhotic patients. Profiling comparisons of non-cirrhotic HCV patients with the HCV/HCC patients was effective (81%/75%), and non-cirrhotic HCV sera could be distinguished from cirrhotic... ...plus cirrhosis were compared to their matched samples taken at the time of diagnosis of HCC, differences in serum protein profiles were detected with a sensitivity of 94% and specificity of... ...system as a surveillance tool to follow progression of viral hepatitis, cirrhosis and development of HCC. Supported by the NCI Early Detection Research Network..

7/3,K/11 (Item 11 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

16847785 Biosis No.: 200200441296
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer

Author: Hoo Linda Soo; Zhang Jianying Y; Chan Edward K L (Reprint)
Author Address: Department of Molecular and Experimental Medicine, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA**USA
Journal: Oncogene 21 (32): p 5006-5015 25 July, 2002 2002
Medium: print
ISSN: 0950-9232
Document Type: Article
Record Type: Abstract
Language: English
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer

Abstract: ...II mRNA. p62 was initially shown to be recognized by auto-antibodies in hepatocellular carcinoma (HCC) but now anti-p62 has been described in diverse malignancies. p62 is uniformly expressed in fetal liver and prominently in 33% of HCC nodules, but not detectable in adult liver or normal tissue adjacent to HCC nodules. In this study, a 90 kDa protein (p90), auto-antibodies to which were found associated with anti-p62 responses in the same HCC patient group, was identified by cDNA expression cloning. Indirect immunofluorescence showed that, like p62, p90... ...anti-p62, anti-Koc, and anti-CENP-F, auto-antibodies to p90 represent a new marker for tumors such as HCC and gastric cancer. Our data support the working hypothesis that auto-antibody production in cancer ...

7/3,K/12 (Item 12 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

16847767 Biosis No.: 200200441278
Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma

Author: Zeng Jin-Zhang; Wang Hong-Yang (Reprint); Chen Zheng-Jun; Ullrich Axel; Wu Meng-Chao
Author Address: International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgical Institute, Secondary Military Medical University, 225 Changhai Road, Shanghai, 200438, China**China

Journal: Oncogene 21 (32): p 4932-4943 25 July, 2002 2002
Medium: print
ISSN: 0950-9232
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...gain new insight into the molecular mechanism underlying the pathogenesis of human primary hepatocellular carcinoma (HCC), we searched for HCC-specific molecules through screening genes that are differentially expressed between cancerous and noncancerous counterparts of liver and identified a novel HCC-associated gene, HCCA1 encoding a apprx80 kDa cytoplasmic protein that contains several proline-rich motifs likely for SH3-binding. HCCA1 transcript, albeit present in some adult tissues, is up-regulated selectively in HCC but not in other tumor cells. High expression of HCCA1 occurs as a late event... ...the degree of tumor progression. When treated with antisense oligonucleotides to HCCA1, HCCA1 expression in HCC cells (HuH-7) was effectively suppressed and cell growth was down-regulated in a time... ...data strongly suggest that HCCA1 is a positive effector in cell proliferation and contributes to HCC carcinogenesis and progression. We believe that this protein will serve as a novel useful marker for HCC and is a potential target for pharmaceutical intervention of this malignant disease.

7/3,K/13 (Item 13 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options

15335731 Biosis No.: 200000054044
Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis

Author: Correale M (Reprint); Giannuzzi V; Iacovazzi P A; Valenza M A; Lanzillotta S; Abbate I; Quaranta M; Caruso M L; Elba S; Manghisi O G
Author Address: IRCCS "S.De Bellis", Via Andrea da Bari 84, 70121, Bari, Italy**Italy
Journal: Anticancer Research 19 (4C): p 3469-3472 July-Aug., 1999 1999
Medium: print
ISSN: 0250-7005
Document Type: Article
Record Type: Abstract
Language: English

Abstract: 90K/MAC-2BP glycoprotein is a serum tumour marker, member of the scavenger receptor cysteine rich (SRCR) protein superfamily, involved in different immunological mechanisms... ...monoclonal antibody in 11 chronic active hepatitis (CAH), 48 liver cirrhosis and 36 hepatocellular carcinoma (HCC). In comparison, the same samples were also tested for AFP. According to a cut-off... ...specificity in 50 controls, we observed increasing positivities from CAH to cirrhosis and then to HCC (27%, 50% and 78%, respectively). In cirrhotic patients 90K levels were associated with the presence... ...hepatic patients. However, further investigations are needed before proposing 90K as a clinical useful tumour marker in the progression from cirrhosis to HCC.
DESCRIPTORS:
Chemicals & Biochemicals: 90-kilodalton-MAC-2BP glycoprotein... ...serum level, tumor progression marker

7/3,K/14 (Item 14 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options

11842279 Biosis No.: 199396006695
A new tumor-associated antigen defined by a monoclonal antibody directed to gastric adenocarcinoma

Author: Watanabe Ryoji; Johzaki Hiroshi; Iwasaki Hiroshi (Reprint); Kikuchi Masahiro; Ikeda Seiyo
Author Address: Dep. Pathology, Fukuoka Univ. Sch. Med., 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-01, Japan**Japan
Journal: Cancer (Philadelphia) 71 (8): p 2439-2447 1993
ISSN: 0008-543X
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...In addition, the MoAb recognized cholangiocarcinomas (CC), but it did not react with hepatocellular carcinomas (HCC). Furthermore, in the combined type tumor consisting of a mixture of HCC and CC, the MoAb react only with CC element, but not with pseudoglandular structures in the HCC areas. These results indicate that FU-MK-1 is a useful antigenic marker for distinguishing HCC from CC in the liver. Furthermore, because this MoAb retains its reactivity with formalin-fixed ... ...embedded material, it may become a useful reagent for routine or retrospective immunohistologic studies. The molecular weight of the FU-MK-1 antigen was estimated to be ca. 41,000 dalton by the Western blot analysis. Periodic acid and trypsin treatment on the antigen suggested that...

7/3,K/15 (Item 1 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

16884775 Genuine Article#: 210DG No. References: 42
Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma

Author: Bachert C; Fimmel C; Linstedt AD (REPRINT)
Corporate Source: Carnegie Mellon Univ,Dept Biol Sci,Pittsburgh//PA/15213 (REPRINT); Carnegie Mellon Univ,Dept Biol Sci,Pittsburgh//PA/15213; Loyola Univ,Stitch Sch Med, Div Gastroenterol Hepatol & Nutr,Maywood//IL/60153
Journal: TRAFFIC , 2007 , V 8 , N10 (OCT) , P 1415-1423
ISSN: 1398-9219 Publication date: 20071000
Publisher: BLACKWELL PUBLISHING , 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma
Abstract: Serum GP73 levels are significantly increased in patients with hepatocellular carcinoma (HCC), potentially providing a marker for early detection. However, GP73 is an integral membrane protein localized to the cis Golgi... ...was released from cultured cells and compared with the Golgi-localized full-length protein, the molecular weight was slightly reduced, suggesting that cleavage releases the GP73 ectodomain. Sequence analysis revealed a proprotein... ...cleavage, resulting in GP73 secretion, and provides a molecular mechanism for its presence as a serum biomarker for HCC.

7/3,K/16 (Item 2 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

15942052 Genuine Article#: 119TJ No. References: 39
New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples

Author: Gobel T; Vorderwulbecke S; Hauck K; Fey H; Haussinger D; Erhardt A (REPRINT)

Corporate Source: Univ Dusseldorf,Klin Gastroenterol Hepatol & Infektiol,Moorenstr 5/D-40225 Dusseldorf//Germany/ (REPRINT); Univ Dusseldorf,Klin Gastroenterol Hepatol

& Infektiol,D-40225 Dusseldorf//Germany/; Ciphergen Biosyst,D-16761 Hennigsdorf//Germany/
Journal: WORLD JOURNAL OF GASTROENTEROLOGY , 2006 , V 12 , N47 (DEC 21) , P 7604-7612
ISSN: 1007-9327 Publication date: 20061221
Publisher: W J G PRESS , PO BOX 2345, BEIJING 100023, PEOPLES R CHINA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: ...for detection and differentiation of liver fibrosis F1-F2), liver cirrhosis (F4) and hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV).

METHODS: Serum samples of 39 patients with F1/F2 fibrosis, 44 patients with F4 fibrosis, 34 patients with HCC were applied to CM10 arrays and analyzed using the SELDI-TOF ProteinChip System (PBS-II... ...after anion-exchange fractionation. All patients had chronic hepatitis C and histologically confirmed fibrosis stage/HCC. Data were analyzed for protein patterns by multivariate statistical techniques and artificial neural networks.

RESULTS: A 4 peptide/protein multimarker panel (7486, 12843, 44293 and 53598 Da) correctly identified HCCs with a sensitivity of 100% and specificity of 85% in a two... ...HCV-cirrhosis versus HCVHCC training samples (AUROC 0.943). Sensitivity and specificity for identification of HCC were 68% and 80% for random test samples. Cirrhotic patients could be discriminated against patients... ...F2 fibrosis using a 5 peptide/protein multimarker pattern (2873, 6646, 7775, 10525 and 67867 Da) with a specificity of 100% and a sensitivity of 85% in training samples (AUROC 0... ...a sensitivity and specificity of 80% and 67% for random test samples. Combination of the biomarker classifiers with APRI score and alfa-fetopotein (AFP) improved the diagnostic performance. The 6646 Da marker protein for liver fibrosis was identified as apolipoprotein C-I.

CONCLUSION: SELDI-TOF-MS technology...

7/3,K/17 (Item 3 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options

15563913 Genuine Article#: 087AK No. References: 27
Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis

Author: Shibata R; Mori T; Du WL; Chuma M; Gotoh M; Shimazu M; Ueda M; Hirohashi S; Sakamoto M (REPRINT)
Corporate Source: Keio Univ,Sch Med, Dept Pathol, Shinjuku Ku,35 Shinanomachi/Tokyo 1608582//Japan/ (REPRINT); Keio Univ,Sch Med, Dept Pathol, Shinjuku Ku,Tokyo 1608582//Japan/; Keio Univ,Sch Med, Div Diagnost Pathol,Tokyo 1608582//Japan/; Keio Univ,Sch Med, Dept Surg,Tokyo 1608582//Japan/; Natl Canc Ctr,Res Inst, Div Pathol,Tokyo 104//Japan/ (msakamot@sc.itc.keio.ac.jp)
Journal: CLINICAL CANCER RESEARCH , 2006 , V 12 , N18 (SEP 15) , P 5363-5368
ISSN: 1078-0432 Publication date: 20060915
Publisher: AMER ASSOC CANCER RESEARCH , 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: Purpose: Hepatocellular carcinoma (HCC) associated with chronic liver disease is known to show an obvious multistage process of tumor progression. We previously identified heat shock protein 70 as a molecular marker of early HCC during investigation of expression profiling in multistage hepatocarcinogenesis. In this report, we examined cyclase-associated protein 2 (CAP2), which is also listed as an up-regulated gene in early HCC.

Experimental Design: We measured the level of CAP2 mRNA by real-time quantitative PCR. We... ...antibody against CAP2 and we confirmed the expression of CAP2 by immunoblotting and immunohistochemistry in HCC cell lines and HCC tissues.

Results: According to real-time quantitative PCR, the level of CAP2 mRNA was up-regulated in early HCC when compared with noncancerous liver tissue, and it was further up-regulated in progressed HCC. We raised a polyclonal antibody against CAP2, which showed a single 53-kDa band of strong intensity in the human HCC cell lines and HCC tissues but only a weak band in the noncancerous liver tissues in Western blot analysis. Immunohistochemical examination of CAP2 revealed its significant overexpression in early HCC when compared with noncancerous and precancerous lesions and in progressed HCC when compared with early HCC.

Conclusion: Our findings show that CAP2 is up-regulated in HCC when compared with noncancerous and precancerous lesions. This is the first report that proves that...

7/3,K/18 (Item 4 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

14828876 Genuine Article#: 010JF No. References: 25
Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis

Author: Ward DG; Cheng Y; N'Kontchou G; Thar TT; Barget N; Wei W; Billingham LJ; Martin A; Beaugrand M; Johnson PJ (REPRINT)
Corporate Source: Univ Birmingham,Sch Med, Canc Res UK Inst Canc Studies,Birmingham B15 2TT/W Midlands/England/ (REPRINT); Univ Birmingham,Sch Med, Canc Res UK Inst Canc Studies,Birmingham B15 2TT/W Midlands/England/; Univ Paris 13,UFR SMBH, UPRES EA 3409,Heptogastroenterol & Pathol Dept, Assistance Publ Hosp ,Bondy//France/ (p.johnson@bham.ac.uk)
Journal: BRITISH JOURNAL OF CANCER , 2006 , V 94 , N2 (JAN 30) , P 287-292
ISSN: 0007-0920 Publication date: 20060130
Publisher: NATURE PUBLISHING GROUP , MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: Early diagnosis of hepatocellular carcinoma (HCC) is the key to the delivery of effective therapies. The conventional serological diagnostic test, estimation... ...to complement ultrasound scanning, the major modality for surveillance of groups at high risk of HCC. We have analysed the serum proteome of 182 patients with hepatitis C-induced liver cirrhosis (77 with HCC) by surface-enhanced laser desorption/ ionisation time-of-flight mass spectrometry (SELDI). The patients were split into a training set (84 non-HCC, 60 HCC) and a 'blind' test set (21 non-HCC, 17 HCC). Neural networks developed on the training set were able to classify the blind test set... ...and 86% specificity (95% CI 65 - 95%). Two of the SELDI peaks (23/23.5 kDa) were elevated by an average of 50% in the serum of HCC patients ($P < 0.001$) and were identified as kappa and lambda immunoglobulin light chains. This... ...identification of several individual proteins, which, in combination, may offer a novel way to diagnose HCC.
Identifiers-- ...ARTIFICIAL NEURAL-NETWORKS; CANCER; DISCOVERY; IDENTIFICATION; BIOMARKERS; MARKER; STAGE

7/3,K/19 (Item 5 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

12700424 Genuine Article#: 811HV No. References: 33
Proteomic analysis of cholangiocarcinoma cell line

Author: Srisomsap C; Sawangareetrakul P; Subhasitanont P; Panichakul T; Keeratichamroen S; Lirdprapamongkol K; Chokchaichamnankit D; Sirisinha S; Svasti J (REPRINT)
Corporate Source: Chulabhorn Res Inst,Biochem Lab,Vibhavadee Rangsit Rd/Bangkok 10210//Thailand/ (REPRINT); Chulabhorn Res Inst,Biochem Lab,Bangkok

10210//Thailand/; Chulabhorn Res Inst,Immunol Lab,Bangkok 10210//Thailand/; Mahidol Univ,Dept Microbiol,Bangkok 10700//Thailand/; Mahidol Univ,Dept Biochem,Bangkok 10700//Thailand/
Journal: PROTEOMICS , 2004 , V 4 , N4 (APR) , P 1135-1144
ISSN: 1615-9853 Publication date: 20040400
Publisher: WILEY-V C H VERLAG GMBH , PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: ...with a higher incidence in tropical countries, such as Thailand. Distinguishing CCA from hepatocellular carcinoma (HCC) of the liver often requires the use of histochemistry, so molecular markers for diagnosis and... ...cell line (HuCCA-1) has been compared to human hepatocellular carcinoma cell lines (HepG2 and HCC-S102) and a human breast epithelial cancer cell line (MCF-7). Our results show that... ...MS (ESI-MS/MS). Cytokeratins CK8 and CK18 were overexpressed in both HuCCA-1 and HCC, while CK7 and CK19 were only expressed in HuCCA-1. Four specific proteins with MW... ...U2 showed high expression in HuCCA-1, while U1 and U4 showed high expression in HCC-S102. U2 could be separated in 2 proteins, U2/1 (alpha-enolase) and U2/2... ...HuCCA-1 by 1-DE immunodetection, and gave only one spot with MW 32.9 kDa and p/8.29 on 2-DE immunoblotting, Thus, certain proteins, namely CK7, CK19, U2...

7/3,K/20 (Item 6 from file: 34) Links
SciSearch(R) Cited Ref Sci

01121042 Genuine Article#: FX644 No. References: 13
HEPATOCARCINOMA IN CIRRHOSIS - IS ANTITHROMBIN-III A NEOPLASTIC MARKER

Author: GRIECO A; DESTEFANO V; CASSANO A; CIABATTONI A; GARUFI C; ASTONE A; LEONE G ; BARONE C
Corporate Source: POLICLIN UNIV A GEMELLI,IST CLIN MED GEN,LARGO GEMELLI 8/I-00168 ROME//ITALY/; CATHOLIC UNIV SACRED HEART,FAC MED A GEMELLI,IST SEMEIOT MED,IST CLIN MED GEN/I-00168 ROME//ITALY/
Journal: DIGESTIVE DISEASES AND SCIENCES , 1991 , V 36 , N7 , P 990-992
Language: ENGLISH Document Type: ARTICLE (Abstract Available)
HEPATOCARCINOMA IN CIRRHOSIS - IS ANTITHROMBIN-III A NEOPLASTIC MARKER
Abstract: It has been reported that hepatoma (HCC) cells produce abnormal proteins such as erytropietin, fibrinogen, prothrombin, and, recently, antithrombin III (AT III). In a preliminary report, we reported increased AT III levels in patients bearing HCC independent of their clinical liver status. The present study was performed to assess antithrombin III ... ...disease. In 70 well-matched patient (47 with cirrhosis and 23 with cirrhosis and proven HCC) serum total cholesterol, albumin, prothrombin, alkaline phosphatase, AFP, aminotransferases, and AT III were determined. Together with AFP and alkaline phosphatase, patients with HCC had higher values of AT III (88 +/- 7%) and total cholesterol (184 +/- 17 mg/100... ...001). No difference was observed between these two groups for albumin, prothrombin, and aminotransferases. In HCC patients, AT III levels were related to the total cholesterol level (R2 = 0.317), whereas... ...patients it correlated with the prothrombin level (R2 = 0.274). These data suggest that in HCC patients a greater rate of synthesis of AT III occurs, whereas in cirrhotic patients lower...
Research Fronts: 89-0071 001 (LOW-MOLECULAR WEIGHT HEPARIN; VENOUS THROMBOSIS; FAMILIAL ANTITHROMBIN-III DEFICIENCY; FIBRINOLYTIC SYSTEM; ACUTE MYOCARDIAL-INFARCTION; HOMOZYGOUS VARIANT)

7/3,K/21 (Item 1 from file: 45) Links
Fulltext available through: STIC Full Text Retrieval Options
EMCare

01951531 EMCare No: 44268169
Global proteomic analysis of microdissected cirrhotic nodules reveals significant biomarkers associated with clonal expansion

Guedj N.; Dargere D.; Degos F.; Janneau J.L.; Vidaud D.; Belghiti J.; Bedossa P.;

Paradis V.
Dr. V. Paradis, Service d'Anatomie Pathologique, Hopital Beaujon, 110 bd du Gen. Leclerc, 92118 Clichy Cedex France
AUTHOR EMAIL: vparadis@teaser.fr
Laboratory Investigation (LAB. INVEST.) (United Kingdom) 05 SEP 2006 , 86/9 (951-958)
CODEN: LAINA ISSN: 0023-6837 eISSN: 1530-0307
PUBLISHER ITEM IDENTIFIER: 3700450
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33
RECORD TYPE: Abstract

...tissue composed of polyclonal regenerative and monoclonal neoplastic, potentially malignant nodules from which hepatocellular carcinoma (HCC) might develop. The aim of this study was to investigate proteomic profile changes associated with... ...malignant transformation of monoclonal nodules. Seventy-one cirrhotic nodules from 10 female patients with six HCC were dissected from liver surgical specimen by laser capture microdissection. Clonal status of each nodule... ...surface-enhanced laser desorption ionisation-time-of-flight technology using Q10 arrays (Cyphergen ProteinChip(R). Molecular weight of differentially expressed protein peaks was assessed. An average of 50 protein peaks was obtained... ...n=26) identified three differentially expressed protein peaks (10 092, 54 025 and 62 133 Da). All were upregulated in monoclonal nodules. Twelve peaks were differentially expressed between monoclonal nodules and HCC with nine proteins upregulated in cancer samples. This study confirms that proteome analysis can be...
DESCRIPTORS:
* liver nodule; *liver cirrhosis; *biological marker
...capture microdissection; X chromosome inactivation; surface enhanced laser desorption ionization time of flight mass spectrometry; molecular weight; upregulation; cancer; sample; malignant transformation; human; female; clinical article; human tissue; aged; adult; article; priority...

7/3,K/22 (Item 2 from file: 45) Links
Fulltext available through: STIC Full Text Retrieval Options
EMCare

01161253 EMCare No: 35332910
Differential expression of beta-galactoside alpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma

Cao Y.; Merling A.; Crocker P.R.; Keller R.; Schwartz-Albiez R.
Dr. R. Schwartz-Albiez, Division of Cellular Immunology, German Cancer Research Centre, Im Neuenheimer Feld 280, D-69120 Heidelberg Germany
AUTHOR EMAIL: r.s-albiez@dkfz.de
Laboratory Investigation (LAB. INVEST.) (United States) 01 NOV 2002 , 82/11 (1515-1524)
CODEN: LAINA ISSN: 0023-6837
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 43
RECORD TYPE: Abstract

...alpha2,6 sialyltransferase (ST6Gal I) and sialoglycans in normal liver, cirrhotic liver, and hepatocellular carcinoma (HCC) using a new ST6Gal I-specific mAb and recombinant fusion proteins of CD22 and sialoadhesin... ...in Kupffer cells, bile ducts, endothelial cells, and oval cells. Well-differentiated and moderately differentiated HCC showed Golgi and diffuse cytoplasmic staining of ST6Gal I and

sialoglycans, whereas the cytoplasmic staining for ST6Gal I and sialoglycans was decreased or even absent in poorly differentiated HCC. Detection of sialoglycans by the recombinant fusion proteins in Western blots of cell lysates derived from cell lines revealed two major double bands of sialoglycoproteins at 65 and 120 kDa for hepatocytes, three major bands at 54, 49, and 44 kDa for colonic epithelial cells, and one band at 60 kDa for endothelial cells. Our results describe the expression patterns of ST6Gal I and sialoglycans in...
DESCRIPTORS:
hybrid protein; sialoglycoprotein; sialoadhesin; plasma protein; unclassified drug; cell enzyme; enzyme; marker; antigen; liver cell; intrahepatic bile duct; endothelium cell; staining; cell differentiation; bile duct; human cell...
...journal; liver cirrhosis; protein localization; rat; controlled study; cell line; protein expression; enzyme activity; disease marker; cell lysate; colon mucosa; liver disease; immunohistology; epithelium cell; animal cell

7/3,K/23 (Item 1 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0082103458 EMBASE No: 2007548023
Using protein chip technology to screen for tissue proteomic profiles and tumor markers in hepatocellular carcinoma

Li D.; Zhang J.-Z.; Zheng Y.-H. // Ji X.-L.; Shu Q.-M.; Fan L.-N. // You H. // Li X.-C. // Zhang J.-Z.
Department of Pathology, 306 Hospital of Chinese PLA, Beijing 100101, China // Department of Pathology, General Hospital of Armed Police Force of Chinese PLA, Beijing 100080, China // Research Center of Liver Disease, Beijing Friendship Hospital, Beijing 100053, China // Department of Sergeant, Academy of Equipment Command and Technology of Chinese PLA, Beijing 102249, China // Department of Pathology, 306 Hospital of Chinese PLA, 9 Anxiang North Road, Beijing 100101, China
Author email: zhangjz55@sina.com; zhangjz55@sina.com
Corresp. Author: Zhang J.-Z.
Corresp. Author Affil: Department of Pathology, 306 Hospital of Chinese PLA, 9 Anxiang North Road, Beijing 100101, China
Corresp. Author email: zhangjz55@sina.com

World Chinese Journal of Digestology (World Chin. J. Dig.) (China) August 1, 2007 , 15/22 (2424-2430)
CODEN: SHXZF ISSN: 10093079
Document Type: Journal ; Article Record Type: Abstract
Language: Chinese Summary language: English; Chinese
Number of References: 32

...spectrometry (SELDI-TOF-MS) technique to screen for tissue biomarkers in patients with hepatocellular carcinoma (HCC), but with different clinicopathological features. METHODS: Proteomic spectra were examined and analyzed by mass spectroscopy in 44 cases, including 26 specimens of HCC tissue that had been pathologically confirmed in patients aged 34-68 years, and 18 specimens... ...cirrhosis tissue in patients aged 38-70 years. The spectra obtained were analyzed using the biomarker wizard system, and the biomarkers were defined by searching www.ExPasy.org. RESULTS: A total... ...16 distinguished proteomic biomarkers, 7 up-regulated and 9 down-regulated, were detected from screening HCC tissue, in contrast with liver cirrhosis tissue. There were significant differences in the protein peaks of different molecular masses of 4.7, 7.2 and 9.8 kDa between HCC and liver cirrhosis tissues. Eleven distinguished proteomic biomarkers were screened when comparing cases of moderately and highly differentiated HCC tissue. All proteins were confirmed by searches of www.ExPasy.org. CONCLUSION: The SELDI-TOF-MS technique offers a unique platform for proteomic detection in HCC. It is also a non-invasive method for studying proteomic changes in the development and progression of HCC.
Drug Descriptors:
tumor marker

7/3,K/24 (Item 2 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0082012034 EMBASE No: 2007451057
Artificial neural networks and decision tree model analysis of liver cancer proteomes

Luk J.M.; Lam B.Y.; Lee N.P.Y.; Ho D.W.; Chen L.; Fan S.-T. // Sham P.C. // Chen L.; Peng J.; Leng X. // Day P.J.
Department of Surgery, Center for Cancer Research, University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong // Genome Research Centre, Department of Psychiatry, University of Hong Kong, Pokfulam, Hong Kong // Department of Surgery, People's Hospital, Peking University, Beijing, China // The Manchester Interdisciplinary Biocentre, University of Manchester, Manchester, United Kingdom
Author email: jmluk@hkucc.hku.hk
Corresp. Author: Luk J.M.
Corresp. Author Affil: Department of Surgery, Center for Cancer Research, University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong
Corresp. Author email: jmluk@hkucc.hku.hk

Biochemical and Biophysical Research Communications (Biochem. Biophys. Res. Commun.) (United States) September 14, 2007 , 361/1 (68-73)
CODEN: BBRCA ISSN: 0006291X eISSN: 10902104
Publisher Item Identifier: S0006291X07014003
Item Identifier (DOI): 10.1016/j.bbrc.2007.06.172
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 25

Hepatocellular carcinoma (HCC) is a heterogeneous cancer and usually diagnosed at late advanced tumor stages of high lethality. The present study attempted to obtain a proteome-wide analysis of HCC in comparison with adjacent non-tumor liver tissues, in order to facilitate biomarkers' discovery and to investigate the mechanisms of HCC development. A cohort of 66 Chinese patients with HCC was included for proteomic profiling study by two-dimensional gel electrophoresis (2-DE) analysis. Artificial... ...employed to analyze the profiling data and to delineate significant patterns and trends for discriminating HCC from non-malignant liver tissues. Protein markers were identified by tandem MS/MS. A total... ...each with 230 consolidated protein expression intensities. Both the data-mining algorithms successfully distinguished the HCC phenotype from other non-malignant liver samples. The detection sensitivity and specificity of ANN were... ...three biological classifiers in the CART model were identified as cytochrome b5, heat shock 70 kDa protein 8 isoform 2, and cathepsin B. The 2-DE-based proteomic profiling approach combined with the ANN or CART algorithm yielded satisfactory performance on identifying HCC and revealed potential candidate cancer biomarkers. (c) 2007 Elsevier Inc. All rights reserved.
Drug Descriptors:
biological marker--endogenous compound--ec; cathepsin B--endogenous compound--ec; cytochrome b5--endogenous compound--ec; heat shock...

7/3,K/25 (Item 3 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0081549702 EMBASE No: 2006613339
Application of surface enhanced laser desorption ionization time-of-flight mass spectrometry technology in the diagnosis of hepatocellular carcinoma

Tian Z.-B.; Kong X.-J.; Zhang C.-P. // Liu H. // Sun G.-R. // Wang B. // Tian

Z.-B.
Department of Gastroenterology, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China // Department of Endoscopy, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China // Clinical Immunologic Center, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China // Department of Microbiology, Qingdao University Medical College, Qingdao 266021, Shandong Province, China // Department of Gastroenterology, Affiliated Hospital of Medical College Qingdao University, 16 Jiangsu Road, Qingdao 266003, Shandong Province, China
Author email: tianzb@qdumh.qd.sd.cn; tianzb@qdumh.qd.sd.cn
Corresp. Author: Tian Z.-B.
Corresp. Author Affil: Department of Gastroenterology, Affiliated Hospital of Medical College Qingdao University, 16 Jiangsu Road, Qingdao 266003, Shandong Province, China
Corresp. Author email: tianzb@qdumh.qd.sd.cn

World Chinese Journal of Digestology (World Chin. J. Dig.) (China) September 1, 2006 , 14/25 (2499-2503)
CODEN: SHXZF ISSN: 10093079
Document Type: Journal ; Article Record Type: Abstract
Language: Chinese Summary language: English; Chinese
Number of References: 11

AIM: To explore tumor markers for the diagnosis of hepatocellular carcinoma (HCC) through detecting the serum protein spectrum differently expressed between hepatitis B virus (HBV) carriers and HCC patients. METHODS: We detected the serum protein spectrum in 27 HCC patients, 27 HBV carriers and 25 healthy controls using surface enhanced laser desorption ionization time... ...TOF-MS) technique, and the diagnosis model was established through analyzing the detected data by biomarker patterns software (BPS) 5.0. RESULTS: The protein peaks, which could discriminate HBV carriers from HCC patients and healthy individuals, as well as healthy individuals from HCC patients, were detected. A diagnosis model based on the detected data was established with the... ...of 93%, 96%, 84%, and sensitivity of 85%, 96%, 89%, respectively. In addition, the 8141-Da protein in HCC patients had a higher expression than that in HBV carriers (P < 10 SUP -5); the expression of 3448-Da protein was higher both in HCC patients and HBV carriers than that in healthy controls (P < 10 SUP -5), but it had no significant difference between HCC patients and HBV carriers (P > 0.05), indicating that 3448-Da protein might be a potential marker for HBV infection; 7771-Da protein was differently expressed between the three groups of patients. CONCLUSION: With a high specificity... ...quickly by SELDI-TOF-MS technique, which provides a serological way for the diagnosis of HCC.
Drug Descriptors:
plasma protein--endogenous compound--ec; tumor marker--endogenous compound--ec

7/3,K/26 (Item 4 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0081416312 EMBASE No: 2006479235
Establishment of serum protein pattern model for screening hepatocellular carcinoma by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Liu C.-B.; Pan C.-Q.; Sun L.-F. // Liu C.-B.
Taizhou Municipal Hospital, Taizhou 318000, Zhejiang Province, China // Taizhou Municipal Hospital, 381 Zhongshan Rd., Jiaojiang Dist., Taizhou 318000, Zhejiang Province, China
Author email: liuchibo@56.com; liuchibo@56.com
Corresp. Author: Liu C.-B.
Corresp. Author Affil: Taizhou Municipal Hospital, 381 Zhongshan Rd., Jiaojiang Dist., Taizhou 318000, Zhejiang Province, China

Corresp. Author email: liuchibo@56.com

World Chinese Journal of Digestology (World Chin. J. Dig.) (China) August 1, 2006 , 14/23 (2354-2357)
CODEN: SHXZF ISSN: 10093079
Document Type: Journal ; Article Record Type: Abstract
Language: Chinese Summary language: English; Chinese
Number of References: 7

...spectrometry (SELDI-TOF-MS) on WCX2 chips. The collected data were compared and analyzed by Biomarker Wizard software. RESULTS: A group of proteomic peaks were detected. The expression of five protein molecules (4477, 8943, 5181, 8617, 13 761 Da) in patients with hepatic cellular carcinoma was significantly higher than those in the controls, and the expression of 4477- and 13 761-Da proteins were higher while the 4097-Da one was lower in HCC patients than cirrhosis ones. The specificity and sensitivity of SELDI-TOF-MS were 100% (60/60) and 90% (18/20), respectively. Four protein molecules (4477, 8943, 13 761, 4097 Da) were screened as a proteomic model. CONCLUSION: The discovered serum protein pattern model can efficiently...

7/3,K/27 (Item 5 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0075922659 EMBASE No: 1994352496
Expression of peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase enzyme and its mRNA in peroxisome proliferator-induced liver tumors

Rao M.S.; Ide H.; Yeldandi A.V.; Kumar S.; Reddy J.K.
Department of Pathology, NW University Medical School, 303 East Chicago Avenue, Chicago, IL 60611, United States
Corresp. Author: Rao M.S.
Corresp. Author Affil: Department of Pathology, Northwestern Univ. Medical School, 303 East Chicago Avenue, Chicago, IL 60611, United States

Carcinogenesis (CARCINOGENESIS) (United Kingdom) November 1, 1994 , 15/11 (2619-2622)
CODEN: CRNGD ISSN: 01433334
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 27

...to the adjacent non-neoplastic liver. SDS-polyacrylamide gel electrophoresis of postnuclear fractions of six HCC and adjacent liver tissue showed a marked increase in an 80 kDa polypeptide. Immunoblot and Northern blot analysis showed a marked increase in PBE enzyme and PBE mRNA respectively in HCC and adjacent non-neoplastic liver tissue. In control livers (animals not treated with peroxisome proliferators...
Drug Descriptors:
antibody; ciprofibrate; prasterone; tumor marker

7/3,K/28 (Item 6 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

0074563256 EMBASE No: 1991068756
A pulmonary large cell carcinoma cell line expressing neuroendocrine cell markers and human chorionic gonadotropin alpha-subunit

Kasai K.; Kameya T.; Kadoya K.; Wada C.
Department of Pathology, Kitasato University, School of Medicine, Kitasato 1-15-1, Sagamihara 228, Japan

Corresp. Author Affil: Department of Pathology, Kitasato University, School of Medicine, Kitasato 1-15-1, Sagamihara 228, Japan

Japanese Journal of Cancer Research (JPN. J. CANCER RES.) (Japan) March 7, 1991 , 82/1 (12-18)
CODEN: JJCRE ISSN: 09105050
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English

...protein of neuroendocrine cells but did not possess either most epithelial markers other than low-molecular-weight keratin (Cytokeratin) or neuron-specific enolase. The KTA7 cells, by immunostaining with anti-hCC subunit antibodies, were shown to produce hCG alpha- but not beta-subunit. Northern blot analysis... ...the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.

7/3,K/29 (Item 1 from file: 144) Links
Pascal

15962183 PASCAL No.: 03-0105753

Expression of p33 SUP I SUP N SUP G SUP 1 in hepatocellular carcinoma: Relationships to tumour differentiation and cyclin E kinase activity

OHGI T; MASAKI T; NAKAI S; MORISHITA A; YUKIMASA S; NAGAI M; MIYAUCHI Y; FUNAKI T; KUROKOHCHI K; WATANABE S; KURIYAMA S
Third and First Depts. of Internal Medicine, Kagawa Medical University, Miki-cho, Kita-gun, Kagawa, Japan
Journal: Scandinavian journal of gastroenterology
, 2002, 37 (12
) 1440-1448
Language: English

... 1 (ING1) is a new candidate for the tumour suppressor gene that encodes a 33k Da protein (p33 SUP I SUP N SUP G SUP 1). While reduction of p33 SUP...
... expression of p33 SUP I SUP N SUP G SUP 1 in human hepatocellular carcinoma (HCC) remains to be examined. We evaluated p33 SUP I SUP N SUP G SUP 1 expression in various liver diseases including HCC. Methods: Expression of p33 SUP I SUP N SUP G SUP 1 was evaluated immunohistochemically...

... the normal liver (n = 5), hut also in specimens of chronic hepatitis (n = 39) and HCC (n = 86). We also analysed the relationship between p33 SUP I SUP N SUP G...

...Results: Expression of p33 SUP I SUP N SUP G SUP 1 was reduced in HCC , especially in moderately and poorly differentiated HCCs, and those at advanced stages. Furthermore, expression of...

... G SUP 1 may contribute to the process of malignant transformation, progression and dedifferentiation of HCC via an increase of cyclin E kinase activity.

English Descriptors: Hepatocellular carcinoma; Tumoral marker; Tumor suppressor gene; Tumor progression; Mechanism of action; Increase; Enzymatic activity; Cyclin E; Kinase; Cell...

7/3,K/30 (Item 2 from file: 144) Links
Pascal

15778005 PASCAL No.: 02-0491582

Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer

SOO HOO Linda; ZHANG Jianying Y; CHAN Edward K L
WM Keck Autoimmune Disease Center and DNA Core Laboratory for Structural Analysis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California, CA 92037, United States
Journal: Oncogene : (Basingstoke), 2002, 21 (32) 5006-5015
Language: English

Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer
... II mRNA. p62 was initially shown to be recognized by auto-antibodies in hepatocellular carcinoma (HCC) but now anti-p62 has been described in diverse malignancies. p62 is uniformly expressed in fetal liver and prominently in 33% of HCC nodules, but not detectable in adult liver or normal tissue adjacent to HCC nodules. In this study, a 90 kDa protein (p90), auto-antibodies to which were found associated with anti-p62 responses in the same HCC patient group, was identified by cDNA expression cloning. Indirect immunofluorescence showed that, like p62, p90...

... anti-p62, anti-Koc, and anti-CENP-F, auto-antibodies to p90 represent a new marker for tumors such as HCC and gastric cancer. Our data support the working hypothesis that auto-antibody production in cancer ...

7/3,K/31 (Item 1 from file: 135) Links
NewsRx Weekly Reports

0000668683 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from Carnegie Mellon University, Department of Biological Sciences detail findings in hepatocellular cancer

Cancer Weekly, October 30, 2007, p.538

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
359

...TEXT: A new study, 'Endosomal trafficking and proprotein convertase cleavage of cis golgi protein GP73 produces marker for hepatocellular carcinoma,' is now available (see also). According to a study from the United States, "'Serum GP73 levels are significantly increased in patients with hepatocellular carcinoma (HCC), potentially providing a marker for early detection. However, GP73 is an integral membrane protein localized to the cis Golgi...

...was released from cultured cells and compared with the Golgi-localized full-length protein, the molecular weight was slightly reduced, suggesting that cleavage releases the GP73 ectodomain. Sequence analysis revealed a proprotein...

...cleavage, resulting in GP73 secretion, and provides a molecular mechanism for its presence as a serum biomarker for HCC." Bachert and colleagues published the results of their research in

Traffic (Endosomal trafficking and proprotein convertase cleavage of cis golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic , 2007;8(10):1415-23). For additional information, contact C. Bachert...

7/3,K/32 (Item 2 from file: 135) Links
NewsRx Weekly Reports

0000553015 (USE FORMAT 7 OR 9 FOR FULLTEXT)

National Taiwan University, Taiwan, scientists detail new medical studies and findings

Pharma Business Week, June 25, 2007, p.2637

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1097

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). "Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University. "We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals. "A

candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported. "The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed. They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/33 (Item 3 from file: 135) Links
NewsRx Weekly Reports

0000544063 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Results of recent studies reported by University of Toronto, Canada

Science Letter, June 12, 2007, p.3027

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1254

...TEXT: cancer. "Tumor recurrence remains the major cause of death after curative resection for hepatocellular carcinoma (HCC). The purpose of this study was to identify risk factors for the recurrence of HCC and to examine long-term outcomes after resection," scientists in Toronto, Canada report. "From July...
...2004, 193 consecutive patients who underwent hepatic resection as primary therapy with curative intent for HCC were included in this single-center analysis. The perioperative mortality rate was 5%. Time to...

...Despite recurrences in >50% of patients, long-term survival can be achieved after resection of HCC," wrote S.A. Shah and colleagues, University of Toronto, Department of Surgery. The researchers concluded...
... Avenue, Toronto, ON M4N 3M5, Canada. Study 3: The Mycobacterium marinum early secretory antigenic 6 kDa/culture filtrate protein 10 secretion system modulates phagosome maturation. "Virulence of Mycobacterium tuberculosis and related pathogenic mycobacteria requires the secretion of early secretory antigenic 6 kDa (ESAT-6) and culture filtrate protein 10 (CFP-10), two small proteins that lack traditional...

...were analyzed in infected macrophages by confocal and electron microscopy using the late endosome/lysosome marker LAMP-1, along with various fluid-phase markers such as rhodamine-dextran and ferritin and ...

7/3,K/34 (Item 4 from file: 135) Links
NewsRx Weekly Reports

0000527462 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' work from National Taiwan University, Taiwan, adds to body of knowledge

Life Science Weekly, May 22, 2007, p.5019

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1074

...TEXT: 100 ms or longer 6 h postresuscitation predicts poor survival outcomes and serves as a marker of poor prognosis." Chang and colleagues published their study in Intensive Care Medicine (Postresuscitation myocardial...
... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). "Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University. "We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals. "A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported. "The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed. They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/35 (Item 5 from file: 135) Links
NewsRx Weekly Reports

0000504046 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent studies involving Keio University, Japan, highlighted

Pharma Business Week, April 23, 2007, p.2613

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1219

...TEXT: in multistage hepatocarcinogenesis," are detailed in a study published in Clinical Cancer Research. "Hepatocellular carcinoma (HCC) associated with chronic liver disease is known to show an obvious multistage process of tumor progression. We previously identified heat shock protein 70 as a molecular marker of early HCC during investigation of expression profiling in multistage hepatocarcinogenesis," scientists writing in the journal Clinical Cancer...

...associated protein 2 (CAP2), which is also listed as an up-regulated gene in early HCC. We measured the level of CAP2 mRNA by real-time quantitative PCR. We raised a...

...antibody against CAP2 and we confirmed the expression of CAP2 by immunoblotting and immunohistochemistry in HCC cell lines and HCC tissues. According to real-time quantitative PCR, the level of CAP2 mRNA was up-regulated in early HCC when compared with noncancerous liver tissue, and it was further up-regulated in progressed HCC. We raised a polyclonal antibody against CAP2, which showed a single 53-kDa band of strong intensity in the human HCC cell lines and HCC tissues but only a weak band in the noncancerous liver tissues in Western blot analysis. Immunohistochemical examination of CAP2 revealed its significant overexpression in early HCC when compared with noncancerous and precancerous lesions and in progressed HCC when compared with early HCC. Our findings show that CAP2 is up-regulated in HCC when compared with noncancerous and precancerous lesions," wrote R. Shibata and colleagues, Keio University, National...

7/3,K/36 (Item 6 from file: 135) Links
NewsRx Weekly Reports

0000493315 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from National Taiwan University, Taiwan, highlight most recent findings

Life Science Weekly, April 10, 2007, p.4318

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1118

...TEXT: received surgical resection," is now available. According to a study from Taipei, Taiwan, "Hepatocellular carcinoma (HCC) is one the most common malignancies in the world. As the prognosis for HCC patients is poor, the quality of life (QOL) is becoming more important on the outcome assessments." "The aim of this study was to evaluate QOL in HCC patients. A total of 161 patients with HCC were enrolled at a university hospital. Most of these patients received surgical resections. They were...

...WHOQOL-BREF, EORTC QLQ-C30, and utility measures. The WHOQOL-BREF domain scores for the HCC patients were compared to healthy normative Taiwan population, using general linear models controlling for gender...

...explore association between a better QOL and clinical/sociodemographic variables. Compared with healthy people, the HCC patients had reduced QOL in physical domains, but better environmental QOL. After controlling gender, age, education, and employment, duration of HCC more than 1 year was associated with better QOL scores. WHOQOL-BREF could be cross-validated with EORTC QLQ-C30. Survival over 1 year was associated with better QOL in HCC patients," wrote L.J. Lee and colleagues, National Taiwan University. The researchers concluded: "WHOQOL-BREF could be a valid QOL instrument for the assessments of QOL in HCC patients." Lee and colleagues published the results of their research in the Journal of Surgical...

...C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). "Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University. "We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals. "A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported. "The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed. They concluded, "The combination of SELDI-TOF MS and 2-DE provides...
n Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/37 (Item 7 from file: 135) Links
NewsRx Weekly Reports

0000466630 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research by Kanazawa University, Japan, advances understanding of human health

Pharma Business Week, March 12, 2007, p.1779

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1053

Study 1: Researchers detail in "Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy," new data in systemic sclerosis...
...polymyositis (PM). In this study, we identified a novel MSA reactive with 155 and 140 kDa nuclear proteins [anti-155/140 antibody (Ab)] and determined the clinical feature of DM patients...

...immunofluorescence staining. Seven of the 52 (13%) Japanese patients with DM immunoprecipitated 155 and 140 kDa proteins from 35S-labelled K562 leukaemia cell extract. No patients with SLE, systemic sclerosis or...

...novel MSA is associated with cancer-associated DM and may serve as a diagnostic serological marker for this specific subset."

Kaji and colleagues published their study in Rheumatology (Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology, 2007;46(1):25...

...AFP)-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma (HCC).

"AFP has been proposed as a potential target for T-cell-based immunotherapy for HCC, but the number of its epitopes that have been identified is limited and the status of AFP-specific immunological responses in HCC patients has not been well-characterized.

"To address the issue," wrote E. Mizukoshi and colleagues...
...analyzed the relationship between its frequency of occurrence and clinical features associated with patients having HCC."

They continued, "Five AFP-derived peptides containing HLA-A*2402 binding motifs and showing high...

...Analyses of the relationships between AFP-specific CTL responses and clinical features of patients with HCC revealed that AFP epitopes were more frequently recognized by CTLs in patients with advanced HCC correlating to tumor factors or the stage of TNM classification. The analyses of CTL responses before and after HCC treatments showed that the treatments changed the frequency of AFP-specific CTLs," the authors reported...

...epitopes derived from AFP. The newly identified AFP epitopes could be a valuable component of HCC immunotherapy and for analyzing host immune responses to HCC."

Mizukoshi and colleagues published their study in International Journal of Cancer (Identification of alpha-fetoprotein...

7/3,K/38 (Item 8 from file: 135) Links
NewsRx Weekly Reports

New findings from National Taiwan University, Taiwan, described

Pharma Business Week, March 5, 2007, p.2661

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1149

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/39 (Item 9 from file: 135) Links
NewsRx Weekly Reports

0000433458 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Scientists from National Taiwan University, Taiwan, publish new research findings

Science Letter, February 6, 2007, p.2150

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1044

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...biomarkers."

Lee and colleagues published their study in (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/40 (Item 10 from file: 135) Links
NewsRx Weekly Reports

0000431300 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from Heinrich-Heine University have provided new information about hepatocellular cancer

Biotech Business Week, February 5, 2007, p.104

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
491

...TEXT: for detection and differentiation of liver fibrosis (F1-F2), liver cirrhosis (F4) and hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV). Serum samples of 39 patients with F1/F2 fibrosis, 44 patients with F4 fibrosis, 34 patients with HCC were applied to CM10 arrays and analyzed using the SELDI-TOF ProteinChip System (PBS-IIc...

...after anion-exchange fractionation.".
"All patients had chronic hepatitis C and histologically confirmed fibrosis stage/HCC. Data were analyzed for protein patterns by multivariate statistical techniques and artificial neural networks. A 4 peptide/protein multimarker panel (7486, 12,843, 44,293 and 53,598 Da) correctly identified HCCs with a sensitivity of 100% and specificity of 85% in a two way-comparison of HCV-cirrhosis versus HCV-HCC training samples (AUROC 0.943). Sensitivity and specificity for identification of HCC were 68% and 80% for random test samples. Cirrhotic patients could be discriminated against patients...

...using a 5 peptide/protein multimarker pattern (2873, 6646, 7775, 10,525 and 67,867 Da) with a specificity of 100% and a sensitivity of 85% in training samples (AUROC 0...

...a sensitivity and specificity of 80% and 67% for random test samples. Combination of the biomarker classifiers with APRI score and alfa-fetopotein (AFP) improved the diagnostic performance. The 6646 Da marker protein for liver fibrosis was identified as apolipoprotein C-I. SELDI-TOF-MS technology combined...

7/3,K/41 (Item 11 from file: 135) Links
NewsRx Weekly Reports

0000421039 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Scientists at Keio University, National Cancer Center Research Institute describe research in cancer immunology

Clinical Oncology Week, January 29, 2007, p.230

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
413

...TEXT: in multistage hepatocarcinogenesis," are detailed in a study published in Clinical Cancer Research. "Hepatocellular carcinoma (HCC) associated with chronic liver disease is known to show an obvious multistage process of tumor progression. We previously identified heat shock protein 70 as a molecular marker of early HCC during investigation of expression profiling in multistage hepatocarcinogenesis," scientists writing in the journal Clinical Cancer...

...associated protein 2 (CAP2), which is also listed as an up-regulated gene in early HCC. We measured the level of CAP2 mRNA by real-time quantitative PCR. We raised a...

...antibody against CAP2 and we confirmed the expression of CAP2 by immunoblotting and immunohistochemistry in HCC cell lines and HCC tissues. According to real-time quantitative PCR, the level of CAP2 mRNA was up-regulated in early HCC when compared with noncancerous liver tissue, and it was further up-regulated in progressed

HCC. We raised a polyclonal antibody against CAP2, which showed a single 53-kDa band of strong intensity in the human HCC cell lines and HCC tissues but only a weak band in the noncancerous liver tissues in Western blot analysis. Immunohistochemical examination of CAP2 revealed its significant overexpression in early HCC when compared with noncancerous and precancerous lesions and in progressed HCC when compared with early HCC. Our findings show that CAP2 is up-regulated in HCC when compared with noncancerous and precancerous lesions," wrote R. Shibata and colleagues, Keio University, National...

7/3,K/42 (Item 12 from file: 135) Links
NewsRx Weekly Reports

0000414604 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New hepatocellular carcinoma study findings recently were reported by scientists in Japan

Hepatitis Weekly, January 22, 2007, p.93

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1100

... 1 (YB-1), the prototype member of this family, is reported to be a prognostic marker of malignant diseases other than hepatocellular carcinoma," wrote M. Yasen and colleagues, Juntendo University.
"The...
...region was related to the nuclear localization of dbpA."
DbpA was a more significant prognostic marker of hepatocellular carcinoma than YB-1," the authors reported.
They concluded, "The T-to-G...

...study from Japan has documented clinical features of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and their association with alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II.
"We investigated the differences in clinical features between AFP-predominant HCC and protein induced by vitamin K absence or antagonist-II (PIVKA-II)-predominant HCC, especially regarding host factors thought to contribute to hepatocarcinogenesis in chronic hepatitis C virus (HCV) infection," wrote Y. Yano and colleagues, Saga Social Insurance Hospital.
"HCV-related HCC patients (n=306) were divided into four groups according to median AFP (48.1 ng...

...platelet count (x 10 /ml) were, respectively, 81, 67, and 8.2 in AFP-predominant HCC (group A; n=66) vs. 50, 42, and 11.4 in PIVKA-II-predominant HCC (group P; n=52)," the authors reported.
"Tumor sizes (mm) in groups A and P...

...nodule in group A, and albumin and tumor distribution in group P. PIVKA-II-predominant HCC had a milder hepatitis and a better-preserved platelet count compared with AFP-predominant HCC,"

the investigators wrote.

The scientists concluded, "Considering the strong relation between hepatocarcinogenesis and hepatic inflammation with chronic HCV infection, these differences indicate that hepatocarcinogenic mechanisms in PIVKA-II-predominant HCC may differ from those in AFP-predominant HCC."

Yano and colleagues published their study in (Clinical features of hepatitis C virus-related hepatocellular...

...researchers in Japan reported on a proteomic analysis of autoantibodies in patients with hepatocellular carcinoma (HCC).

"To detect autoantibodies that could be diagnostic markers for HCC, we analyzed serum autoantibodies comprehensively that showed immunoreactivity to proteins in tumor tissue obtained from patients with HCC. Fifteen paired samples of HCC tissue and corresponding nontumorous liver tissue as well as five normal liver tissue samples were ...

...DE gels were identified by LC-MS/MS. These immunoreactive proteins were heat shock 70 kDa protein 1 (HSP70), glyceraldehyde 3-phosphate dehydrogenase, peroxiredoxin, and manganese superoxide dismutase (Mn-SOD).

"In HCC sera, occurrences of autoantibodies against these proteins were 7/15 (46.7%), 5/15 (33...

...statistical analysis, autoantibodies against FISP70, peroxiredoxin, and Mn-SOD showed significantly high-frequency immunoreaction in HCC sera," the scientists wrote.

The authors concluded, "The three antibodies were considered patient-specific antibodies in HCC and may be candidate diagnostic biomarkers for HCC."

Takashima and colleagues published their study in (Proteomic analysis of autoantibodies in patients with hepatocellular...

7/3,K/43 (Item 13 from file: 135) Links
NewsRx Weekly Reports

0000412955 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from Chinese University of Hong Kong, People's Republic of China, publish new studies and findings

Pharma Business Week, January 22, 2007, p.1086

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1169

... According to recent research from Hong Kong, People's Republic of China, "A monomeric 17-kDa hemolysin designated as eryngeolysin was isolated from fresh fruiting bodies of the mushroom Pleurotus eryngii...

...China, quality of life (QoL) is predictive of survival in patients with unresectable hepatocellular carcinoma (HCC).

"Patients with unresectable HCC have a dismal prognosis. The

objective of this study was to evaluate whether patient-reported...

...and colleagues, Chinese University of Hong Kong.
"Two hundred and thirty-three patients with unresectable HCC (mainly hepatitis B-associated) who were recruited into two separate randomized phase III clinical studies...

...QoL questionnaire, were associated with longer survival," the investigators wrote.
They concluded, "In the studied HCC population, patient-reported baseline QoL provides additional prognostic information that supplements traditional clinical factors, and is a new prognostic marker for survival for patients with unresectable HCC."
Yeo and colleagues published the results of their research in Annals of Oncology (Quality of...

7/3,K/44 (Item 14 from file: 135) Links
NewsRx Weekly Reports

0000398205 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' work from University of Tokyo, Japan, adds to cancer treatment body of knowledge

Clinical Oncology Week, January 8, 2007, p.532

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1079

...TEXT: using three tumor markers" new findings in hepatocellular cancer. "Three tumor markers for hepatocellular carcinoma (HCC) are available in daily practice in Japan: alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP)...
...fraction of alpha-fetoprotein (AFP-L3). To elucidate the predictability of these tumor markers on HCC recurrence after curative ablation, we enrolled 416 consecutive patients with naove HCC who had been treated by percutaneous ablation at our department from July 1997 to December...
"Tumor marker levels were determined immediately before and 2 months after the treatment. Complete ablation was defined...

...of Gastroenterology.
The researchers concluded: "Tumor markers pre-and post-ablation were significant predictors for HCC recurrence and can complement imaging modalities in the evaluation of treatment efficacy."
Tateishi and colleagues...

...Japan.
Study 2: Recent research from Japan has reported on the identification of TOMM34 (34 kDa-translocase of the outer mitochondrial membrane), which shows elevated expression in the majority of human...

7/3,K/45 (Item 15 from file: 135) Links
NewsRx Weekly Reports

0000378742 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Journal reports outline National Taiwan University, Taiwan, research

Life Science Weekly, December 12, 2006, p.901

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1096

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/46 (Item 16 from file: 135) Links
NewsRx Weekly Reports

0000371573 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from National Taiwan University, Taiwan, report details of new studies and findings

Biotech Business Week, November 27, 2006, p.530

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1143

... C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/47 (Item 17 from file: 135) Links
NewsRx Weekly Reports

0000367319 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New data from Kumamoto University, Japan, shed light on cancer treatment research

Cancer Vaccine Week, November 20, 2006, p.12

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1011

According to investigators in Japan, "Heat shock protein (HSP) 105 is a 105-kDa protein, recently discovered by serological analysis of recombinant cDNA expression libraries prepared from tumor cells...

...hepatocellular carcinoma.

"We previously reported that glypican-3 (GPC3) was overexpressed, specifically in hepatocellular carcinoma (HCC) and melanoma in humans, and it was useful as a novel tumor marker. We also reported that the preimmunization of BALB/c mice with dendritic cells pulsed with...

...GPC3 peptide therefore seemed to be useful for the immunotherapy of HLA-A24+ patients with HCC and melanoma," scientists in Japan report.

"In this report, we investigated whether the GPC3298-306...

...GPC3-reactive CTLs from the peripheral blood mononuclear cells (PBMC) of HLA-A24 (A*2402)+ HCC patients," said Hiroyuki Komori at Kumamoto University and collaborators in Japan. "In addition, we used...

...restricted GPC3 epitopes to expand the applications of GPC3-based immunotherapy to the HLA-A2+ HCC patients. We found that the GPC3 (FVGEFFTDV) peptide could induce peptide-reactive CTLs in HLA...

...without inducing autoimmunity."

Komori and colleagues reported, "In five out of eight HLA-A2+ GPC3+ HCC patients, the GPC3 peptide-reactive CTLs were generated from PBMCs by in vitro stimulation with...

...peptide-reactive CTLs were also generated from PBMCs in four of six HLA-A24+ GPC3+ HCC patients."

The researchers concluded: "The inoculation of these CTLs reduced the human HCC tumor mass implanted into nonobese diabetic/severe combined immunodeficiency mice. Our study raises the possibility...

...these GPC3 peptides may therefore be applicable to cancer immunotherapy for a large number of HCC patients."

Komori and colleagues published their study in Clinical Cancer Research (Identification of HLA-A2...

7/3,K/48 (Item 18 from file: 135) Links
NewsRx Weekly Reports

0000337170 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from Israel, Taiwan and France add new findings to diagnostics body of knowledge

AIDS Weekly, September 25, 2006, p.58

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1156

... Recently, non-invasive biomarkers have been used to assess

histological features. The most thoroughly evaluated biomarker is the FibroTest (FT) (AUROC 0.80 for fibrosis stages F2F3F4 vs. F0F1)."
Y. Maor...
...is in concordance with APRI and/or Forns, then we may confidently rely on the biomarker," reported the authors.
"Concordance rate for patients with presumably advanced or minimal liver disease was...

...C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).
"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.
"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.
"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.
"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.
They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/49 (Item 19 from file: 135) Links
NewsRx Weekly Reports

0000327571 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent findings in diagnostics described by researchers from Taiwan, the United States and France

Cancer Weekly, August 22, 2006, p.409

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1156

...TEXT: C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...
...to cancer researchers in the United States, the "utility of EBV load as a tumor marker" in NPC patients "suggests that it might also serve as a screening test for individuals...

7/3,K/50 (Item 20 from file: 135) Links
NewsRx Weekly Reports

0000319893 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New findings from Taiwan, the United States and France in the area of diagnostics described

Cancer Weekly, July 25, 2006, p.393

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1156

...TEXT: C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed

proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...
...to cancer researchers in the United States, the "utility of EBV load as a tumor marker" in NPC patients "suggests that it might also serve as a screening test for individuals...

7/3,K/51 (Item 21 from file: 135) Links
NewsRx Weekly Reports

0000316265 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Complement C3a may be diagnostic of chronic hepatitis C and HCV-related HCC

Cancer Weekly, July 11, 2006, p.139

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
360

Complement C3a may be diagnostic of chronic hepatitis C and HCV-related HCC

...TEXT: C3a may be diagnostic of chronic hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC).

"Although the significant risk factors for HCC are well known from epidemiological studies, diagnosis of this disease at an early stage is difficult, and HCC remains one of the leading causes of cancer death worldwide. Thus, to identify any useful HCC-related biomarkers is still a need," wrote I.N. Lee and colleagues, National Taiwan University.

"We performed SELDI-TOF MS to identify differentially expressed proteins in HCC serum using weak cation exchange protein chips. Protein characterization was performed by 2-DE separation and nano flow LC-MS/MS. A total of 55 sera were collected from HCC patients and compared with those from 48 patients with chronic hepatitis and 9 healthy individuals.

"A candidate marker of about 8900 Da was detected as differentially expressed in patients with chronic hepatitis C and HCV related HCC. We identified this differentially expressed protein as complement C3a," the authors reported.

"The expression of C3a in HCC sera was further validated by PS20 chip immunoassay and Western blotting. Complement C3a was found to be elevated in patients with chronic hepatitis C and HCV-related HCC," the scientists observed.

They concluded, "The combination of SELDI-TOF MS and 2-DE provides...

...Lee and colleagues published their study in Proteomics (Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics...

7/3,K/52 (Item 22 from file: 135) Links
NewsRx Weekly Reports

0000198973 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Protein profiles find cancer markers in patients with chronic liver disease

Cancer Vaccine Week, March 14, 2005, p.31

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
421

...TEXT: any biological material studied. We used this approach to identify new biomarkers of hepatocellular carcinoma (HCC) in the sera of patients with cirrhosis.".

"Sera from 82 patients with cirrhosis, either without (n=38) or with (n=44) HCC, were analyzed by SELDI-TOF MS, and the results of the two groups were compared...

...Anatomical Pathology service wrote.

"The most efficient protein peaks leading to discrimination of patients with HCC were selected (receiver operative characteristic curves). The highest-scoring peak combination was established in a...

...further.

"The intensity of 30 protein peaks significantly differed between cirrhotic patients with and without HCC. An algorithm including the 6 highest-scoring peaks allowed correct classification (presence or absence of HCC) of 92.5% of patients in the test sample set and 90% in the validation sample set. The highest discriminating peak (8900 Da) was purified further and was characterized as the C-terminal part of the V10 fragment of vitronectin.

"An in vitro study suggested that the increase of the 8900-Da fragment in the serum of patients with HCC may proceed from the cleavage of native vitronectin with metalloproteases, a family of enzymes whose activity is enhanced in HCC," researchers commented.

"In conclusion, global protein profiling is an efficient approach that

enabled us to identify a catalytic fragment of vitronectin as a new serum marker of HCC in patients with chronic liver diseases," they said.

Paradis and colleagues published their study in Hepatology (Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology, 2005
...

7/3,K/53 (Item 23 from file: 135) Links
NewsRx Weekly Reports

0000003188 (USE FORMAT 7 OR 9 FOR FULLTEXT)

"Liposomes for Targeted Gene Delivery in Vivo: Intracellular Fate of Liposome-Encapsulated DNA in Rodent Lines."

Gene Therapy Weekly, July 31, 1995, p.13

DOCUMENT TYPE: Research News LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
584

...TEXT: the tissue. Part of this DNA follows the subcellular fractionation profile of the mitochondrial matrix marker, malate dehydrogenase. In contrast, 14% of the liposomal DNA taken up by the liver was...
...by covalently attaching a monoclonal antibody (AF-20) which recognizes with high affinity a 180 KDa cell surface glycoprotein that is abundantly expressed on the surface of human HCC cells and that undergoes rapid internaliation upon antibody binding. A plasmid containing the lac Z...

7/3,K/54 (Item 1 from file: 357) Links
Derwent Biotech Res.

0304067 DBA Accession No.: 2003-05852 PATENT
Diagnosing neoplasm and inhibiting tumor growth, by contacting tissue of mammal with detectably-labeled antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase antibody production against enzyme protein, vector expression in host cell for use in disease gene therapy

Author: WANDS J R; DE LA MONTE S M; DEUTCH A H; GHANBARI H A
Patent Assignee: WANDS J R; DE LA MONTE S M; DEUTCH A H; GHANBARI H A 2002
Patent Number: US 20020110559 Patent Date: 20020815 WPI Accession No.: 2003-066676 (200306)
Priority Application Number: US 859604 Application Date: 20010517
National Application Number: US 859604 Application Date: 20010517
Language: English
Abstract: ...a transfection enhancing agent. Preferred Kit: The kit further comprises a means (e.g. detectable marker such as radioactive compound or Gd3+ or

Fe++, for detecting binding of (I) to the... ...were specifically overexpressed in transformed malignant cells of human hepatocyte origin, the FOCUS hepatocellular carcinoma (HCC) cell line was used as an immunogen to generate monoclonal antibodies (mAb) that specifically or... ...recognize proteins associated with the malignant phenotype. A lambdagt11 cDNA expression library derived from HepG2 HCC cells was screened, ...cultures that were 70-80% confluent demonstrated that constitutively increased levels of AAH expression (85 kDa) in pHAAH-transfected cells were associated with significantly increased levels of PCNA (35 kDa) and Bcl-2 (25 kDa) and reduced levels of p21/Wafl (21 kDa) and p16 (16 kDa). However, the pHAAH stable transfectants also exhibited higher levels of wild-type p53 (53-55 kDa). Although AAH expression (85 kDa protein) in the stable transfectants was increased by only 75-100%, the levels of p16...

7/3,K/55 (Item 2 from file: 357) Links
Derwent Biotech Res.

0291403 DBA Accession No.: 2002-13250 PATENT
New nucleic acids useful for in vitro detection of homozygous deletion in human chromosome 8p23 of a hepatocellular carcinoma cell line DNA isolation, polymerase chain reaction and high throughput genomic sequence for disease detection and diagnosis

Author: PINEAU P; MARCHIO A; DEJEAN A
Patent Assignee: INST PASTEUR; INSERM INST NAT SANTE and RECH MEDICALE 2002
Patent Number: WO 200224948 Patent Date: 20020328 WPI Accession No.: 2002-383197 (200241)
Priority Application Number: US 234308 Application Date: 20000921
National Application Number: WO 2001IB2274 Application Date: 20010921
Language: English
Abstract: ...are also included for the following: (1) in vitro detecting (M1) of human hepatocellular carcinoma (HCC), by detecting a homozygous deletion in human chromosome 8p23; and (2) a kit (K) for diagnosing HCC comprising (I) having (S1) and (S2).cttgtatgtatataaacgcc (A) gctgatcatggtaccacatg (B) cttccagcgtttattgcatc (C) ttgccagtcagtatgtcaag (D) cattaaatttgtagctacag... ...for in vitro detection of a homozygous deletion in human chromosome 8p23 of hepatocellular carcinoma (HCC) within the 345 kilobase region flanked by 370L3SP6 and 315117fg8D loci markers (claimed). EXAMPLE - A... ...cell lines included 58 hepatobiliary and 37 non-hepatobiliary cell lines were extensively cultured. High molecular weight genomic DNAs were extracted and purified. The 95 human cells were assayed for deletion by... ...of 4 amplified products were compared to unfinished high throughput genomic sequences (ntgs). Only D8S262 marker showed 100 % homology with a sequence of human bacterial artificial chromosome (BAC) clone named 188e04...

7/3,K/56 (Item 1 from file: 8) Links
Fulltext available through: STIC Full Text Retrieval Options
Ei Compendex(R)

11279302 E.I. No: EIP06421017434
Title: Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts

Author: Nakagawa, Tsutomu; Uozumi, Naofumi; Nakano, Miyako; Mizuno-Horikawa, Yoko; Okuyama, Noriko; Taguchi, Tomohiko; Gu, Jianguo; Kondo, Akihiro; Taniguchi, Naoyuki; Miyoshi, Eiji
Corporate Source: Dept. of Biochemistry Osaka University Graduate School of Medicine, Suita, 565-0871 Osaka, Japan
Source: Journal of Biological Chemistry v 281 n 40 Oct 6 2006. p 29797-29806
Publication Year: 2006
CODEN: JBCHA3 ISSN: 0021-9258 eISSN: 1083-351X
DOI: 10.1074/jbc.M605697200
DOI: 10.1074/jbc.M605697200

Language: English
Abstract: Fucosylated alpha-fetoprotein (AFP) is a highly specific tumor marker for hepatocellular carcinoma (HCC). However, the molecular mechanism by which serum level of fucosylated AFP increases in patients with HCC remains largely unknown. Here, we report that the fucosylation of glycoproteins could be a possible...
...this system might involve an increase in fucosylated AFP in the serum of patients with HCC. copy 2006 by The American Society for Biochemistry and Molecular Biology, Inc. 31 Refs.
Descriptors: *Proteins; Tumors; Carcinogens; Liquid chromatography; Mass spectrometry; Molecular weight; Biodiversity
Identifiers: alpha-fetoprotein (AFP); Hepatocellular carcinoma (HCC); Fucosylation

7/3,K/57 (Item 1 from file: 266) Links
FEDRIP

00604054
Identifying No.: 1R03CA119313-01A2 Agency Code: CRISP
Novel Machine Learning Methods for Analysis of MALDI-TOF Mass Spectrometry Data

Principal Investigator: RESSOM, HABTOM W
Address: HWR@GEORGETOWN.EDU LOMBARDI COMPREHENSIVE CANCER CT 3970 RESERVOIR ROAD, NW WASHINGTON, DC 20057
Performing Org.: GEORGETOWN UNIVERSITY , WASHINGTON , DIST OF COL
Sponsoring Org.: NATIONAL CANCER INSTITUTE
Dates: 2003/01/07 To 2002/28/09 Fy : 2007
Summary: DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is a common cancer worldwide with as many as 500,000 new cases each year. Between 1981 to 1998, the 5-year patient survival rate with HCC only rose from 2% to 5%. This poor survival rate is in part related to the diagnosis of HCC at advanced stages, where effective therapies are lacking. Early detection of HCC improves patient survival. Patients with cirrhosis are typically the ones to develop HCC. Hence, monitoring cirrhotic patients can potentially decrease the cancer-related mortality rate. The poor sensitivity and specificity of currently available tools has prevented widespread implementation of HCC surveillance. Therefore, additional serum markers that provide higher sensitivity and specificity are needed to improve the detection rate of early HCC. The goal of this collaborative project is to identify a panel of serum biomarkers for early diagnosis of HCC. The long-term goal is to find and validate markers that would help identify HCC at a treatable stage in high-risk population of cirrhotic patients. This project will lead to the development of innovative mass spectral data preprocessing and biomarker selection methods that for the identification of candidate biomarkers specific to HCC by using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS) of low-molecular-weight (LMW) enriched sera. The specific aims of the project are the following: Aim 1: To... ...in replicate spectra of a standard serum and to enhance the prediction accuracy in distinguishing HCC patients from cirrhotic patients or healthy individuals. Aim 2: To develop a novel algorithm that is superior to currently used biomarker selection methods by combining two popular machine learning methods, particle swarm optimization (PSO) and support vector machines (SVMs). The proposed algorithm will be used to identify HCC-specific markers from the preprocessed MALDI-TOF spectra. To avoid confounding effects, peaks will be removed prior to biomarker selection if they are associated with viral infection or covariates such as age, gender, smoking... ...or rural). From the remaining peaks, a small set of candidate biomarkers that accurately distinguishes HCC patients from cirrhotic patients will be identified. The capability of the algorithm to identify a... ...Additionally, the algorithm will identify markers that distinguish various pairs (normal vs. cirrhosis, normal vs. HCC, cirrhosis vs. early-stage HCC, and cirrhosis vs. late-stage HCC). This will enable us to isolate HCC- specific markers and identify disease progression markers. Furthermore, the peptides represented by the selected candidate...

7/3,K/58 (Item 2 from file: 266) Links

FEDRIP

00604048
Identifying No.: 5R03CA119288-02 Agency Code: CRISP
Optimization of enrichment for MALDI TOF/TOF identification of cancer biomarkers

Principal Investigator: GOLDMAN, RADOSLAV
Address: RG26@GEORGETOWN.EDU DEPARTMENT OF ONCOLOGY 3970 RESERVOIR ROAD, NW WASHINGTON, DC 20057
Performing Org.: GEORGETOWN UNIVERSITY , WASHINGTON , DIST OF COL
Sponsoring Org.: NATIONAL CANCER INSTITUTE
Dates: 2009/13/06 To 2006/30/08 Fy : 2007
Summary: ...diagnostic set of peptides and proteins (P/P) in serum of patients with hepatocellular carcinoma (HCC). To identify biomarkers of HCC , we developed enrichment of low molecular weight (LMW) fraction of serum for matrix assisted laser desorption ionization-time of flight (MALDI- TOF... ...well as identification of the peptides of interest by TOF/TOF sequencing. We tested the biomarker discovery method on a pilot set of HCC cases and matched controls, which identified a set of P/P predictive of HCC with greater than 90% prediction accuracy. In this study, we propose to adjust the method... ...liver disease (150 cases, 150 matched controls, 50 cirrhosis), and to begin identification of the biomarker-candidates by sequencing. The samples come from our ongoing case-control study of HCC in Egypt, a country with an epidemic of hepatitis C infection and HCC. Our goal is to identify biomarkers that would improved early detection of HCC and track the natural progression of chronic viral infection to cancer. The identity of the...

7/3,K/59 (Item 3 from file: 266) Links
FEDRIP

00603360
Identifying No.: 1R01CA115625-01A2 Agency Code: CRISP
Proteomic Analysis of Serum in Liver Cancer

Principal Investigator: GOLDMAN, RADOSLAV
Address: RG26@GEORGETOWN.EDU LOMBARDI COMPREHENSIVE CA CTR 3970 RESERVOIR ROAD, NW WASHINGTON, DC 20057
Performing Org.: GEORGETOWN UNIVERSITY , WASHINGTON , DIST OF COL
Sponsoring Org.: NATIONAL CANCER INSTITUTE
Dates: 2002/15/07 To 2001/31/11 Fy : 2007
Summary: ...identify a set of peptides and proteins (P/P) in serum associated with hepatocellular carcinoma (HCC). To achieve this goal, we developed enrichment of the low molecular weight (LMW) serum fraction for matrix assisted laser desorption ionization-time of flight (MALD1-TOF/TOF... ...well as identification of the peptides of interest by TOF/TOF sequencing. We tested the biomarker discovery method on a pilot set of HCC cases and matched controls from our unique study of HCC in Egypt, a country with an epidemic of hepatitis C viral infection. The pilot-study identified a set of six peptides that predict HCC with 96% prediction accuracy. In this study, we propose to expand the project and focus... ...of liver cirrhosis. Our goal is to identify biomarkers that would improve early detection of HCC in this high-risk group and track the natural progression of chronic viral hepatitis to cancer. We will cross validate our ongoing study in Egypt with a study of HCC in the US population; verify peptide- identification by MALDI-TOF/TOF sequencing, complementary liquid chromatography... ...and immunodepletion; develop improved methods for quantification of the peptides; and test performance of the biomarker-candidates. Defining clinically applicable biomarkers of early-stage cancer has potentially far-reaching consequences for...

7/3,K/60 (Item 4 from file: 266) Links
FEDRIP

00599661

Identifying No.: 2R01CA093840-05A2 Agency Code: CRISP
Genesis of Liver Carcinomas with Oval Cell Traits

Principal Investigator: HIXSON, DOUGLAS C
Address: DOUGLAS HIXSON@BROWN.EDU RHODE ISLAND HOSPITAL 593 EDDY STREET PROVIDENCE, RI 02903
Performing Org.: RHODE ISLAND HOSPITAL (PROVIDENCE, RI) , PROVIDENCE , RHODE ISLAND
Sponsoring Org.: NATIONAL CANCER INSTITUTE
Dates: 2004/01/02 To 2005/31/12 Fy : 2007
Summary: ...role in hepato-and cholangio-carcinogenesis. Over the past 4 years, our studies of cholangiocyte marker positive (CMP), bipotent, fetal liver epithelial cells (FLEC) have yielded novel monoclonal antibody based schemes... ...oval cells and will retain this capacity following spontaneous transformation in vitro and progression to HCC in vivo. In Specific Aim 1, we will employ a rapid transplantation model that replaces... ...with mitomycin C (mitoC/PH) to test the hypothesis that the expression of the cholangiocyte marker OC.4, a marker first seen at 2 after birth, identifies mature CMP-LEC that have a greatly diminished... ...BDEC will undergo incomplete hepatocytic differentiation in mitoC/PH treated rats and progress to CMP-HCC. Spontaneous transformation of CMP-LEC will be accelerated by selection on plastic and/or soft... ...invasive growth. Specific Aim 4 will continue with the characterization of BD.1, a 170 kDa protein expressed by cholangiocytes but not oval cells that forms stable complexes with CLIP170, a...

7/3,K/61 (Item 1 from file: 149) Links
TGG Health&Wellness DB(SM)

03392460 Supplier Number: 168416261 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Endosomal Trafficking and Proprotein Convertase Cleavage of cis Golgi Protein GP73 Produces Marker for Hepatocellular Carcinoma.(Author abstract)(Report)

Bachert, Collin; Fimmel, Claus; Linstedt, Adam D.
Traffic , 8 , 10 , 1415(9)
Oct ,
2007
Document Type: Report; Author abstract Publication Format: Magazine/Journal
ISSN: 1398-9219
Language: English
Record Type: Abstract Target Audience: Academic
Endosomal Trafficking and Proprotein Convertase Cleavage of cis Golgi Protein GP73 Produces Marker for Hepatocellular Carcinoma.(Author abstract)(Report)
Author Abstract: ...2007.00621.x
    Byline: Collin Bachert (1), Claus Fimmel (2), Adam D. Linstedt (1,)
    Keywords:
    biomarker; Golgi; GP73; endosome; furin; hepatocellular carcinoma
    Abstract:
    Serum GP73 levels are significantly increased in patients with hepatocellular carcinoma (HCC), potentially providing a marker for early detection. However, GP73 is an integral membrane protein localized to the cis Golgi... ...was released from cultured cells and compared with the Golgi-localized full-length protein, the molecular weight was slightly reduced, suggesting that cleavage releases the GP73 ectodomain. Sequence analysis revealed a proprotein... ...cleavage, resulting in GP73 secretion, and provides a molecular mechanism for its presence as a serum biomarker for HCC.
    Author Affiliation:
    (1)Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA 15213, USA
    (2...

7/3,K/62 (Item 2 from file: 149) Links
TGG Health&Wellness DB(SM)

02944498 Supplier Number: 106422241 (USE FORMAT 7 OR 9 FOR FULL TEXT)
The role of genetic polymorphisms in environmental health. (Research Review).

Kelada, Samir N.; Eaton, David L.; Wang, Sophia S.; Rothman, Nathaniel R.; Khoury, Muin J.
Environmental Health Perspectives , 111 , 8 , 1055(10)
June 15 ,
2003
Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
Word Count: 11400 Line Count: 01145

...sub.1), a mycotoxin found in some foodstuffs, and an established risk for hepatocellular carcinoma (HCC), especially when combined with hepatitis virus exposure (Ross et al. 1992). The biotransformation of aflatoxin...

...a lack of enzyme and less active enzyme, respectively, was shown to result in increased HCC risk (London et al. 1995; McGlynn et al. 1995). Similarly, functional variants in CYP1A2 and...

...phase I metabolism (epoxidation) of aflatoxin (B.sub.1), would also be expected to modify HCC risk in exposed persons, although epidemiologic data for this have not yet been gathered. Biomarker studies of urinary aflatoxin metabolites and aflatoxin--albumin adducts in peripheral blood have validated their use as indicators of HCC risk at the group level, and polymorphisms in GSTM1 and EPHX1 yielded higher levels of...

...studies of exposures to environmental toxicants and toxins. Stratification of a studied health outcome or biomarker by relevant genotype (or phenotype) may allow for detection of different levels of risk among...

...epidemiologic studies and ultimately contributed to the development of a chemoprevention strategy for aflatoxin-induced HCC.

Additionally, studies on the health effects of exposure to regulated environmental contaminants that incorporate genetic...

profiles	UROD	
Alcohol	Esophageal cancer	ALDH2
Aflatoxin (B.sub.1)	Aflatoxin-albumin adducts	CYP1A2
		CYP3A4
	HCC	GSTM1
		EPHX1
Heterocyclic amines	Colon cancer	NAT2
	Breast cancer	NAT2
		SULT1A1
Aromatic amines	Bladder cancer...	

...Binkova B, Lewtas J, Miskova I, Rossner P, Cerna M, Mrackova G, et al. 1996. Biomarker studies in northern Bohemia. Environ Health Perspect 104:591-597.

Botto LD, Khoury MJ. 2001...

...Tokyo 110:559-565.

Heath EM, Morken NW, Campbell KA, Tkach D, Boyd EA, Strom DA. 2001. Use of buccal cells collected in mouthwash as a source of DNA for clinical...

...and XRCC1 genes associated with ionizing radiation sensitivity.

Carcinogenesis 22:917-922.
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. 1993. The molecular basis of the human...CF, Haugen A, Valerio F, et al. 1998. Urinary excretion of 1-hydroxypyrene as a marker for exposure to urban air levels of polycyclic aromatic hydrocarbons. Cancer EpidemioI Biomarkers Prey 7...

...337-340.
Richeldi L, Sorrentino R, Saltini C. 1993. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 262:242-244.
Rosipal R, Lamoril J, Puy H, Da Silva V, Gouya L, De Rooij FW, et al. 1999. Systematic analysis of coproporphyrinogen oxidase...

...Rothman N, Stewart WF, Schulte PA. 1995. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. Cancer Epidemiol Biomarkers Prev 4:301-311.
Rothman N, Wacholder S...

...Rebbeck TR. 1999. Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect 107:517-520.
Ward MH, Nuckols JR, Weigel SJ, Maxwell SK...

...Perspect 102:215-219.
Whyatt RM, Perera FP, Jedrychowski W, Santella RM, Garte S, Bell DA. 2000. Association between polycyclic aromatic hydrocarbon-DNA adduct levels in maternal and newborn white blood...

7/3,K/63 (Item 3 from file: 149) Links
TGG Health&Wellness DB(SM)

02923077 Supplier Number: 80744269 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Variability in Aflatoxin-Albumin adduct levels and effects of hepatitis B and C virus infection and glutathione S-transferase M1 and T1 genotype. (Articles).

Ahsan, Habibul; Wang, Li-Yu; Chen, Chien-Jen; Tsai, Wei-Yann; Santella, Regina M.
Environmental Health Perspectives , 109 , 8 , 833(5)
August ,
2001
Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
Word Count: 5183 Line Count: 00477

Text:

...the intraindividual variability in AF(B.sub.1)-albumin adducts, the most reliable long-term biomarker of AF(B.sub.1) exposure, and whether the baseline or follow-up adduct levels...

****
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in the world. In Taiwan, it is the most common cause of cancer death among men (1). Risk factors for HCC include chronic hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, cigarette smoking, and...

...albumin adduct, but AF(B.sub.1)-albumin adducts have been considered the

most reliable biomarker of AF(B.sub.1) exposure in humans (5). Because of a relatively long half...

...months (5). AF(B.sub.1)-albumin adduct has been shown to be related to HCC risk in a dose-response fashion among HBV surface antigen (HBsAg) carriers, and the biological...

...Hu-Hsi, Ma-Kung, and Pai-Hsa) in Penghu Islets, an area with the highest HCC incidence in Taiwan, but in a manner so that half (n = 132) of them were...

...status could not be determined.

Discussion

Although HBV infection is the key etiologic element in HCC, AF(B.sub.1) exposure is an important cofactor in HCC carcinogenesis. AF(B.sub.1)-albumin adduct is considered a reliable indicator of the biologically...

...recruitment (i.e., at time 1), the respondents were briefed about the risk factors for HCC, including hepatitis viruses and dietary aria-toxin exposure. Therefore, one possibility is that the participants...

...nested study carried out in Shanghai that found an association between aflatoxin-albumin adducts and HCC found no association with dietary aflatoxin consumption based on in-person food frequency interview combined ...

...of 42 residents of Guangxi Province in China established that albumin adducts were a valid marker of aflatoxin exposure by comparing adduct levels to the levels of aflatoxin in portions of...

...Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, Hirvonen A, Bell DA, Santella RM. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and...risk of hepatocellular carcinoma in Taiwan. Int J Cancer 87:620-625 (1996).

(9.) Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure...

7/3,K/64 (Item 4 from file: 149) Links
TGG Health&Wellness DB(SM)

02915238 Supplier Number: 67183911 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Applying Biomarker Research.

Bennett, David A.; Waters, Michael D.
Environmental Health Perspectives , 108 , 9 , 907
Sept ,
2000
Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
Word Count: 4152 Line Count: 00364
Applying Biomarker Research.

...to understand environmentally mediated disease and to improve the process of risk assessment. A valid biomarker could also be considered a key event linking a specific environmental exposure to a health...

...most closely related to the disease.

(Figure 1 ILLUSTRATION OMITTED)

Over the last decade the biomarker model has resulted in considerable research enterprise and nourished and challenged the emerging field of...

...field and their extension into the clinical environment. At the same time, much of the biomarker research has remained confined to the laboratory, with the promise of successful applications to improve public health or mitigate disease largely unmet.

A biomarker should allow better measurements of exposure or earlier identification of health effects. Biomarkers can provide...

...U.S. EPA held "Biomarkers: Taking Stock, An EPA/NIEHS In-House Workshop on Applying Biomarker Research" on 30-31 August 1999 in Chapel Hill, North Carolina. Approximately 90 participants explored biomarker research through presentations by invited plenary speakers, posters on individual research projects, and breakout discussion...

...precursor step that is a necessary element of the mode of action or is a marker for such an element. Examples of key events include metabolism, receptor--ligand changes, increased cell...

...to accidental mercury or methylparathion exposures. Lead in blood, plasma, or bone is an excellent biomarker of exposure and potentially of effects. Lead biomarkers also illustrate a challenge in understanding the...

...backward to look at populations that have exposures to various agents to see if the biomarker rises as their exposure rises. In either case establishing linkage between exposure and disease is...

...relating a) exposures to aflatoxin (B.sub.1), b) the etiology of human hepatocellular carcinoma (HCC), and c) intervention with oltipraz as a chemo-preventive agent for HCC (8). Biomarkers included aflatoxin--albumin adducts in serum and aflatoxin--mercapturic acid excreted in urine...

...one might develop an hypothesis to test. This was appropriate in the early stages of biomarker validation. Our understanding of the science supporting molecular epidemiology has now advanced so that we...

...studies and the regulatory community trying to apply this information.

An intended use of the biomarker may be in the clinical setting, where the focus is on the individual and there...

...fetus. Environ Health Perspect 107(suppl 3):451-460 (1999).

(10.) El-Masri HA, Bell DA, Portier CJ. Effects of glutathione transferase polymorphism on the risk estimates of dichloromethane to humans ...

...NW, Washington DC 20460. Telephone: (703) 603-8759. Fax: (703) 603-9146. E-mail: bennett.da@epa.gov

(*) On assignment from the U.S. EPA Office of Emergency and Remedial Response...

7/3,K/65 (Item 5 from file: 149) Links
TGG Health&Wellness DB(SM)

01713503 Supplier Number: 19696795 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Hepatitis G virus: is it a hepatitis virus?

Cheung, Ramsey C.; Keeffe, Emmet B.; Greenberg, Harry B.

The Western Journal of Medicine , v167 , n1 , p23(11)
July ,
1997
Publication Format: Magazine/Journal; Refereed
ISSN: 0093-0415
Language: English
Record Type: Fulltext; Abstract Target Audience: Professional
Word Count: 9257 Line Count: 00752

...antibodies to recombinant HGV putative envelope protein E2 was recently described as a potential serological marker for immunity to HGV infection.(20) Antibodies to E2 were found in 9% of 80...
...became HGV RNA negative. These data suggest that antibodies to E2 might be a serological marker for diagnosing recovery from HGV infection, but further studies are necessary. Detection of HGV RNA...44) The disease in the three patients with HGV RNA as the only identifiable viral marker was mild, and only one remained persistently viremic with elevated SGPT levels for 4 years...positive posttransplant.

Hepatocellular Carcinoma

Serum HGV RNA has been found in patients with hepatocellular carcinoma (HCC). HGV RNA was found in only one of 28 HCV-infected patients with HCC.(77) Among patients transplanted with HCC. HGV RNA was found in four of 34 patients of whom three were coinfected with ...

...with HBV.(78) GBV-C RNA was found in 11 of 111 (10%) cases of HCC in Japan, but 10 of 11 were coinfected with HCV and one with HBV. HGV...

...found as the only infectious viral agent in seven (8%) of 85 Austrian patients with HCC.(79) Since the majority of patients with HCC were coinfected with either HBV or HCV, the role of HGV in the etiology of HCC is unclear. Therefore, with the exception of the Austrian study,(71) HGV is unlikely to be a major etiologic agent of HCC.

Response of HGV to Antiviral Therapy

There are no data on treatment of patients who...Med 1996; 336:747-754

(45.) Aach RD. Stevens CE, Hollinger FB, Mosley JW, Peterson DA , Taylor PE. et al. Hepatitis C virus infection in post-transfusion hepatitis. N Engl J...

7/3,K/66 (Item 6 from file: 149) Links

01438001 Supplier Number: 14699208 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Molecular virology and pathogenesis of hepatitis B.

Lau, Johnson Y.N.; Wright, Teresa L.
The Lancet , v342 , n8883 , p1335(6)
Nov 27 ,
1993
Publication Format: Magazine/Journal
ISSN: 0099-5355
Language: English
Record Type: Fulltext; Abstract Target Audience: Professional
Word Count: 4638 Line Count: 00403

...HBV-associated hepatocarcinogenesis, and current and future approaches to treatment.

Testing Assays Clinical significance

HBsAg		Marker of HBV infection
Anti-HBs		Immune against/protected from HBV([dagger])
HBeAg	RIA/EIA/RPHA...	

...and HBsAg. The smallest transcript (0.7 kb) encodes the X protein.

HBV proteln	Size (kDa)(*)	Function, clinical significance
Core	p21	Protein of core particle; kinase activity (role in replication?)
Pre-core (HBeAg)	p25[right arrow]p p16	Pre-core/core cleaves to HBeAg; good marker of active HBV replication and role in inducing immunotolerance
Surface (HBsAg)	p24/gp27	Envelope protein...

...Even though the pre-core sequence is not essential for replication, HBeAg is a good marker of active HBV replication because the pre-core/core gene product is generated from the...enhancer and hence replication.

Hepatocarcinogenesis

The strong association of persistent HBV infection and hepatocellular carcinoma (HCC) is intriguing, yet poorly understood. Although the relative risk of HCC developing in HBV carriers is as high as 100 times that in matched controls, it usually takes decades for HCC to emerge. Since HBV integration can occur early, this suggests that HBV does not have...

...c-ras, have been implicated but none has been shown to be consistently activated in HCC. The strong association of cirrhosis with HCC suggests that the common pathway for hepatocarcinogenesis may be chronic hepatic injury and regeneration, which in some way promote the induction or selection of a malignant clone.

HCC may well be a heterogeneous disease with cellular oncogene and common pathway models both operating...

...Further understanding of this heterogeneity may help in the establishment of the mechanisms involved in HCC--as happened with our understanding of the pathobiology of lymphoma and leukaemia in the wake ...

7/3,K/67 (Item 1 from file: 444) Links
New England Journal of Med.

00126660

Case 23-2005: A 57-Year-Old Man with a Mass in the Liver (Case Records of the Massachusetts General Hospital)

Tanabe, Kenneth K.; Blaszkowsky, Lawrence S.; Chung, Raymond T.; Blake, Michael A.; Lauwers, Gregory Y.
The New England Journal of Medicine
Jul 28 , 2005 ; 353 (4),pp 401-410
Line Count: 00429 Word Count: 05928

Text:

...products from the precore or core region yield secreted hepatitis B e antigen (HBeAg), a marker of active replication that can also be confirmed by molecular tests for circulating HBV DNA... ...growth control and set the stage for malignant transformation in the form of hepatocellular carcinoma (HCC). The illustration is adapted from Chisari (Ref. 4) *.**FIGURE OMITTED...

Cited References
...hepatocellular carcinoma. Am J Surg 1995;169:28-34.
34. Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of...

```
? d s
Set     Items   Description
S1      78025   S HEPATOCELLULAR ADJ CARCINOMA OR HCC
S2        696   S S1 AND (DALTON OR KILODALTON OR KDA OR DA)
S3        109   S S2 AND (SERUM ADJ MARKER OR SERUM ADJ BIOMARKER OR MARKER OR
BIOMARKER)
S4         56   RD  (unique items)
S5        951   S S1 AND (DALTON OR KILODALTON OR KDA OR DA OR MOLECULAR(W)WEIGHT)
S6        128   S S5 AND (SERUM(W)MARKER OR SERUM(W)BIOMARKER OR MARKER OR
BIOMARKER)
S7         67   RD  (unique items)
```